carbon monoxide has been researched along with Smoking Cessation in 440 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
Smoking Cessation: Discontinuing the habit of SMOKING.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to determine the efficacy and safety of the nicotine patch for smoking cessation in an over-the-counter environment." | 10.19 | Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. ( Croghan, IT; Davidson, M; Hays, JT; Hurt, RD; Nides, MA; Offord, KP; Schroeder, DR; Wolter, TD, 1999) |
| "Expired carbon monoxide (ECO) is often used in smoking cessation trials to biochemically validate self-reported smoking status." | 9.69 | Evaluating the impact of varying expired carbon monoxide thresholds on smoking relapse identification: insights from the E3 trial on e-cigarette efficacy for smoking cessation. ( Eisenberg, MJ; Filion, KB; Hébert-Losier, A; Prell, C; Reynier, P, 2023) |
| "Nicotine replacement therapy (NRT) has been demonstrated to be an effective pharmacological treatment for smoking cessation, and most types of NRT have been approved as over-the-counter (OTC) medications." | 9.34 | Efficacy and Safety of a Nicotine Mouth Spray for Smoking Cessation: A Randomized, Multicenter, Controlled Study in a Naturalistic Setting. ( Danielsson, T; Kapikian, R; Leischow, SJ; Myers, A; Nides, M; Perfekt, R; Saunders, F; Solla, J, 2020) |
| "Body weight mostly and to a smaller extent genetic polymorphisms of UGT2B7 can influence varenicline exposure." | 9.30 | Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. ( Cornuz, J; Csajka, C; Dobrinas, M; Eap, CB; Glatard, A; Guidi, M, 2019) |
| "A smoking cessation program using varenicline or NRT for 3 months resulted in a decrease of CO, oxidative stress, arterial stiffness and restored endothelial glycocalyx." | 9.24 | Effects of varenicline and nicotine replacement therapy on arterial elasticity, endothelial glycocalyx and oxidative stress during a 3-month smoking cessation program. ( Andreadou, I; Ikonomidis, I; Kourea, K; Lekakis, J; Liarakos, N; Marinou, M; Parissis, J; Pavlidis, G; Triantafyllidi, H; Tsougos, E; Vlastos, D, 2017) |
| "Results from this study will inform FDA on the potential effects of regulating the nicotine content of cigarettes and help determine whether smokers with mood and/or anxiety disorders can safely transition to significantly reduced nicotine content cigarettes." | 9.24 | A two-site, two-arm, 34-week, double-blind, parallel-group, randomized controlled trial of reduced nicotine cigarettes in smokers with mood and/or anxiety disorders: trial design and protocol. ( Allen, SI; Azzouz, N; Cather, C; Evins, AE; Foulds, J; Hameed, A; Hammett, E; Hrabovsky, S; Krebs, NM; Liao, J; Modesto, J; Muscat, JE; Pachas, GN; Richie, J; Veldheer, S; Yingst, J; Zhu, J, 2017) |
| "Participants were randomized to one of three 12-week open-label smoking cessation pharmacotherapy groups: (1) nicotine patch only (n = 241); (2) varenicline only (including 1 prequit week; n = 424); and (3) C-NRT (nicotine patch + nicotine lozenge; n = 421)." | 9.22 | Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. ( Baker, TB; Bolt, DM; Fiore, MC; Fraser, DL; Piper, ME; Smith, SS; Stein, JH, 2016) |
| "Objective We evaluated the short-term effects of smoking cessation therapy with varenicline on the lung function." | 9.22 | Twelve Weeks of Successful Smoking Cessation Therapy with Varenicline Reduces Spirometric Lung Age. ( Iwaoka, M; Tsuji, T, 2016) |
| "To evaluate the efficacy and safety of combining varenicline and a nicotine patch vs varenicline alone in smoking cessation." | 9.19 | Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. ( Abdool-Gaffar, MS; Bateman, ED; Bruning, A; Emanuel, S; Esterhuizen, TM; Irusen, EM; Koegelenberg, CF; Noor, F; O'Brien, JA; Smith, C; van Zyl-Smit, RN, 2014) |
| " Smoking cessation rates in methadone-maintained smokers are low and novel treatment strategies are required." | 9.17 | Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. ( Anderson, BJ; Audet, D; Caviness, CM; Kurth, ME; Olson, J; Stein, MD, 2013) |
| " This multicentre, randomised (2:1), double-blind, placebo-controlled efficacy and safety study evaluated self-reported, carbon monoxide-verified continuous abstinence from smoking from week 2 until weeks 6, 24, and 52 in 479 smokers (≥ 1 cigarette per day) who were treated with either active (n=318) or placebo (n=161) spray for 12 weeks and low-intensity counselling at three smoking cessation clinics in Denmark and Germany." | 9.16 | Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. ( Batra, A; Lauri, H; Mann, K; Perfekt, R; Tønnesen, P, 2012) |
| "This proof-of-concept study investigated the feasibility and initial efficacy of combining a contingency management intervention with bupropion to reduce smoking in people with schizophrenia." | 9.15 | Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. ( Kaplan, GB; Reid, N; Rohsenow, DJ; Swift, RM; Tidey, JW, 2011) |
| "The purpose of this study is to assess social support and demographic factors that influence the success of smoking cessation aided with sublingual nicotine tablets in a Han Chinese population." | 9.14 | Family support and employment as predictors of smoking cessation success: a randomized, double-blind, placebo-controlled trial of nicotine sublingual tablets in chinese smokers. ( Chen, DF; Di, XL; Guo, S; Jiang, ZN; Kosten, TR; Liu, Y; Lu, L; Sun, HQ; Yang, FD; Zhang, XY, 2009) |
| "The primary aim of this study was to determine the safety and efficacy of the monoamine oxidase-B (MAO-B) inhibitor selegiline hydrochloride (SEL, l-Deprenyl; Eldepryl) as an aid for smoking cessation in cigarette smokers." | 9.14 | A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. ( George, TP; Jatlow, PI; O'Malley, SS; Potenza, MN; Reutenauer, EL; Weinberger, AH, 2010) |
| " This report describes the results of a Phase 2a study exploring the efficacy of a liquid nicotine delivery system as an aid to smoking cessation assessed after 12 weeks of therapy." | 9.14 | Use of a liquid nicotine delivery product to promote smoking cessation. ( Baumgarten, D; Geimer, N; Kepner, JL; Mahoney, MC; Olson, CE, 2010) |
| "The objective of this study was to examine whether there is a benefit of adding bupropion SR to high-dose combination nicotine replacement therapy (NRT) and weekly group cognitive behavioral therapy (CBT) for smoking reduction or cessation in schizophrenia." | 9.12 | A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. ( Birnbaum, A; Cather, C; Culhane, MA; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Horowitz, J; Hsieh, E; Rigotti, NA; Schoenfeld, DA, 2007) |
| "The purpose of this study was to determine the effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia." | 9.11 | The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. ( Chen, R; Chou, KR; Ku, CH; Lee, JF; Lu, RB, 2004) |
| "Smoking cessation improved CV parameters despite the measured cotinine and thiocyanate plasma levels, and use of nicotine medications did not negate these improvements." | 9.11 | Changes in hemorheological and biochemical parameters following short-term and long-term smoking cessation induced by nicotine replacement therapy (NRT). ( Cort, N; Haustein, H; Haustein, KO; Krause, J; Rasmussen, T, 2004) |
| " Since dopamine may play a critical role in mediating the reinforcing effects of nicotine, we hypothesized that administering levodopa in its therapeutic form (carbidopa/levodopa) might be effective for smoking cessation by replacing the effects of dopamine that smokers may seek during smoking." | 9.09 | Carbidopa/levodopa for smoking cessation: a pilot study with negative results. ( Ahlskog, JE; Croghan, GA; Croghan, IT; Hurt, RD; Moyer, TP; Offord, KP; Wolter, TD, 2000) |
| "To compare the efficacy and safety of 22-mg and 44-mg doses of transdermal nicotine therapy when it is paired with minimal, individual, or group counseling to improve smoking cessation rates." | 9.08 | Varying nicotine patch dose and type of smoking cessation counseling. ( Baker, TB; Croghan, IT; Fiore, MC; Hays, JT; Hurt, RD; Jorenby, DE; Lewis, SF; Offord, KP; Smith, SS, 1995) |
| " Main outcome measures were (1) self-reported abstinence with validation by carbon monoxide in expired air and serum cotinine and (2) weight gain." | 9.08 | The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain. ( Iversen, E; Jakobsen, HB; Jørgensen, S; Mikkelsen, KL; Nørregaard, J; Søeberg, B; Sørensen, T; Tønnesen, P, 1996) |
| "To evaluate concurrent administration of mecamylamine (nicotine antagonist) with nicotine skin patch treatment for smoking cessation." | 9.07 | Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. ( Behm, FM; Levin, ED; Ripka, GV; Rose, JE; Stein, RM; Westman, EC, 1994) |
| "Pretreatment markers, such as the Fagerstrom Tolerance Questionnaire score, number of cigarettes smoked per day, years smoked, expired air carbon monoxide level, or baseline blood nicotine and cotinine levels, showed no consistent relationship with successful smoking cessation across both studies." | 9.07 | Predicting smoking cessation. Who will quit with and without the nicotine patch. ( Baker, TB; Fiore, MC; Jorenby, DE; Kenford, SL; Smith, SS; Wetter, D, 1994) |
| "To determine the efficacy of a 22-mg nicotine patch combined with the National Cancer Institute program for physician advice and nurse follow-up in providing withdrawal symptom relief, 1-year smoking cessation outcome, and percentage of nicotine replacement." | 9.07 | Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. ( Caldwell, CC; Dale, LC; Fredrickson, PA; Hurt, RD; Lauger, GG; Lee, GA; Lundberg, TG; Marŭsić, Z; Neese, LW; Offord, KP, 1994) |
| "To evaluate the efficacy of a new nicotine inhaler system for smoking cessation." | 9.07 | A double-blind trial of a nicotine inhaler for smoking cessation. ( Jørgensen, S; Mikkelsen, K; Nilsson, F; Nørregaard, J; Tønnesen, P, 1993) |
| " This study investigated the effects of smoking cessation with varenicline (a partial agonist of nicotinic acetylcholine receptors) on the levels of oxHDL in the serum of subjects compared with those of high-density lipoprotein cholesterol (HDL-C)." | 8.12 | Effects of smoking cessation using varenicline on the serum concentrations of oxidized high-density lipoprotein: Comparison with high-density lipoprotein cholesterol. ( Kato, T; Kotani, K; Miyagawa, K; Mochida, A; Ohira, Y; Okada, Y; Takeda, H; Umeda, A, 2022) |
| "Secondary analysis of data from three sequential, observational, mixed-methods cohort studies conducted as part of the Nicotine Replacement Effectiveness and Delivery in Pregnancy programme." | 8.12 | Comparison of saliva cotinine and exhaled carbon monoxide concentrations when smoking and after being offered dual nicotine replacement therapy in pregnancy. ( Claire, R; Clark, M; Coleman, T; Cooper, S; Dickinson, A; Emery, J; Kinahan-Goodwin, D; Lewis, S; McDaid, L; Naughton, F; Phillips, L; Slaich, B; Thomson, R, 2022) |
| " Here, we evaluated the effect of smoking cessation on definitive radiation therapy for early stage glottic carcinoma by monitoring expiratory carbon monoxide (CO)." | 8.02 | Monitoring expiratory carbon monoxide to study the effect of complete smoking cessation on definitive radiation therapy for early stage glottic carcinoma. ( Hirata, T; Inohara, H; Isohashi, F; Miyata, Y; Ogawa, K; Seo, Y; Shimamoto, S; Tamari, K; Tatekawa, S; Uno, A; Yamamoto, Y; Yoshino, Y, 2021) |
| "To determine whether an in-office exhaled carbon monoxide (CO) monitor can increase interest in smoking cessation among the orthopaedic trauma population." | 7.91 | Novel Application of Exhaled Carbon Monoxide Monitors: Smoking Cessation in Orthopaedic Trauma Patients. ( Coale, M; Comadoll, SM; Costales, T; Matuszewski, PE; OʼToole, RV; Zerhusen, T, 2019) |
| " This premise is used to justify targeting pregnant women with a unique approach to smoking cessation including policies such as the routine testing of all pregnant women for carbon monoxide at every antenatal appointment." | 7.91 | Are We Justified in Introducing Carbon Monoxide Testing to Encourage Smoking Cessation in Pregnant Women? ( Bowden, C, 2019) |
| "Researchers have used breath carbon monoxide (CO) cutoff values ranging from 4 to 10 ppm to define abstinence in cigarette-smoking cessation research and reductions in CO as a measure of acute abstinence in laboratory research." | 7.76 | Breath carbon monoxide output is affected by speed of emptying the lungs: implications for laboratory and smoking cessation research. ( Dallery, J; Faix, C; Raiff, BR; Turturici, M, 2010) |
| "All patients were part of a smoking cessation program of the Nicotine Institute in collaboration with the general sick fund of Lower Austria." | 7.75 | Nocturnal sleep-disturbing nicotine craving and accomplishment with a smoking cessation program. ( Groman, E; Kunze, U; Riemerth, A, 2009) |
| "The current investigation explored the main and interactive effects of panic attacks in response to laboratory-induced bodily sensations and anxiety sensitivity in predicting acute nicotine withdrawal symptoms among daily smokers making a self-guided quit attempt." | 7.75 | Anxiety sensitivity and panic reactivity to bodily sensations: relation to quit-day (acute) nicotine withdrawal symptom severity among daily smokers making a self-guided quit attempt. ( Bergman, J; Gibson, LE; Johnson, K; Marshall, EC; Zvolensky, MJ, 2009) |
| "To determine the effectiveness of bupropion treatment for smoking cessation in a general practice setting, measuring continuous abstinence from smoking, from 8 weeks to 52 weeks." | 7.73 | Pragmatic, observational study of bupropion treatment for smoking cessation in general practice. ( Evans, A; Gibson, J; Henderson, M; Wilkes, S, 2005) |
| "Three hundred thirty-one consecutive outpatients (161 with asthma and 170 with COPD) were examined cross-sectionally by self-reported smoking status, breath CO monitoring, and serum cotinine concentration." | 7.72 | Optimal cutoff level of breath carbon monoxide for assessing smoking status in patients with asthma and COPD. ( Hajiro, T; Koyama, H; Mishima, M; Nishimura, K; Oga, T; Sato, S; Tsukino, M, 2003) |
| "This is an exploratory study of compliance to nicotine chewing gum in a multicomponent group smoking cessation program where usage was optional." | 7.68 | Compliance to nicotine gum recommendations in a multicomponent group smoking cessation program: an exploratory study. ( McEntee, M; Millard, RW; Waranch, HR, 1992) |
| "Varenicline for 12 weeks was not more effective than placebo to achieve abstinence among daily waterpipe smokers." | 7.30 | Varenicline Treatment for Waterpipe Smoking Cessation. ( Chami, HA; Makki, M; Shaya, M; Talih, F; Tamim, H; Zaouk, N, 2023) |
| "Smokers with chronic obstructive pulmonary disease (COPD) have particular difficulty quitting." | 6.87 | Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease: A Randomized Clinical Trial. ( Ellerbeck, EF; Fitzgerald, SA; Hutcheson, TD; Nollen, N; Phadnis, M; Richter, KP; Salzman, GA; Sharpe, MR; Vacek, J, 2018) |
| "To identify the predictors of success in a randomised controlled trial comparing varenicline alone or in combination with nicotine replacement therapy (NRT)." | 6.84 | Predictors of treatment success in smoking cessation with varenicline combined with nicotine replacement therapy v. varenicline alone. ( Esterhuizen, TM; Irusen, EM; Koegelenberg, CFN; Noor, F, 2017) |
| "Smoking cessation is beneficial for our health at any point in life, both in healthy people and in people already suffering from a smoking-related disease." | 6.77 | Clinical trial on the efficacy of exhaled carbon monoxide measurement in smoking cessation in primary health care. ( Alvarez-Ossorio, C; Buades, A; Esteva, M; García, E; Girauta, H; Gorreto, L; Medina-Bombardó, D; Pastor, A; Ramos, M; Ripoll, J; Torres, E; Uréndez, A, 2012) |
| "Smoking cessation is a key intervention for prevention of several lung diseases." | 6.69 | Smoking cessation with four nicotine replacement regimes in a lung clinic. ( Mikkelsen, KL; Tønnesen, P, 2000) |
| "The purpose of this study was to determine the efficacy and safety of the nicotine patch for smoking cessation in an over-the-counter environment." | 6.19 | Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. ( Croghan, IT; Davidson, M; Hays, JT; Hurt, RD; Nides, MA; Offord, KP; Schroeder, DR; Wolter, TD, 1999) |
| "Time to first quit attempt (duration from TAB experience to primary outcome) and carbon monoxide level-verified smoking cessation at 6-month follow-up." | 5.51 | Effect of Technology-Assisted Brief Abstinence Game on Long-term Smoking Cessation in Individuals Not Yet Ready to Quit: A Randomized Clinical Trial. ( Allison, JJ; Amante, DJ; Blok, AC; Chen, J; Conigliaro, J; Flahive, J; Garber, L; Houston, TK; Kamberi, A; Mattocks, KM; Morley, J; Nagawa, CS; Person, SD; Sadasivam, RS; Wijesundara, JG, 2022) |
| " Pivot, a US Clinical Practice Guideline-based mobile smoking cessation program, comprises a personal carbon monoxide breath sensor; a smartphone app; in-app, text-based human-provided coaching; nicotine replacement therapy; and a moderated web-based community." | 5.51 | Outcomes of a Comprehensive Mobile Smoking Cessation Program With Nicotine Replacement Therapy in Adult Smokers: Pilot Randomized Controlled Trial. ( Balbierz, DJ; Fujii, CA; Galanko, JA; Marler, JD; Utley, DS; Utley, MT, 2022) |
| "Life-long smoking cessation is a critical public health objective, but it is difficult for numerous people." | 5.46 | Levels of exhaled carbon monoxide measured during an intervention program predict 1-year smoking cessation: a retrospective observational cohort study. ( Chen, WC; Ho, LI; Ko, HK; Pan, SW; Shie, HG; Yu, WK, 2017) |
| "Nicotine replacement therapy (NRT) has been demonstrated to be an effective pharmacological treatment for smoking cessation, and most types of NRT have been approved as over-the-counter (OTC) medications." | 5.34 | Efficacy and Safety of a Nicotine Mouth Spray for Smoking Cessation: A Randomized, Multicenter, Controlled Study in a Naturalistic Setting. ( Danielsson, T; Kapikian, R; Leischow, SJ; Myers, A; Nides, M; Perfekt, R; Saunders, F; Solla, J, 2020) |
| "Body weight mostly and to a smaller extent genetic polymorphisms of UGT2B7 can influence varenicline exposure." | 5.30 | Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. ( Cornuz, J; Csajka, C; Dobrinas, M; Eap, CB; Glatard, A; Guidi, M, 2019) |
| ", 24 h/day) treatment for SUD received 19 consecutive days of either contingent vouchers (CV) for smoking abstinence (twice-daily carbon monoxide [CO] readings) or non-contingent vouchers (NV) plus counseling to motivate smoking cessation." | 5.27 | Smoking outcome expectancies predict smoking during voucher-based treatment for smokers with substance use disorders. ( Colby, SM; Martin, RA; Murphy, CM; Rohsenow, DJ; Tidey, JW, 2018) |
| "A smoking cessation program using varenicline or NRT for 3 months resulted in a decrease of CO, oxidative stress, arterial stiffness and restored endothelial glycocalyx." | 5.24 | Effects of varenicline and nicotine replacement therapy on arterial elasticity, endothelial glycocalyx and oxidative stress during a 3-month smoking cessation program. ( Andreadou, I; Ikonomidis, I; Kourea, K; Lekakis, J; Liarakos, N; Marinou, M; Parissis, J; Pavlidis, G; Triantafyllidi, H; Tsougos, E; Vlastos, D, 2017) |
| "Results from this study will inform FDA on the potential effects of regulating the nicotine content of cigarettes and help determine whether smokers with mood and/or anxiety disorders can safely transition to significantly reduced nicotine content cigarettes." | 5.24 | A two-site, two-arm, 34-week, double-blind, parallel-group, randomized controlled trial of reduced nicotine cigarettes in smokers with mood and/or anxiety disorders: trial design and protocol. ( Allen, SI; Azzouz, N; Cather, C; Evins, AE; Foulds, J; Hameed, A; Hammett, E; Hrabovsky, S; Krebs, NM; Liao, J; Modesto, J; Muscat, JE; Pachas, GN; Richie, J; Veldheer, S; Yingst, J; Zhu, J, 2017) |
| "Participants were randomized to one of three 12-week open-label smoking cessation pharmacotherapy groups: (1) nicotine patch only (n = 241); (2) varenicline only (including 1 prequit week; n = 424); and (3) C-NRT (nicotine patch + nicotine lozenge; n = 421)." | 5.22 | Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. ( Baker, TB; Bolt, DM; Fiore, MC; Fraser, DL; Piper, ME; Smith, SS; Stein, JH, 2016) |
| "the effectiveness will be evaluated every 3, 6, 9 and 12 months as: pattern of tobacco use (self-reported tobacco use), smoking cessation rates, carbon monoxide (CO) levels in exhaled air measured by CO-oximetry, urinary cotinine tests, nicotine dependence (Fagerström test), motivational stages of change (Prochaska and DiClemente's stages) and motivation to stop smoking (the Richmond test)." | 5.22 | A randomized clinical trial to determine the effectiveness of CO-oximetry and anti-smoking brief advice in a cohort of kidney transplant patients who smoke: study protocol for a randomized controlled trial. ( Alonso-Hernández, Á; Cao-López, M; Fernández-Rivera, C; González-Martín, C; López-Calviño, B; Pértega-Díaz, S; Pita-Fernández, S; Seijo-Bestilleiro, R; Seoane-Pillado, T; Valdés-Cañedo, F, 2016) |
| "Objective We evaluated the short-term effects of smoking cessation therapy with varenicline on the lung function." | 5.22 | Twelve Weeks of Successful Smoking Cessation Therapy with Varenicline Reduces Spirometric Lung Age. ( Iwaoka, M; Tsuji, T, 2016) |
| "To evaluate the efficacy and safety of combining varenicline and a nicotine patch vs varenicline alone in smoking cessation." | 5.19 | Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. ( Abdool-Gaffar, MS; Bateman, ED; Bruning, A; Emanuel, S; Esterhuizen, TM; Irusen, EM; Koegelenberg, CF; Noor, F; O'Brien, JA; Smith, C; van Zyl-Smit, RN, 2014) |
| " To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment protocol." | 5.19 | Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. ( Cosimano, MP; Garcia-Romeu, A; Griffiths, RR; Johnson, MW, 2014) |
| " Smoking cessation rates in methadone-maintained smokers are low and novel treatment strategies are required." | 5.17 | Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. ( Anderson, BJ; Audet, D; Caviness, CM; Kurth, ME; Olson, J; Stein, MD, 2013) |
| "Effectiveness of nicotine replacement therapy (NRT) for smoking cessation has not been evaluated in low income countries, such as Syria, where it is expensive and not widely available." | 5.17 | Randomized trial of the effectiveness of combined behavioral/pharmacological smoking cessation treatment in Syrian primary care clinics. ( Al Ali, R; Asfar, T; Eissenberg, T; Maziak, W; Rastam, S; Ward, KD; Weg, MW, 2013) |
| "Smoking cessation is typically verified biochemically by expired-air carbon monoxide (CO) levels below 9 ppm (i." | 5.17 | Optimal carbon monoxide criteria to confirm 24-hr smoking abstinence. ( Jao, NC; Karelitz, JL; Perkins, KA, 2013) |
| " This multicentre, randomised (2:1), double-blind, placebo-controlled efficacy and safety study evaluated self-reported, carbon monoxide-verified continuous abstinence from smoking from week 2 until weeks 6, 24, and 52 in 479 smokers (≥ 1 cigarette per day) who were treated with either active (n=318) or placebo (n=161) spray for 12 weeks and low-intensity counselling at three smoking cessation clinics in Denmark and Germany." | 5.16 | Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. ( Batra, A; Lauri, H; Mann, K; Perfekt, R; Tønnesen, P, 2012) |
| "To determine the effect of adding biomarker feedback (expired air carbon monoxide) to standard quit advice on cognitive antecedents of behavior change and smoking cessation and to identify potential effect moderators and mediators." | 5.15 | A randomized, controlled trial of adding expired carbon monoxide feedback to brief stop smoking advice: evaluation of cognitive and behavioral effects. ( McNeill, A; Shahab, L; West, R, 2011) |
| "This proof-of-concept study investigated the feasibility and initial efficacy of combining a contingency management intervention with bupropion to reduce smoking in people with schizophrenia." | 5.15 | Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. ( Kaplan, GB; Reid, N; Rohsenow, DJ; Swift, RM; Tidey, JW, 2011) |
| "The purpose of this study is to assess social support and demographic factors that influence the success of smoking cessation aided with sublingual nicotine tablets in a Han Chinese population." | 5.14 | Family support and employment as predictors of smoking cessation success: a randomized, double-blind, placebo-controlled trial of nicotine sublingual tablets in chinese smokers. ( Chen, DF; Di, XL; Guo, S; Jiang, ZN; Kosten, TR; Liu, Y; Lu, L; Sun, HQ; Yang, FD; Zhang, XY, 2009) |
| "The primary aim of this study was to determine the safety and efficacy of the monoamine oxidase-B (MAO-B) inhibitor selegiline hydrochloride (SEL, l-Deprenyl; Eldepryl) as an aid for smoking cessation in cigarette smokers." | 5.14 | A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. ( George, TP; Jatlow, PI; O'Malley, SS; Potenza, MN; Reutenauer, EL; Weinberger, AH, 2010) |
| " This report describes the results of a Phase 2a study exploring the efficacy of a liquid nicotine delivery system as an aid to smoking cessation assessed after 12 weeks of therapy." | 5.14 | Use of a liquid nicotine delivery product to promote smoking cessation. ( Baumgarten, D; Geimer, N; Kepner, JL; Mahoney, MC; Olson, CE, 2010) |
| " The aim of our paper is to evaluate the effectiveness of adding exhaled carbon monoxide (CO) measurement using a CO analyser to a normal smoking cessation practice in a GP's office." | 5.14 | [Impact of exhaled CO measurement. A randomised study among 578 smoking patients in general practice]. ( Delcroix, M; Fanello, S; Pare, F; Parot-Schinckel, E; Rouquette, A; Sejourne, C, 2010) |
| "Transdermal selegiline does not appear generally effective in aiding smoking cessation though there may be a selective effect in those smokers with low 'behavioral activation'." | 5.14 | Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. ( Bryson, SW; Fong, D; Fortmann, SP; Hayward, C; Killen, DT; Killen, JD; Lowenthal, K; Murphy, GM; Schatzberg, AF, 2010) |
| "Exercise combined with nicotine therapy may help smoking cessation and minimise weight gain after quitting." | 5.14 | Participation in a population-based physical activity programme as an aid for smoking cessation: a randomised trial. ( Bize, R; Chiolero, A; Cornuz, J; Locatelli, I; Payot, S; Stoianov, R; Willi, C, 2010) |
| " Although, expired carbon monoxide (CO) is frequently used to confirm self reports, it has a relatively short half life, calling into question whether this measure might provide misleading information by exaggerating smoking cessation success rates." | 5.13 | Comparison of expired carbon monoxide and plasma cotinine as markers of cigarette abstinence. ( Jatlow, P; Krishnan-Sarin, S; Leary, V; O'Malley, SS; Toll, BA, 2008) |
| "Nicotine replacement products are commonly used to promote smoking cessation, but alternative and complementary methods may increase cessation rates." | 5.12 | Effects of internet-based voucher reinforcement and a transdermal nicotine patch on cigarette smoking. ( Dallery, J; Glenn, IM, 2007) |
| "The objective of this study was to examine whether there is a benefit of adding bupropion SR to high-dose combination nicotine replacement therapy (NRT) and weekly group cognitive behavioral therapy (CBT) for smoking reduction or cessation in schizophrenia." | 5.12 | A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. ( Birnbaum, A; Cather, C; Culhane, MA; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Horowitz, J; Hsieh, E; Rigotti, NA; Schoenfeld, DA, 2007) |
| "The purpose of this study was to determine the effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia." | 5.11 | The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. ( Chen, R; Chou, KR; Ku, CH; Lee, JF; Lu, RB, 2004) |
| "Smoking cessation improved CV parameters despite the measured cotinine and thiocyanate plasma levels, and use of nicotine medications did not negate these improvements." | 5.11 | Changes in hemorheological and biochemical parameters following short-term and long-term smoking cessation induced by nicotine replacement therapy (NRT). ( Cort, N; Haustein, H; Haustein, KO; Krause, J; Rasmussen, T, 2004) |
| " We tested the efficacy of bupropion in improving smoking cessation rates in this setting by enrolling 47 patients from the elective surgery waiting list in a double-blind randomised controlled trial." | 5.11 | Effectiveness of bupropion as an aid to stopping smoking before elective surgery: a randomised controlled trial. ( Angliss, M; Lee, L; Leslie, K; Mezzavia, P; Myles, PS, 2004) |
| "Nicotine gum may be an efficacious harm-reduction alternative for smokers who are not ready to quit and may promote smoking cessation, the ultimate goal in the treatment of tobacco dependence." | 5.11 | Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. ( Batra, A; Danielsson, T; Friederich, HM; Klingler, K; Landfeldt, B; Westin, A, 2005) |
| "Patients referred by their hospital doctor to the smoking cessation counsellor and who agreed to participate in the study were randomised to receive either NRT given as a nicotine patch daily and a nicotine inhalator on an as needed basis plus advice and support (AS+NRT), or to receive just advice and support (AS)." | 5.10 | Controlled trial of three weeks nicotine replacement treatment in hospital patients also given advice and support. ( Campbell, IA; Cannings, R; Edwards, S; Hand, S, 2002) |
| " Twenty-four healthy volunteers, not intending to quit smoking, were housed in an experimental unit during three 72-h conditions, consisting of either free smoking, enforced smoking cessation with nicotine replacement therapy (NRT) patches, or enforced smoking cessation with placebo patches." | 5.10 | Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal. ( Bye, A; Milleri, S; Squassante, L; Teneggi, V; Tiffany, ST; Ziviani, L, 2002) |
| "Our study compared the results of self-report (SR) plus breath carbon monoxide (CO) monitoring to SR plus urine cotinine (COT) analysis of recent tobacco use for a recently completed smoking cessation study that compared the efficacy of different intensities of psychosocial treatments coupled with 8 weeks of patch treatment." | 5.10 | Detecting smoking following smoking cessation treatment. ( Alterman, AI; Ehrman, R; Gariti, P; Mulvaney, FD; O'Brien, CP, 2002) |
| " Since dopamine may play a critical role in mediating the reinforcing effects of nicotine, we hypothesized that administering levodopa in its therapeutic form (carbidopa/levodopa) might be effective for smoking cessation by replacing the effects of dopamine that smokers may seek during smoking." | 5.09 | Carbidopa/levodopa for smoking cessation: a pilot study with negative results. ( Ahlskog, JE; Croghan, GA; Croghan, IT; Hurt, RD; Moyer, TP; Offord, KP; Wolter, TD, 2000) |
| "Although nicotine replacement therapy (NRT) is mainly licensed as an aid for smoking cessation, many smokers alternate NRT with cigarettes." | 5.09 | Tolerability of concurrent use of nicotine gum and smoking in healthy volunteers. ( Pahlm, O; Stahl, MM; Wohlfart, B, 2001) |
| "To compare the efficacy and safety of 22-mg and 44-mg doses of transdermal nicotine therapy when it is paired with minimal, individual, or group counseling to improve smoking cessation rates." | 5.08 | Varying nicotine patch dose and type of smoking cessation counseling. ( Baker, TB; Croghan, IT; Fiore, MC; Hays, JT; Hurt, RD; Jorenby, DE; Lewis, SF; Offord, KP; Smith, SS, 1995) |
| "Mecamylamine is an antihypertensive that acts via nicotinic antagonism and has been suggested as an aid in smoking cessation." | 5.08 | Mecamylamine does not precipitate withdrawal in cigarette smokers. ( Eissenberg, T; Griffiths, RR; Stitzer, ML, 1996) |
| " Main outcome measures were (1) self-reported abstinence with validation by carbon monoxide in expired air and serum cotinine and (2) weight gain." | 5.08 | The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain. ( Iversen, E; Jakobsen, HB; Jørgensen, S; Mikkelsen, KL; Nørregaard, J; Søeberg, B; Sørensen, T; Tønnesen, P, 1996) |
| "The effects of using several nicotine replacement treatments on self-reported withdrawal symptoms and side effects during 2-day periods of smoking cessation, with 5 days of ad lib smoking between cessation days, were evaluated." | 5.08 | Effects of nicotine dose and administration method on withdrawal symptoms and side effects during short-term smoking abstinence. ( Aickin, M; Cook, G; Hill, AL; Holden, T; Kligman, E; Leischow, SJ; Otte, PS; Valente, SN, 1997) |
| "Nicotine nasal spray (NNS) is generally considered to be an effective smoking cessation aid, but all studies to date of NNS effectiveness have also utilized group therapy sessions or frequent laboratory visits to support their subjects' stop smoking efforts." | 5.08 | Nicotine and cotinine replacement when nicotine nasal spray is used to quit smoking. ( Jones, RL; Man, SF; Nguyen, A, 1998) |
| " The manufacturer claims that the solution reduces exposure to nicotine, carbon monoxide (CO), and other constituents of tobacco smoke and may aid in smoking cessation by providing a means of gradual nicotine dose reduction." | 5.08 | Effects of cigarette smoking through a partially occluded filter. ( Fant, RV; Henningfield, JE; Nelson, RA; Pickworth, WB, 1998) |
| "The effects of transdermal nicotine-assisted smoking cessation on digital perfusion and health-related quality of life were assessed in 10 chronic smokers." | 5.08 | The effect of transdermal nicotine on digital perfusion in reformed habitual smokers. ( Fulcher, SM; Holden, M; Koman, LA; Smith, BP; Smith, TL, 1998) |
| "Nicotine replacement therapy is believed to facilitate smoking cessation both by relieving withdrawal symptoms and by reducing the psychological reward from smoking." | 5.08 | Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. ( Benowitz, NL; Jacob, P; Zevin, S, 1998) |
| "To evaluate the efficacy of the transdermal nicotine patch as an aid to smoking cessation when used as an adjunct to a cognitive-behavioural group intervention and to assess the effectiveness of the patch in ameliorating withdrawal symptoms." | 5.07 | The transdermal nicotine patch: results of a randomised placebo-controlled trial. ( de Almeida Neto, A; Harris, K; Richmond, RL, 1994) |
| "To evaluate concurrent administration of mecamylamine (nicotine antagonist) with nicotine skin patch treatment for smoking cessation." | 5.07 | Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. ( Behm, FM; Levin, ED; Ripka, GV; Rose, JE; Stein, RM; Westman, EC, 1994) |
| "A variety of studies have shown that nicotine skin patches are effective in promoting smoking cessation." | 5.07 | Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. ( Behm, FM; Carnahan, E; Herman, S; Levin, ED; Rose, JE; Sanchez, M; Stein, RM; Westman, EC, 1994) |
| "Pretreatment markers, such as the Fagerstrom Tolerance Questionnaire score, number of cigarettes smoked per day, years smoked, expired air carbon monoxide level, or baseline blood nicotine and cotinine levels, showed no consistent relationship with successful smoking cessation across both studies." | 5.07 | Predicting smoking cessation. Who will quit with and without the nicotine patch. ( Baker, TB; Fiore, MC; Jorenby, DE; Kenford, SL; Smith, SS; Wetter, D, 1994) |
| "To determine the efficacy of a 22-mg nicotine patch combined with the National Cancer Institute program for physician advice and nurse follow-up in providing withdrawal symptom relief, 1-year smoking cessation outcome, and percentage of nicotine replacement." | 5.07 | Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. ( Caldwell, CC; Dale, LC; Fredrickson, PA; Hurt, RD; Lauger, GG; Lee, GA; Lundberg, TG; Marŭsić, Z; Neese, LW; Offord, KP, 1994) |
| " Also, we examined the impact of the nicotine patch on specific withdrawal symptoms (anger, anxiety, awakening, difficulty concentrating, depression, hunger, impatience, and craving)." | 5.07 | Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. ( Baker, TB; Fiore, MC; Jorenby, DE; Kenford, SL; Smith, SS; Wetter, DW, 1994) |
| "To evaluate the efficacy of a new nicotine inhaler system for smoking cessation." | 5.07 | A double-blind trial of a nicotine inhaler for smoking cessation. ( Jørgensen, S; Mikkelsen, K; Nilsson, F; Nørregaard, J; Tønnesen, P, 1993) |
| "A possible strategy for increasing smoking cessation rates could be to provide smokers with feedback on the current or potential future biomedical effects of smoking using, for example, measurement of exhaled carbon monoxide (CO), lung function, or genetic susceptibility to lung cancer or other diseases." | 5.01 | Biomedical risk assessment as an aid for smoking cessation. ( Bize, R; Burnand, B; Camain, JY; Clair, C; Cornuz, J; Livingstone-Banks, J; Mueller, Y; Rège-Walther, M; Selby, K, 2019) |
| " This review examines the current literature related to: (1) smoking, lipoproteins, and lipid-related enzymes; (2) the impact of nicotine, carbon monoxide and free radicals on physiologic parameters related to health; and (3) metabolic issues involving smoking cessation and nicotine replacement therapy." | 4.84 | Smoking and smoking cessation -- the relationship between cardiovascular disease and lipoprotein metabolism: a review. ( Chelland Campbell, S; Moffatt, RJ; Stamford, BA, 2008) |
| " As part of an adolescent smoking cessation trial, we examined whether MJ smoking, and specifically "blunt" (gutted cigars filled with MJ) smoking, elevated participants' likelihood of a false indication of cigarette smoking on the basis of breath carbon monoxide (CO) testing." | 4.82 | Recent marijuana blunt smoking impacts carbon monoxide as a measure of adolescent tobacco abstinence. ( Epstein, DH; Huestis, MA; Moolchan, ET; Sehnert, SS; Zimmerman, D, 2005) |
| " This study investigated the effects of smoking cessation with varenicline (a partial agonist of nicotinic acetylcholine receptors) on the levels of oxHDL in the serum of subjects compared with those of high-density lipoprotein cholesterol (HDL-C)." | 4.12 | Effects of smoking cessation using varenicline on the serum concentrations of oxidized high-density lipoprotein: Comparison with high-density lipoprotein cholesterol. ( Kato, T; Kotani, K; Miyagawa, K; Mochida, A; Ohira, Y; Okada, Y; Takeda, H; Umeda, A, 2022) |
| "Secondary analysis of data from three sequential, observational, mixed-methods cohort studies conducted as part of the Nicotine Replacement Effectiveness and Delivery in Pregnancy programme." | 4.12 | Comparison of saliva cotinine and exhaled carbon monoxide concentrations when smoking and after being offered dual nicotine replacement therapy in pregnancy. ( Claire, R; Clark, M; Coleman, T; Cooper, S; Dickinson, A; Emery, J; Kinahan-Goodwin, D; Lewis, S; McDaid, L; Naughton, F; Phillips, L; Slaich, B; Thomson, R, 2022) |
| " Here, we evaluated the effect of smoking cessation on definitive radiation therapy for early stage glottic carcinoma by monitoring expiratory carbon monoxide (CO)." | 4.02 | Monitoring expiratory carbon monoxide to study the effect of complete smoking cessation on definitive radiation therapy for early stage glottic carcinoma. ( Hirata, T; Inohara, H; Isohashi, F; Miyata, Y; Ogawa, K; Seo, Y; Shimamoto, S; Tamari, K; Tatekawa, S; Uno, A; Yamamoto, Y; Yoshino, Y, 2021) |
| " This premise is used to justify targeting pregnant women with a unique approach to smoking cessation including policies such as the routine testing of all pregnant women for carbon monoxide at every antenatal appointment." | 3.91 | Are We Justified in Introducing Carbon Monoxide Testing to Encourage Smoking Cessation in Pregnant Women? ( Bowden, C, 2019) |
| "Controlled pre-post design stratified by intervention condition from the 'Study of Nicotine Patch in Pregnancy', a randomized, placebo-controlled trial." | 3.91 | Saliva cotinine concentrations in pregnant women who smoke and use nicotine patches. ( Berlin, I; Claire, R; Coleman, T; Leonardi-Bee, J, 2019) |
| " Nicotine dependence, depression scores and exhaled carbon monoxide levels were formally evaluated." | 3.91 | Challenges for dedicated smoking cessation services in developing countries. ( Cooper, C; Day, C; Dheda, K; Esmail, A; Kamkuemah, M; Tadzimirwa, GY; Van Zyl-Smit, RN, 2019) |
| "A package of measures implemented in trusts and smoking cessation services, aimed at increasing the proportion of pregnant smokers quitting during pregnancy, comprising skills training for healthcare and smoking cessation staff; universal carbon monoxide monitoring with routine opt-out referral for smoking cessation support; provision of carbon monoxide monitors and supporting materials; and an explicit referral pathway and follow-up protocol." | 3.88 | Evaluation of a complex healthcare intervention to increase smoking cessation in pregnant women: interrupted time series analysis with economic evaluation. ( Araújo-Soares, V; Bell, R; Close, A; Glinianaia, SV; Hamilton, S; Jones, S; Milne, EM; Moloney, E; Rushton, S; Shucksmith, J; Vale, L; Waal, ZV; White, M; Willmore, M, 2018) |
| "Using random-effect logistic regression models, we analysed the effects of baseline measures of cigarette dependence, including numbers of cigarettes smoked daily, Fagerström Test of Cigarette Dependence (FTCD) score, the two FTCD subscales of Heaviness of Smoking Index (HSI) and non-Heaviness of Smoking Index (non-HSI), expired carbon monoxide (CO) level and urges to smoke (strength and frequency) on smoking cessation." | 3.83 | Which measures of cigarette dependence are predictors of smoking cessation during pregnancy? Analysis of data from a randomized controlled trial. ( Aveyard, P; Coleman, T; Lewis, S; Naughton, F; Riaz, M; Ussher, M; West, R, 2016) |
| "This study examined the relationship between CO and cotinine in a sample of 662 individuals participating in a smoking cessation clinical trial." | 3.80 | How low should you go? Determining the optimal cutoff for exhaled carbon monoxide to confirm smoking abstinence when using cotinine as reference. ( Clark, CB; Cropsey, KL; Hendricks, PS; Lahti, AC; Stevens, EN; Trent, LR, 2014) |
| " All underwent a baseline imaging, exhaled carbon monoxide level evaluation and spirometry, repeated at three months from smoking cessation therapy." | 3.80 | Lung nodule and functional changes in smokers after smoking cessation short-term treatment. ( Comito, F; Frezza, AM; Maci, E; Pezzuto, A; Tonini, G, 2014) |
| " This study investigated the ability of peptide YY (PYY) and ghrelin during the initial 24-48 h of a smoking cessation attempt to predict smoking relapse at 4 weeks." | 3.80 | Peptide YY and ghrelin predict craving and risk for relapse in abstinent smokers. ( al'Absi, M; Lemieux, A; Nakajima, M, 2014) |
| "Cross-study comparisons of effect sizes suggest that varenicline is more effective than nicotine replacement therapy (NRT) in aiding smoking cessation, but evidence from direct comparisons is limited." | 3.79 | Fifty-two-week continuous abstinence rates of smokers being treated with varenicline versus nicotine replacement therapy. ( Davis, R; Kmetova, A; Kralikova, E; Stepankova, L; West, R; Zvolska, K, 2013) |
| "Fixed-dose nicotine replacement therapy (NRT) is efficacious for smoking cessation in the general population of smokers." | 3.79 | Escalating doses of transdermal nicotine in heavy smokers: effects on smoking behavior and craving. ( Andriash, K; Busto, UE; Persad, D; Selby, P; Zack, M; Zawertailo, L, 2013) |
| "Fifty urine samples from pregnant women enrolled in a smoking cessation program were analyzed to compare three different methods for verifying smoking status: NicAlert strips, a bench-top enzyme multiplied immunoassay technique (EMIT) analyzer, and gas chromatography (GC), the current gold standard for determining cotinine levels in urine." | 3.77 | Using NicAlert strips to verify smoking status among pregnant cigarette smokers. ( Bernstein, IM; Bradstreet, MP; Gaalema, DE; Heil, SH; Higgins, ST, 2011) |
| " Logistic regression analysis revealed that the independent predictors of success in smoking cessation were being male; low nicotine dependence; smoking few cigarettes per day at baseline; having no history of depression; having low values for craving for cigarettes, irritability, frustration, anger, or nocturnal awakening at baseline; decreased craving for cigarettes and restlessness with time; and use of nicotine replacement therapy (NRT)." | 3.77 | Predictors of short-term success in smoking cessation in relation to attendance at a smoking cessation program. ( Dorner, TE; Groman, E; Tröstl, A; Womastek, I, 2011) |
| "identification and referral of pregnant smokers to specialist services using self-report gathered on routine pregnancy booking questionnaire augmented by a carbon monoxide breath test." | 3.76 | 'Breathe': the stop smoking service for pregnant women in Glasgow. ( Barnett, D; Hamilton, S; McGowan, A; Nsofor, M; Proudfoot, J; Tappin, DM, 2010) |
| "All patients were part of a smoking cessation program of the Nicotine Institute in collaboration with the general sick fund of Lower Austria." | 3.75 | Nocturnal sleep-disturbing nicotine craving and accomplishment with a smoking cessation program. ( Groman, E; Kunze, U; Riemerth, A, 2009) |
| " Correlations between baseline smoking cessation self-efficacy and the changes in breath carbon monoxide (CO) and the reduction in breath CO and increases in smoking cessation self-efficacy from baseline were obtained from a contingency management smoking cessation procedure." | 3.75 | The relationship between self-efficacy and reductions in smoking in a contingency management procedure. ( Lamb, RJ; Mintz, J; Romanowich, P, 2009) |
| "The current investigation explored the main and interactive effects of panic attacks in response to laboratory-induced bodily sensations and anxiety sensitivity in predicting acute nicotine withdrawal symptoms among daily smokers making a self-guided quit attempt." | 3.75 | Anxiety sensitivity and panic reactivity to bodily sensations: relation to quit-day (acute) nicotine withdrawal symptom severity among daily smokers making a self-guided quit attempt. ( Bergman, J; Gibson, LE; Johnson, K; Marshall, EC; Zvolensky, MJ, 2009) |
| " The following variables were analyzed: age, sex, nicotine dependence (Fagerström test), daily cigarette consumption, number of pack-years, pharmacological treatment (nicotine replacement/bupropion), use of nicotine gum (yes/no), weight gain, body mass index, and degree of state and trait anxiety." | 3.74 | [Weight gain and anxiety levels in recent ex-smokers]. ( Beamonte, A; Gargallo, P; Jiménez-Muro, A; Marqueta, A; Nerín, I, 2007) |
| " Self-reported smoking status, urine cotinine levels determined by gas chromatography (GC) and by enzyme immunoassay testing (EMIT), and breath carbon monoxide (CO) levels were assessed at 28 weeks antepartum and 12 and 24 weeks postpartum in 131 women enrolled in studies on smoking cessation and relapse prevention." | 3.74 | Biochemical verification of smoking status in pregnant and recently postpartum women. ( Badger, GJ; Bernstein, IM; Heil, SH; Higgins, ST; McHale, L; Mongeon, JA; Solomon, LJ, 2007) |
| "Exhaled carbon monoxide (CO(Exh)) measurement is used to confirm smoking status in smoking cessation programs, but the cut-off level is still a matter for discussion." | 3.74 | Exhaled carbon monoxide as a marker for evaluating smoking abstinence in a Brazilian population sample. ( Cavalet-Blanco, D; Chatkin, G; Chatkin, J; de Abreu, C; Fritscher, C; Fritscher, L; Wagner, M, 2007) |
| " A carbon monoxide longitudinal data set in a smoking cessation study is used for illustration." | 3.73 | Assessing missing data assumptions in longitudinal studies: an example using a smoking cessation trial. ( Shoptaw, S; Yang, X, 2005) |
| "A multicenter, prospective, longitudinal study was carried out on patients over 18 years of age from 5 smoking cessation clinics who underwent treatment with nicotine or bupropion." | 3.73 | [Veracity of smokers' reports of abstinence at smoking cessation clinics]. ( Barrueco, M; Jiménez Ruiz, C; Palomo, L; Riesco, JA; Romero, P; Torrecilla, M, 2005) |
| ", cotinine, CPD, carbon monoxide [CO], nicotine content, and nicotine dependence) with respect to race, gender, and menthol content in a sample of 307 smokers recruited from the greater Boston area to participate in a smoking cessation treatment trial." | 3.73 | The influence of gender, race, and menthol content on tobacco exposure measures. ( Garvey, AJ; Hoskinson, RA; Mustonen, TK; Sachs, DP; Spencer, SM, 2005) |
| "To determine the effectiveness of bupropion treatment for smoking cessation in a general practice setting, measuring continuous abstinence from smoking, from 8 weeks to 52 weeks." | 3.73 | Pragmatic, observational study of bupropion treatment for smoking cessation in general practice. ( Evans, A; Gibson, J; Henderson, M; Wilkes, S, 2005) |
| "Three hundred thirty-one consecutive outpatients (161 with asthma and 170 with COPD) were examined cross-sectionally by self-reported smoking status, breath CO monitoring, and serum cotinine concentration." | 3.72 | Optimal cutoff level of breath carbon monoxide for assessing smoking status in patients with asthma and COPD. ( Hajiro, T; Koyama, H; Mishima, M; Nishimura, K; Oga, T; Sato, S; Tsukino, M, 2003) |
| "To assess use of free nicotine patches by Indigenous people when offered a brief intervention for smoking cessation, and to assess changes in smoking behaviour at six months." | 3.72 | A study of the use of free nicotine patches by Indigenous people. ( Bailie, RS; Burns, CB; D'Abbs, PH; Farrington, M; Ivers, RG; Richmond, RL; Tipiloura, E, 2003) |
| " Two chemical markers, cotinine in plasma and carbon monoxide (CO) in expired air, validated self-reports concerning smoking cessation." | 3.71 | Are patients truthful about their smoking habits? A validation of self-report about smoking cessation with biochemical markers of smoking activity amongst patients with ischaemic heart disease. ( Berndt, AK; From Attebring, M; Herlitz, J; Hjalmarson, A; Karlsson, T, 2001) |
| "In this study was evaluated the relationship between self-reported smoking rate and expired air carbon monoxide in 208 smokers who had attended a behavioral program for smoking cessation." | 3.70 | Self-reported smoking and measurement of expired air carbon monoxide in a clinical treatment. ( Becoña, E; Vázquez, FL, 1998) |
| "This is an exploratory study of compliance to nicotine chewing gum in a multicomponent group smoking cessation program where usage was optional." | 3.68 | Compliance to nicotine gum recommendations in a multicomponent group smoking cessation program: an exploratory study. ( McEntee, M; Millard, RW; Waranch, HR, 1992) |
| "Varenicline for 12 weeks was not more effective than placebo to achieve abstinence among daily waterpipe smokers." | 3.30 | Varenicline Treatment for Waterpipe Smoking Cessation. ( Chami, HA; Makki, M; Shaya, M; Talih, F; Tamim, H; Zaouk, N, 2023) |
| "Our finding suggests that withdrawal symptoms can occur in never-smokers who stop e-cigarettes abruptly." | 2.94 | Withdrawal Symptoms From E-Cigarette Abstinence Among Adult Never-Smokers: A Pilot Experimental Study. ( Callas, PW; Etter, JF; Hughes, JR; Morley, N; Oga, E; Peasley-Miklus, C; Peters, EN, 2020) |
| "Smokers with chronic obstructive pulmonary disease (COPD) have particular difficulty quitting." | 2.87 | Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease: A Randomized Clinical Trial. ( Ellerbeck, EF; Fitzgerald, SA; Hutcheson, TD; Nollen, N; Phadnis, M; Richter, KP; Salzman, GA; Sharpe, MR; Vacek, J, 2018) |
| "To identify the predictors of success in a randomised controlled trial comparing varenicline alone or in combination with nicotine replacement therapy (NRT)." | 2.84 | Predictors of treatment success in smoking cessation with varenicline combined with nicotine replacement therapy v. varenicline alone. ( Esterhuizen, TM; Irusen, EM; Koegelenberg, CFN; Noor, F, 2017) |
| "menthol cigarettes was 2." | 2.82 | Effect of menthol on nicotine reduction: Pooled results from two double-blind randomized controlled trials. ( Foulds, J; Hayes, JE; Hobkirk, AL; Horn, K; Krebs, NM; Liao, J; Lin, W; Muscat, JE; Richie, JP; Zhu, J, 2022) |
| " All smoked ad libitum during weeks 1 (baseline) and 3 (washout) and began fenofibrate (160 mg/d; dosing approved for lipid control) or placebo near the end of weeks 1 and 3." | 2.82 | Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence. ( Chengappa, KN; Conklin, CA; Fromuth, M; Hope, C; Karelitz, JL; Lerman, C; Michael, VC; Perkins, KA, 2016) |
| " Outcomes included adverse events (AEs), vital signs, exhaled carbon monoxide (CO), clinical laboratory parameters, smoking urges and withdrawal symptoms." | 2.82 | A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part B: Safety and subjective effects. ( Martin, C; Savioz, R; Sharma, G; Walele, T; Williams, J, 2016) |
| "Smoking cessation was verified by expired carbon monoxide at the end of the program." | 2.82 | A Community-Based Participatory Research on Smoking Cessation Intervention for Urban Communities. ( Bleich, L; Buccheri, J; Gunning, M; Schutzman, C; Sheikhattari, P; Wagner, FA, 2016) |
| "Smokers with substance use disorders have very low smoking cessation rates so identifying predictors of smoking treatment response is particularly important for these difficult-to-treat smokers." | 2.80 | Intolerance for withdrawal discomfort and motivation predict voucher-based smoking treatment outcomes for smokers with substance use disorders. ( Colby, SM; Kahler, CW; Martin, RA; Rohsenow, DJ; Sirota, AD; Tidey, JW, 2015) |
| "The mean birth weight was 3140 g (SD 600 g) in the incentives group and 3120 (SD 590) g in the control group (P=0." | 2.80 | Financial incentives for smoking cessation in pregnancy: randomised controlled trial. ( Bauld, L; Boyd, K; Coleman, T; de Caestecker, L; Friel, B; MacAskill, S; McConnachie, A; McKell, J; Purves, D; Radley, A; Sinclair, L; Tannahill, C; Tappin, D, 2015) |
| "Carbon monoxide levels were tested in a sample of those declaring tobacco smoking abstinence." | 2.80 | Electronic Cigarettes Efficacy and Safety at 12 Months: Cohort Study. ( Boccia, S; Capasso, L; Cicolini, G; D'Amario, C; Fiore, M; Flacco, ME; Gualano, MR; La Vecchia, C; Liguori, G; Manzoli, L; Marzuillo, C; Ricciardi, W; Siliquini, R; Villari, P, 2015) |
| "Individuals with substance use disorders (SUDs) experience increased smoking-related morbidity and mortality but severely compromised smoking treatment benefits." | 2.79 | Smoking reductions and increased self-efficacy in a randomized controlled trial of smoking abstinence-contingent incentives in residential substance abuse treatment patients. ( Alessi, SM; Petry, NM, 2014) |
| " Two different nicotine replacement therapy dosing regiments were administered according to the baseline salivary cotinine level." | 2.78 | A randomized clinical trial of trans-dermal nicotine replacement in pregnant African-American smokers. ( El-Mohandes, AA; Gantz, MG; Kiely, M; Perry, DC; Tan, S; Windsor, R, 2013) |
| "Smoking cessation is widely recommended for secondary stroke prevention." | 2.77 | Smoking cessation intervention after ischemic stroke or transient ischemic attack. A randomized controlled pilot trial. ( Bak, S; Brunner Frandsen, N; Henriksen, RM; Hyldahl, TK; Sørensen, M, 2012) |
| "However, caution is warranted, because nicotine dependence appears to be the primary predictor of smoking intensity among young adult smokers in this study." | 2.75 | Exposure to movie smoking, antismoking ads and smoking intensity: an experimental study with a factorial design. ( Engels, RC; Harakeh, Z; Sargent, J; van Baaren, RB; Vohs, K, 2010) |
| "Regardless of quit phase, most withdrawal symptoms were associated with an increased risk of relapse at 14 and 30 days post quit date." | 2.75 | Severity of withdrawal symptomatology in follicular versus luteal quitters: The combined effects of menstrual phase and withdrawal on smoking cessation outcome. ( Allen, AM; Allen, SS; Lunos, S; Pomerleau, CS, 2010) |
| "SJW did not attenuate withdrawal symptoms among abstinent subjects." | 2.75 | A randomized clinical trial of St. John's wort for smoking cessation. ( Bauer, B; Croghan, IT; Ebbert, JO; Prasad, K; Schroeder, DR; Sood, A, 2010) |
| "Nicotine nasal spray has been 1 of the most successful forms of nicotine-replacement therapy in adult populations." | 2.73 | A randomized trial of nicotine nasal spray in adolescent smokers. ( Auerback, GM; Benowitz, NL; Moscicki, AB; Rubinstein, ML, 2008) |
| "Stopping smoking in pregnancy is a public health priority and a clinical imperative." | 2.72 | A randomised-controlled pilot study using nicotine patches with pregnant women. ( Atkinson, ER; Gilbert, AL; Hotham, ED, 2006) |
| "The nicotine inhaler was significantly superior to placebo in achieving reduction in daily cigarette consumption by at least 50% after 4 months, compared with baseline (18% vs." | 2.72 | Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. ( Danielsson, T; Daughton, DM; Franzon, M; Glover, ED; Glover, PN; Landfeldt, B; Leischow, S; Muramoto, M; Rennard, SI; Westin, A, 2006) |
| "Nicotine was administered using programmed presentations of either pulsed injections or continuous infusions, with i." | 2.71 | Pharmacologic and sensorimotor components of satiation in cigarette smoking. ( Bates, JE; Behm, FM; Rose, JE; Salley, A; Westman, EC, 2003) |
| "Nicotine withdrawal symptoms such as craving, irritability, tension, frustration, anxiety and restlessness were significantly increased in both patch conditions after 48 h of smoking abstinence." | 2.70 | Nicotine patches and the subjective effects of cigarette smoking: a pilot study. ( Busto, UE; Cárdenas, L; Corrigall, WA; MacDonald, A, 2002) |
| "Issues about the measurement of nicotine dependence and withdrawal are highlighted." | 2.70 | Assessing the impact of a nurse-led health education intervention for people with peripheral vascular disease who smoke: the use of physiological markers, nicotine dependence and withdrawal. ( Galvin, K; Hillier, V; Webb, C, 2001) |
| "Smoking cessation is a key intervention for prevention of several lung diseases." | 2.69 | Smoking cessation with four nicotine replacement regimes in a lung clinic. ( Mikkelsen, KL; Tønnesen, P, 2000) |
| "The ineffectiveness of CES to reduce withdrawal symptoms and facilitate smoking cessation are similar to results of other clinical studies of CES in drug dependence, although positive effects of CES in animal studies have been reported." | 2.68 | Evaluation of cranial electrostimulation therapy on short-term smoking cessation. ( Butschky, MF; Fant, RV; Goffman, AL; Henningfield, JE; Pickworth, WB, 1997) |
| "Sensitivity and specificity were calculated by comparing a biochemical measure with self-report to produce an undifferentiated estimate of error." | 2.67 | Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group. ( Connett, JE; Lauger, GG; Murray, RP; Voelker, HT, 1993) |
| "Although smoking cessation is currently the only guaranteed way to reduce the harm caused by tobacco smoking, a reasonable secondary tobacco control approach may be to try and reduce the harm from continued tobacco use amongst smokers unable or unwilling to quit." | 2.53 | Interventions to reduce harm from continued tobacco use. ( Begh, R; Fanshawe, TR; Farley, A; Hartmann-Boyce, J; Lancaster, T; Lindson-Hawley, N, 2016) |
| "Smoking during pregnancy is known to contribute to numerous poor birth outcomes, such as low birth weight, preterm birth as well as life-long health and developmental problems." | 2.50 | The pathophysiology of smoking during pregnancy: a systems biology approach. ( Bailey, B; Khraisha, N; Stone, WL, 2014) |
| "Mentholation has little effect on other smoke constituents, and no apparent effect on nicotine absorption, airway patency and smoking initiation, dependency or cessation." | 2.44 | Possible effects on smokers of cigarette mentholation: a review of the evidence relating to key research questions. ( Coggins, CR; Lee, PN; Werley, MS, 2007) |
| "Smoking cessation is an important factor in the primary and secondary prevention of cardiac events." | 2.43 | Smoking cessation in patients with coronary artery disease. ( Eisenberg, MJ; Ludvig, J; Miner, B, 2005) |
| "One of the eight used CO alone and CO + Genetic Susceptibility as two different intervention groups, giving rise to three possible comparisons." | 2.43 | Biomedical risk assessment as an aid for smoking cessation. ( Bize, R; Burnand, B; Cornuz, J; Mueller, Y, 2005) |
| "Smoking cessation was achieved by varenicline plus individual counselling." | 1.56 | Effectiveness of smoking cessation in smokers with COPD and nocturnal oxygen desaturation: Functional analysis. ( Carico, E; Pezzuto, A, 2020) |
| "Out of the 155 COPD patients with nicotine dependence (female/male = 39/116; mean age, 67." | 1.56 | Outcomes and predictive factors for successful smoking cessation therapy in COPD patients with nicotine dependence. ( Hashimoto, R; Tomioka, H; Wada, T; Yoshizumi, Y, 2020) |
| " This study aimed to characterize the nicotine pharmacokinetic profile of Spectrum cigarettes." | 1.56 | Pharmacokinetic Profile of Spectrum Reduced Nicotine Cigarettes. ( Branstetter, SA; Foulds, J; Kamens, HM; Miller, CN; Muscat, JE; Nye, RT; Richie, JP; Silva, CP; Singh, N; Sipko, J; Sun, D; Trushin, N, 2020) |
| "Patients with AECOPD were also stratified according to sputum bacteria." | 1.43 | Assessment of exhaled carbon monoxide in exacerbations of chronic obstructive pulmonary disease. ( Antus, B; Barta, I; Drozdovszky, O, 2016) |
| "The percentage of smoking cessation is better in SSCP, although a high smoking cessation rate was obtained in PCP (active search)." | 1.43 | [Use of COPD-6 Vitalograph in Primary Care as tool for smoking cessation]. ( Antón-García, F; Correcher-Salvador, E; Pruteanu, DF, 2016) |
| "Tobacco dependence has been defined as a chronic relapsing disease." | 1.43 | Reasons for failure to quit: a cross-sectional survey of tobacco use in major cities in Pakistan. ( Awan, S; Haque, AS; Irfan, M; Khan, JA; Samani, ZA; Shahzad, H, 2016) |
| "Readiness for smoking cessation is an important predictor of quit attempts and cessation success." | 1.42 | Readiness for smoking cessation in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. ( De Backer, G; De Bacquer, D; Empana, JP; Fras, Z; Heidrich, J; Jennings, C; Keil, U; Kotseva, K; Périer, MC; Prugger, C; Reiner, Ž; Wellmann, J; Wood, D, 2015) |
| "Leptin has been linked to tobacco craving and withdrawal-related symptoms." | 1.42 | Changes in circulating leptin levels during the initial stage of cessation are associated with smoking relapse. ( al'Absi, M; Allen, S; Hatsukami, DK; Lemieux, A; Nakajima, M, 2015) |
| "Smoking cessation is possible for individuals with schizophrenia but the relapse rate is high." | 1.39 | Counseling and exercise intervention for smoking reduction in patients with schizophrenia: a feasibility study. ( Bernard, PP; Carayol, MS; Dandonneau, L; Esseul, EC; Ninot, GJ; Raymond, L; Xambo, JJ, 2013) |
| "Smoking outcomes among lung and head and neck cancer patients appear to have remained the same over the last two decades despite the availability of an increased number of pharmacotherapy options to treat tobacco dependence." | 1.38 | Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer. ( Bueno, R; Catalano, P; Cooley, ME; Emmons, KM; Haddad, RI; Johnson, BE; Wang, Q, 2012) |
| "Emphysema has been diagnosed at 22 women (11-50% active smokers, 3-13." | 1.35 | Comparison assessment methods of smoking consequences use in primary care. ( Kałucka, S, 2009) |
| "All subjects received periodontal treatment and smoking cessation advice as part of an individual, patient-based programme provided by dental hygienists trained in smoking cessation counselling." | 1.33 | Smoking cessation advice for patients with chronic periodontitis. ( Heasman, L; Heasman, PA; Nasry, HA; Preshaw, PM; Stacey, F; Swan, M, 2006) |
| "Withdrawal symptoms were measured daily, and smoking behavior was assessed on the first and last day of each condition." | 1.33 | Clinical laboratory evaluation of potential reduced exposure products for smokers. ( Breland, AB; Eissenberg, T; Kleykamp, BA, 2006) |
| "Abstinence produced significant withdrawal symptoms in all participants and reduced cotinine and carbon monoxide levels." | 1.32 | Prospective examination of effects of smoking abstinence on cortisol and withdrawal symptoms as predictors of early smoking relapse. ( al'Absi, M; Davis, GL; Hatsukami, D; Wittmers, LE, 2004) |
| "To study nicotine dependence (ND) basing on special questionnaires and measurement of CO concentrations in the exhaled air." | 1.32 | [Complex assessment of nicotine dependence using questionnaires and measurement of carbon oxide concentration in exhaled air]. ( Brimkulov, NN; Cholurova, RA; Vinnikov, DV, 2004) |
| "The nicotine content was not related to urinary cotinine (rs =-0,10NS)." | 1.32 | [Usefulness of biological markers in the evaluation of smoking at the first visit of a smoking cessation program]. ( Favreau, M; Ingrand, P; Meurice, JC; Mura, P; Underner, M, 2004) |
| "The nicotine patch dose was positively correlated (p < 0." | 1.30 | Usefulness of markers in managing tobacco withdrawal. ( Brahimi, N; Callais, F; Labrousse, F; Lequang, NT; Momas, I; Roche, D; Roussel, G, 1997) |
| " Results for Experiment 2 showed very little effect of acute nicotine dosing on the overall responding and varying effects on the responding during the interval following unavoidable point losses." | 1.28 | Human avoidance responding with added point loss: effects of tobacco and abstinence. ( Bennett, RH; Cherek, DR, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.23) | 18.7374 |
| 1990's | 63 (14.32) | 18.2507 |
| 2000's | 146 (33.18) | 29.6817 |
| 2010's | 190 (43.18) | 24.3611 |
| 2020's | 40 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, TB | 6 |
| Piper, ME | 4 |
| Smith, SS | 6 |
| Bolt, DM | 2 |
| Stein, JH | 2 |
| Fiore, MC | 5 |
| Houston, TK | 1 |
| Chen, J | 1 |
| Amante, DJ | 1 |
| Blok, AC | 1 |
| Nagawa, CS | 1 |
| Wijesundara, JG | 1 |
| Kamberi, A | 1 |
| Allison, JJ | 1 |
| Person, SD | 1 |
| Flahive, J | 1 |
| Morley, J | 1 |
| Conigliaro, J | 1 |
| Mattocks, KM | 1 |
| Garber, L | 1 |
| Sadasivam, RS | 1 |
| Pratt, SI | 1 |
| Ferron, JC | 2 |
| Brunette, MF | 2 |
| Santos, M | 1 |
| Sargent, J | 2 |
| Xie, H | 1 |
| Webb, J | 1 |
| Peerbux, S | 1 |
| Ang, A | 1 |
| Siddiqui, S | 1 |
| Sherwani, Y | 1 |
| Ahmed, M | 1 |
| MacRae, H | 1 |
| Puri, H | 1 |
| Majeed, A | 1 |
| Glasner, S | 1 |
| Chami, HA | 1 |
| Zaouk, N | 1 |
| Makki, M | 1 |
| Tamim, H | 1 |
| Shaya, M | 1 |
| Talih, F | 1 |
| Lin, W | 1 |
| Hobkirk, AL | 1 |
| Zhu, J | 2 |
| Krebs, NM | 2 |
| Hayes, JE | 1 |
| Richie, JP | 3 |
| Liao, J | 2 |
| Horn, K | 1 |
| Foulds, J | 6 |
| Muscat, JE | 3 |
| Marler, JD | 1 |
| Fujii, CA | 1 |
| Utley, MT | 1 |
| Balbierz, DJ | 1 |
| Galanko, JA | 1 |
| Utley, DS | 1 |
| Umeda, A | 3 |
| Miyagawa, K | 3 |
| Mochida, A | 3 |
| Takeda, H | 3 |
| Ohira, Y | 3 |
| Kato, T | 3 |
| Okada, Y | 3 |
| Kotani, K | 3 |
| Taylor, AH | 2 |
| Thompson, TP | 1 |
| Streeter, A | 1 |
| Chynoweth, J | 1 |
| Snowsill, T | 1 |
| Ingram, W | 1 |
| Ussher, M | 3 |
| Aveyard, P | 4 |
| Murray, RL | 2 |
| Harris, T | 1 |
| Green, C | 1 |
| Horrell, J | 1 |
| Callaghan, L | 1 |
| Greaves, CJ | 1 |
| Price, L | 1 |
| Cartwright, L | 1 |
| Wilks, J | 1 |
| Campbell, S | 1 |
| Preece, D | 1 |
| Creanor, S | 1 |
| Sanford, BT | 1 |
| Toll, BA | 2 |
| Fucito, LM | 1 |
| Baker, NL | 1 |
| Krishnan-Sarin, S | 5 |
| Carpenter, MJ | 2 |
| Bernstein, SL | 1 |
| Rojewski, AM | 1 |
| Xie, L | 1 |
| Xiao, L | 1 |
| Tonkin, S | 1 |
| Kezbers, KM | 1 |
| Noble, B | 1 |
| Cropsey, K | 1 |
| Kendzor, DE | 2 |
| Oliver, J | 1 |
| Businelle, M | 1 |
| Prell, C | 1 |
| Hébert-Losier, A | 1 |
| Filion, KB | 1 |
| Reynier, P | 1 |
| Eisenberg, MJ | 2 |
| Chang, YC | 1 |
| Huang, WH | 1 |
| Tsai, CY | 1 |
| Hwang, LC | 1 |
| Hughes, JR | 6 |
| Peters, EN | 2 |
| Callas, PW | 3 |
| Peasley-Miklus, C | 2 |
| Oga, E | 2 |
| Etter, JF | 2 |
| Morley, N | 2 |
| Benowitz, NL | 7 |
| Bernert, JT | 1 |
| Hecht, SS | 8 |
| Jacob, P | 3 |
| Jarvis, MJ | 2 |
| Joseph, A | 1 |
| Oncken, C | 1 |
| Pezzuto, A | 3 |
| Carico, E | 1 |
| Beatrice, F | 2 |
| Massaro, G | 2 |
| Matuszewski, PE | 2 |
| Comadoll, SM | 1 |
| Costales, T | 1 |
| Zerhusen, T | 1 |
| Coale, M | 1 |
| OʼToole, RV | 1 |
| Li, WHC | 1 |
| Ho, KY | 1 |
| Wang, MP | 3 |
| Cheung, DYT | 1 |
| Lam, KKW | 1 |
| Xia, W | 1 |
| Cheung, KY | 1 |
| Wong, CKH | 1 |
| Chan, SSC | 1 |
| Lam, TH | 3 |
| Hatsukami, DK | 8 |
| Meier, E | 3 |
| Lindgren, BR | 3 |
| Anderson, A | 2 |
| Reisinger, SA | 2 |
| Norton, KJ | 2 |
| Strayer, L | 2 |
| Jensen, JA | 3 |
| Dick, L | 2 |
| Murphy, SE | 6 |
| Carmella, SG | 6 |
| Tang, MK | 3 |
| Chen, M | 3 |
| O'connor, RJ | 3 |
| Shields, PG | 2 |
| Hashimoto, R | 1 |
| Tomioka, H | 2 |
| Wada, T | 2 |
| Yoshizumi, Y | 2 |
| Gryaznov, D | 1 |
| Chammartin, F | 1 |
| Stoeckle, M | 1 |
| Anagnostopoulos, A | 1 |
| Braun, DL | 1 |
| Furrer, H | 1 |
| Boillat-Blanco, N | 1 |
| Bernasconi, E | 1 |
| Schmid, P | 1 |
| Nordmann, A | 1 |
| Bucher, HC | 1 |
| González-Roz, A | 2 |
| MacKillop, J | 1 |
| Tuck, BM | 1 |
| Karelitz, JL | 6 |
| Tomko, RL | 2 |
| Dahne, J | 1 |
| Cato, P | 1 |
| McClure, EA | 3 |
| Seijo-Bestilleiro, R | 2 |
| Seoane-Pillado, T | 2 |
| Pertega-Diaz, S | 2 |
| González-Martín, C | 2 |
| Valdes-Cañedo, F | 2 |
| Balboa-Barreiro, V | 1 |
| Fernandez-Rivera, C | 2 |
| Alonso-Hernandez, A | 2 |
| Cao-Vilariño, M | 1 |
| Gil-Guillen, V | 1 |
| Garcia-Rodriguez, MT | 1 |
| Raffetto, M | 1 |
| Joseph, K | 1 |
| O'Toole, RV | 1 |
| Valencia, S | 1 |
| Callinan, L | 1 |
| Shic, F | 1 |
| Smith, M | 1 |
| Vijayaraghavan, M | 1 |
| Elser, H | 1 |
| Frazer, K | 1 |
| Lindson, N | 1 |
| Apollonio, D | 1 |
| Luk, TT | 2 |
| Wu, Y | 1 |
| Li, WH | 2 |
| Cheung, DY | 1 |
| Kwong, AC | 1 |
| Lai, V | 1 |
| Chan, SS | 1 |
| Tatekawa, S | 1 |
| Shimamoto, S | 1 |
| Miyata, Y | 1 |
| Yoshino, Y | 1 |
| Hirata, T | 1 |
| Tamari, K | 1 |
| Seo, Y | 1 |
| Isohashi, F | 1 |
| Yamamoto, Y | 1 |
| Uno, A | 1 |
| Inohara, H | 1 |
| Ogawa, K | 1 |
| Rüther, T | 1 |
| Kahnert, K | 1 |
| Mader, M | 1 |
| Rabenstein, A | 1 |
| Falkai, P | 1 |
| Fischer, E | 1 |
| Pogarell, O | 1 |
| Jörres, RA | 1 |
| Wolford-Clevenger, C | 1 |
| Pacek, LR | 1 |
| Cropsey, KL | 2 |
| Das, D | 1 |
| Menon, I | 1 |
| Gupta, R | 1 |
| Sharma, A | 1 |
| Ahsan, I | 1 |
| Ashraf, A | 1 |
| Bloom, EL | 2 |
| Japuntich, SJ | 1 |
| Pierro, A | 1 |
| Dallery, J | 12 |
| Leahey, TM | 1 |
| Rosen, J | 1 |
| Leung, WC | 1 |
| Leung, KY | 1 |
| Cheung, KW | 1 |
| Kwa, C | 1 |
| Siong, KH | 1 |
| Tang, KK | 1 |
| Lee, KW | 1 |
| Hsieh, CJ | 1 |
| Wu, YS | 1 |
| Minami, H | 1 |
| Nahvi, S | 1 |
| Arnsten, JH | 1 |
| Brinkman, HR | 1 |
| Rivera-Mindt, M | 1 |
| Wetter, DW | 2 |
| Price, LH | 1 |
| Richman, EK | 1 |
| Betzler, TF | 1 |
| Stockmal, C | 1 |
| Donnelly, R | 1 |
| McClain, LM | 1 |
| Kennedy, KA | 1 |
| Vieira, C | 1 |
| Fine, M | 1 |
| McCarthy, DE | 1 |
| Thomas, JG | 1 |
| Hecht, J | 1 |
| Brown, RA | 1 |
| Slaich, B | 1 |
| Claire, R | 2 |
| Emery, J | 1 |
| Lewis, S | 2 |
| Cooper, S | 3 |
| Thomson, R | 1 |
| Phillips, L | 1 |
| Kinahan-Goodwin, D | 1 |
| Naughton, F | 3 |
| McDaid, L | 1 |
| Clark, M | 1 |
| Dickinson, A | 1 |
| Coleman, T | 8 |
| Balwicki, L | 1 |
| Smith, DM | 1 |
| Pierucka, M | 1 |
| Goniewicz, ML | 3 |
| Zarzeczna-Baran, M | 1 |
| Jedrzejczyk, T | 1 |
| Strahl, M | 1 |
| Zdrojewski, T | 1 |
| Ikonomidis, I | 1 |
| Marinou, M | 1 |
| Vlastos, D | 1 |
| Kourea, K | 1 |
| Andreadou, I | 1 |
| Liarakos, N | 1 |
| Triantafyllidi, H | 1 |
| Pavlidis, G | 1 |
| Tsougos, E | 1 |
| Parissis, J | 1 |
| Lekakis, J | 1 |
| Antus, B | 1 |
| Drozdovszky, O | 1 |
| Barta, I | 1 |
| Wang, HL | 1 |
| Wang, PC | 1 |
| Wu, YW | 1 |
| Shyu, KG | 1 |
| Shie, HG | 1 |
| Pan, SW | 1 |
| Yu, WK | 1 |
| Chen, WC | 1 |
| Ho, LI | 1 |
| Ko, HK | 1 |
| Kong, G | 1 |
| Goldberg, AL | 1 |
| Goldstein, AO | 1 |
| Gans, SP | 1 |
| Ripley-Moffitt, C | 1 |
| Kotsen, C | 1 |
| Bars, M | 1 |
| Noor, F | 2 |
| Koegelenberg, CFN | 1 |
| Esterhuizen, TM | 2 |
| Irusen, EM | 2 |
| Beckham, JC | 1 |
| Adkisson, KA | 1 |
| Hertzberg, J | 1 |
| Kimbrel, NA | 1 |
| Budney, AJ | 1 |
| Stephens, RS | 1 |
| Moore, SD | 1 |
| Calhoun, PS | 1 |
| Rohsenow, DJ | 6 |
| Tidey, JW | 9 |
| Martin, RA | 3 |
| Colby, SM | 6 |
| Eissenberg, T | 7 |
| Cassidy, RN | 2 |
| Jackson, KM | 2 |
| Tevyaw, TOL | 1 |
| Barnett, NP | 1 |
| Monti, PM | 2 |
| Miller, ME | 2 |
| Herbeć, A | 1 |
| Perski, O | 1 |
| Shahab, L | 4 |
| West, R | 10 |
| De Jesus, S | 1 |
| Prapavessis, H | 1 |
| Treiber, FA | 1 |
| Gray, KM | 1 |
| Cioe, PA | 1 |
| Hatsukami, D | 5 |
| Murphy, CM | 1 |
| LaRowe, LR | 1 |
| Kosiba, JD | 1 |
| Zale, EL | 1 |
| Ditre, JW | 2 |
| Krishnan, N | 1 |
| Elf, JL | 1 |
| Chon, S | 1 |
| Golub, JE | 1 |
| Luo, X | 1 |
| al'Absi, M | 5 |
| Allen, SS | 2 |
| Cinciripini, PM | 1 |
| Denlinger-Apte, R | 1 |
| Drobes, DJ | 2 |
| Koopmeiners, JS | 1 |
| Lane, T | 1 |
| Le, CT | 2 |
| Leischow, S | 2 |
| Luo, K | 1 |
| McClernon, FJ | 2 |
| Paiano, V | 1 |
| Robinson, JD | 1 |
| Severson, H | 1 |
| Sipe, C | 1 |
| Strasser, AA | 3 |
| Strayer, LG | 1 |
| Vandrey, R | 1 |
| Donny, EC | 2 |
| Czoli, CD | 1 |
| Fong, GT | 1 |
| Hammond, D | 1 |
| Fallin-Bennett, A | 1 |
| Barnett, J | 1 |
| Ducas, L | 1 |
| Wiggins, AT | 1 |
| McCubbin, A | 1 |
| Ashford, K | 1 |
| Hernández Zenteno, RJ | 1 |
| Lara, DF | 1 |
| Venegas, AR | 1 |
| Sansores, RH | 2 |
| Pineda, JR | 1 |
| Trujillo, FF | 1 |
| Pérez Padilla, JR | 1 |
| Matera, MG | 1 |
| Cazzola, M | 1 |
| Harvanko, A | 1 |
| Slone, S | 1 |
| Shelton, B | 1 |
| Fields, S | 1 |
| Reynolds, B | 2 |
| Nides, M | 1 |
| Danielsson, T | 3 |
| Saunders, F | 1 |
| Perfekt, R | 2 |
| Kapikian, R | 1 |
| Solla, J | 1 |
| Leischow, SJ | 2 |
| Myers, A | 1 |
| Coughlin, LN | 1 |
| Tegge, AN | 1 |
| Sheffer, CE | 1 |
| Bickel, WK | 1 |
| Bowden, C | 1 |
| Ellerbeck, EF | 1 |
| Nollen, N | 1 |
| Hutcheson, TD | 1 |
| Phadnis, M | 1 |
| Fitzgerald, SA | 1 |
| Vacek, J | 1 |
| Sharpe, MR | 1 |
| Salzman, GA | 1 |
| Richter, KP | 1 |
| Yamazoe, M | 1 |
| Nishio, C | 1 |
| Ishimoto, G | 1 |
| Muhammad Aidil, ZA | 1 |
| Hayati, K | 1 |
| Rosliza, AM | 1 |
| Glatard, A | 1 |
| Guidi, M | 1 |
| Dobrinas, M | 1 |
| Cornuz, J | 6 |
| Csajka, C | 1 |
| Eap, CB | 1 |
| Kamens, HM | 1 |
| Silva, CP | 1 |
| Nye, RT | 1 |
| Miller, CN | 1 |
| Singh, N | 1 |
| Sipko, J | 1 |
| Trushin, N | 1 |
| Sun, D | 1 |
| Branstetter, SA | 1 |
| Clair, C | 1 |
| Mueller, Y | 4 |
| Livingstone-Banks, J | 1 |
| Burnand, B | 4 |
| Camain, JY | 2 |
| Rège-Walther, M | 2 |
| Selby, K | 1 |
| Bize, R | 5 |
| De La Garza, R | 1 |
| Shuman, SL | 1 |
| Yammine, L | 1 |
| Yoon, JH | 1 |
| Salas, R | 1 |
| Holst, M | 1 |
| Leonardi-Bee, J | 3 |
| Berlin, I | 1 |
| Sarramea Crespo, F | 1 |
| Jaén-Moreno, MJ | 1 |
| Gutiérrez-Rojas, L | 1 |
| Balanzá-Martínez, V | 1 |
| García-Alvarez, L | 1 |
| Saiz Martínez, PA | 1 |
| Garcia-Portilla, MP | 1 |
| Guler, I | 1 |
| Bobes, J | 1 |
| Thorley, R | 1 |
| Britton, J | 1 |
| Nyakutsikwa, B | 1 |
| Opazo Breton, M | 1 |
| Lewis, SA | 1 |
| Tadzimirwa, GY | 1 |
| Day, C | 1 |
| Esmail, A | 1 |
| Cooper, C | 1 |
| Kamkuemah, M | 1 |
| Dheda, K | 1 |
| Van Zyl-Smit, RN | 2 |
| Jensen, J | 2 |
| Yang, J | 1 |
| Stepanov, I | 2 |
| Nosen, E | 1 |
| Woody, SR | 1 |
| Piñeiro, B | 1 |
| Fernández Del Río, E | 2 |
| López-Durán, A | 2 |
| Martínez, U | 2 |
| Becoña, E | 6 |
| Kralikova, E | 2 |
| Kmetova, A | 1 |
| Stepankova, L | 1 |
| Zvolska, K | 1 |
| Davis, R | 1 |
| Thomas, D | 1 |
| Abramson, MJ | 1 |
| Bonevski, B | 1 |
| Taylor, S | 1 |
| Poole, S | 1 |
| Weeks, GR | 1 |
| Dooley, MJ | 1 |
| George, J | 1 |
| Drake, RE | 1 |
| Devitt, TS | 1 |
| Geiger, PT | 1 |
| McHugo, GJ | 1 |
| Jonikas, JA | 1 |
| Cook, JA | 1 |
| Perkins, KA | 8 |
| Lerman, C | 5 |
| Jao, NC | 2 |
| Chengappa, KN | 2 |
| Sparks, GM | 1 |
| Brose, LS | 2 |
| Tombor, I | 1 |
| Stein, MD | 1 |
| Caviness, CM | 1 |
| Kurth, ME | 1 |
| Audet, D | 1 |
| Olson, J | 1 |
| Anderson, BJ | 1 |
| Selby, P | 1 |
| Andriash, K | 1 |
| Zawertailo, L | 1 |
| Persad, D | 1 |
| Zack, M | 1 |
| Busto, UE | 2 |
| Bullen, C | 2 |
| Howe, C | 1 |
| Laugesen, M | 1 |
| McRobbie, H | 4 |
| Parag, V | 1 |
| Williman, J | 1 |
| Walker, N | 1 |
| Kong, JH | 1 |
| Ha, Y | 1 |
| Raiff, BR | 4 |
| Grabinski, MJ | 3 |
| Spoto, C | 1 |
| Vincenzi, B | 1 |
| Tonini, G | 2 |
| Chen, CC | 1 |
| Chang, CH | 1 |
| Tsai, YC | 1 |
| Tseng, CW | 1 |
| Tu, ML | 1 |
| Wang, CC | 1 |
| Lin, MC | 1 |
| Liu, SF | 1 |
| Capron, DW | 1 |
| Allan, NP | 1 |
| Norr, AM | 1 |
| Zvolensky, MJ | 2 |
| Schmidt, NB | 1 |
| Daniels, MJ | 1 |
| Wang, C | 1 |
| Marcus, BH | 1 |
| Shah, SB | 1 |
| Chestnutt, IG | 1 |
| Lewis, MA | 1 |
| Ponciano-Rodriguez, G | 1 |
| Paez-Martinez, N | 1 |
| Villa-Romero, A | 1 |
| Gutierrez-Grobe, Y | 1 |
| Mendez-Sanchez, N | 1 |
| Ledgerwood, DM | 2 |
| Arfken, CL | 1 |
| Petry, NM | 3 |
| Alessi, SM | 3 |
| Romanowich, P | 4 |
| Lamb, RJ | 8 |
| Rodrigues, FM | 1 |
| Ramos, D | 2 |
| Xavier, RF | 2 |
| Ito, JT | 1 |
| Souza, AP | 1 |
| Fernandes, RA | 1 |
| Cecchini, R | 1 |
| Rossi e Silva, RC | 1 |
| Macchione, M | 1 |
| Toledo-Arruda, AC | 1 |
| Guarnier, FA | 1 |
| Ramos, EM | 2 |
| Trent, LR | 1 |
| Clark, CB | 1 |
| Stevens, EN | 1 |
| Lahti, AC | 1 |
| Hendricks, PS | 3 |
| Stone, WL | 1 |
| Bailey, B | 1 |
| Khraisha, N | 1 |
| Maci, E | 1 |
| Comito, F | 1 |
| Frezza, AM | 1 |
| Paek, YJ | 1 |
| Lee, S | 1 |
| Kim, YH | 2 |
| Lee, KS | 1 |
| Yim, HW | 1 |
| Kim, MS | 1 |
| Kim, CH | 1 |
| Jeung, O | 1 |
| Koegelenberg, CF | 1 |
| Bateman, ED | 1 |
| Bruning, A | 1 |
| O'Brien, JA | 1 |
| Smith, C | 1 |
| Abdool-Gaffar, MS | 1 |
| Emanuel, S | 1 |
| Bloom, AJ | 1 |
| Hartz, SM | 1 |
| Chen, LS | 1 |
| Fox, L | 1 |
| Martinez, M | 1 |
| Johnson, EO | 1 |
| Laurie, CC | 1 |
| Saccone, NL | 1 |
| Goate, A | 1 |
| Bierut, LJ | 1 |
| Shuter, J | 1 |
| Morales, DA | 1 |
| Considine-Dunn, SE | 1 |
| An, LC | 1 |
| Stanton, CA | 1 |
| Lemieux, A | 2 |
| Nakajima, M | 2 |
| Johnson, MW | 1 |
| Garcia-Romeu, A | 1 |
| Cosimano, MP | 1 |
| Griffiths, RR | 2 |
| Rosa, EF | 3 |
| Corraini, P | 3 |
| Inoue, G | 3 |
| Gomes, EF | 3 |
| Guglielmetti, MR | 2 |
| Sanda, SR | 1 |
| Lotufo, JP | 3 |
| Romito, GA | 2 |
| Pannuti, CM | 3 |
| Grant, A | 1 |
| Ashton, K | 1 |
| Phillips, R | 1 |
| Kish, DH | 1 |
| Reitzel, LR | 1 |
| Okamoto, H | 1 |
| Businelle, MS | 1 |
| Prugger, C | 1 |
| Wellmann, J | 1 |
| Heidrich, J | 1 |
| De Bacquer, D | 1 |
| De Backer, G | 1 |
| Périer, MC | 1 |
| Empana, JP | 1 |
| Reiner, Ž | 1 |
| Fras, Z | 1 |
| Jennings, C | 1 |
| Kotseva, K | 1 |
| Wood, D | 1 |
| Keil, U | 1 |
| Kahler, CW | 2 |
| Sirota, AD | 1 |
| Al-Sheyab, N | 1 |
| Kheirallah, KA | 1 |
| Mangnall, LJ | 1 |
| Gallagher, R | 1 |
| Tappin, D | 1 |
| Bauld, L | 3 |
| Purves, D | 1 |
| Boyd, K | 1 |
| Sinclair, L | 1 |
| MacAskill, S | 1 |
| McKell, J | 1 |
| Friel, B | 1 |
| McConnachie, A | 1 |
| de Caestecker, L | 1 |
| Tannahill, C | 1 |
| Radley, A | 1 |
| Tackett, AP | 1 |
| Lechner, WV | 1 |
| Grant, DM | 1 |
| Driskill, LM | 1 |
| Tahirkheli, NN | 1 |
| Wagener, TL | 1 |
| Klemperer, EM | 1 |
| Schoberberger, R | 1 |
| Böhm, G | 1 |
| Schroeder, Y | 1 |
| Antón-García, F | 1 |
| Pruteanu, DF | 1 |
| Correcher-Salvador, E | 1 |
| Davis, JM | 1 |
| Manley, AR | 1 |
| Goldberg, SB | 1 |
| Stankevitz, KA | 1 |
| Wee, LH | 2 |
| Mariapun, J | 1 |
| Chan, CM | 1 |
| Bulgiba, A | 2 |
| Peramalah, D | 1 |
| Jit, S | 1 |
| Michael, VC | 2 |
| Fromuth, M | 1 |
| Conklin, CA | 1 |
| Hope, C | 1 |
| Veldheer, S | 2 |
| Hrabovsky, S | 2 |
| Yingst, J | 2 |
| Sciamanna, C | 1 |
| Chen, G | 1 |
| Maccani, JZ | 1 |
| Berg, A | 1 |
| Manzoli, L | 1 |
| Flacco, ME | 1 |
| Fiore, M | 1 |
| La Vecchia, C | 1 |
| Marzuillo, C | 1 |
| Gualano, MR | 1 |
| Liguori, G | 1 |
| Cicolini, G | 1 |
| Capasso, L | 1 |
| D'Amario, C | 1 |
| Boccia, S | 1 |
| Siliquini, R | 1 |
| Ricciardi, W | 1 |
| Villari, P | 1 |
| Gonzálvez, MT | 1 |
| Espada, JP | 1 |
| Orgilés, M | 1 |
| Soto, D | 1 |
| Sussman, S | 1 |
| Allen, S | 1 |
| Pacifici, R | 1 |
| Pichini, S | 1 |
| Graziano, S | 1 |
| Pellegrini, M | 1 |
| Nardone, N | 1 |
| Dains, KM | 1 |
| Hall, SM | 1 |
| Stewart, S | 1 |
| Dempsey, D | 1 |
| Secades-Villa, R | 1 |
| Vallejo-Seco, G | 1 |
| García-Rodríguez, O | 1 |
| López-Núñez, C | 1 |
| Weidberg, S | 1 |
| Harris, M | 1 |
| Slone, SA | 1 |
| Shelton, BJ | 1 |
| Stoops, W | 1 |
| Lewis, R | 1 |
| Chandrashekar, M | 1 |
| Sattar, FA | 1 |
| Bondade, S | 1 |
| Kumar, KK | 1 |
| Phillips, A | 1 |
| Smith, KM | 1 |
| Knight-West, O | 1 |
| Przulj, D | 1 |
| Hajek, P | 3 |
| Sigmon, SC | 1 |
| Meyer, AC | 1 |
| Saulsgiver, K | 1 |
| Badger, GJ | 3 |
| Heil, SH | 4 |
| Higgins, ST | 5 |
| Walele, T | 1 |
| Sharma, G | 1 |
| Savioz, R | 1 |
| Martin, C | 2 |
| Williams, J | 1 |
| Fraser, DL | 1 |
| Hatzigeorgiadis, A | 1 |
| Pappa, V | 1 |
| Tsiami, A | 1 |
| Tzatzaki, T | 1 |
| Georgakouli, K | 1 |
| Zourbanos, N | 1 |
| Goudas, M | 1 |
| Chatzisarantis, N | 1 |
| Theodorakis, Y | 1 |
| McPherson, S | 1 |
| Howell, D | 1 |
| Lewis, J | 1 |
| Barbosa-Leiker, C | 1 |
| Bertotti Metoyer, P | 1 |
| Roll, J | 1 |
| Brath, H | 1 |
| Grabovac, I | 1 |
| Schalk, H | 1 |
| Degen, O | 1 |
| Dorner, TE | 2 |
| Lindson-Hawley, N | 2 |
| Shinkins, B | 1 |
| Michie, S | 1 |
| Riaz, M | 1 |
| Pita-Fernández, S | 1 |
| Cao-López, M | 1 |
| López-Calviño, B | 1 |
| Irfan, M | 1 |
| Haque, AS | 1 |
| Shahzad, H | 1 |
| Samani, ZA | 1 |
| Awan, S | 1 |
| Khan, JA | 1 |
| Syrjänen, K | 1 |
| Salminen, J | 1 |
| Aresvuo, U | 1 |
| Hendolin, P | 1 |
| Paloheimo, L | 1 |
| Eklund, C | 1 |
| Salaspuro, M | 1 |
| Suovaniemi, O | 1 |
| Campbell, KA | 2 |
| Fahy, SJ | 1 |
| Bowker, K | 1 |
| McEwen, A | 3 |
| Whitemore, R | 1 |
| Dautzenberg, B | 1 |
| Garelik, D | 1 |
| Campagna, D | 1 |
| Cibella, F | 1 |
| Caponnetto, P | 2 |
| Amaradio, MD | 1 |
| Caruso, M | 1 |
| Morjaria, JB | 1 |
| Malerba, M | 1 |
| Polosa, R | 2 |
| Riddle, PJ | 1 |
| Newman-Norlund, RD | 1 |
| Baer, J | 1 |
| Thrasher, JF | 1 |
| Utiyama, DM | 1 |
| Yoshida, CT | 1 |
| Goto, DM | 1 |
| de Santana Carvalho, T | 1 |
| de Paula Santos, U | 1 |
| Koczulla, AR | 1 |
| Saldiva, PH | 1 |
| Nakagawa, NK | 1 |
| Iwaoka, M | 1 |
| Tsuji, T | 2 |
| Rash, CJ | 1 |
| Hartmann-Boyce, J | 1 |
| Fanshawe, TR | 1 |
| Begh, R | 1 |
| Farley, A | 1 |
| Lancaster, T | 2 |
| Takano, RK | 1 |
| Ferreira, VL | 1 |
| Souza, ET | 1 |
| Bowker, KA | 1 |
| Sloan, M | 1 |
| Wagner, FA | 1 |
| Sheikhattari, P | 1 |
| Buccheri, J | 1 |
| Gunning, M | 1 |
| Bleich, L | 1 |
| Schutzman, C | 1 |
| Hiscock, R | 1 |
| Dobbie, F | 1 |
| Kim, SJ | 1 |
| Marsch, LA | 1 |
| Stitzer, M | 1 |
| Boldry, M | 1 |
| Allen, SI | 1 |
| Pachas, GN | 1 |
| Cather, C | 2 |
| Azzouz, N | 1 |
| Hameed, A | 1 |
| Hammett, E | 1 |
| Modesto, J | 1 |
| Richie, J | 1 |
| Evins, AE | 2 |
| Bell, R | 1 |
| Glinianaia, SV | 1 |
| Waal, ZV | 1 |
| Close, A | 1 |
| Moloney, E | 1 |
| Jones, S | 1 |
| Araújo-Soares, V | 1 |
| Hamilton, S | 2 |
| Milne, EM | 1 |
| Shucksmith, J | 1 |
| Vale, L | 1 |
| Willmore, M | 1 |
| White, M | 1 |
| Rushton, S | 1 |
| Jarvis, BP | 1 |
| Irons, JG | 1 |
| Correia, CJ | 2 |
| Kelly, DL | 1 |
| McMahon, RP | 1 |
| Weiner, E | 1 |
| Boggs, DL | 1 |
| Dickinson, D | 1 |
| Conley, RR | 1 |
| Buchanan, RW | 2 |
| Guay, A | 1 |
| Chelland Campbell, S | 1 |
| Moffatt, RJ | 1 |
| Stamford, BA | 1 |
| Kaplan, GB | 2 |
| Swift, RM | 2 |
| Adolfo, AB | 1 |
| Míguez, MC | 2 |
| Jatlow, P | 2 |
| Leary, V | 1 |
| O'Malley, SS | 2 |
| McGowan, A | 1 |
| Barnett, D | 1 |
| Nsofor, M | 1 |
| Proudfoot, J | 1 |
| Tappin, DM | 1 |
| Rubinstein, ML | 1 |
| Auerback, GM | 1 |
| Moscicki, AB | 1 |
| Killen, JD | 2 |
| Fortmann, SP | 2 |
| Schatzberg, AF | 2 |
| Arredondo, C | 1 |
| Murphy, G | 1 |
| Hayward, C | 2 |
| Celio, M | 1 |
| Cromp, D | 1 |
| Fong, D | 2 |
| Pandurangi, M | 1 |
| Schepis, TS | 1 |
| Duhig, AM | 1 |
| Liss, T | 1 |
| McFetridge, A | 1 |
| Wu, R | 1 |
| Cavallo, DA | 1 |
| Dahl, T | 1 |
| Glasgow, RE | 2 |
| Gaglio, B | 2 |
| Estabrooks, PA | 2 |
| Marcus, AC | 1 |
| Ritzwoller, DP | 1 |
| Smith, TL | 2 |
| Levinson, AH | 1 |
| Sukhanova, A | 1 |
| O'Donnell, C | 1 |
| Ferro, EF | 1 |
| France, EK | 1 |
| Hering, T | 1 |
| Kunze, M | 1 |
| Groman, E | 7 |
| Riemerth, A | 2 |
| Steiner-Ringl, A | 1 |
| Veitsmeier, I | 1 |
| Kroat, A | 1 |
| Kroat, U | 1 |
| Bernhard, G | 2 |
| Kunze, U | 2 |
| Briski, J | 1 |
| Fonte, C | 2 |
| Scott, J | 1 |
| McClure, JB | 2 |
| Ludman, E | 1 |
| Grothaus, L | 2 |
| Pabiniak, C | 2 |
| Richards, J | 2 |
| Mohelnitzky, A | 1 |
| Rège Walther, M | 1 |
| Jones, M | 1 |
| Sun, HQ | 1 |
| Guo, S | 1 |
| Chen, DF | 1 |
| Jiang, ZN | 1 |
| Liu, Y | 1 |
| Di, XL | 1 |
| Yang, FD | 1 |
| Zhang, XY | 1 |
| Kosten, TR | 1 |
| Lu, L | 1 |
| Khazaal, Y | 1 |
| Zullino, DF | 1 |
| Ludman, EJ | 1 |
| Mintz, J | 1 |
| Collins, SE | 1 |
| Eck, S | 1 |
| Torchalla, I | 1 |
| Schröter, M | 1 |
| Batra, A | 3 |
| Stoops, WW | 1 |
| Fields, NM | 1 |
| Nuzzo, PA | 2 |
| Schoenberg, NE | 1 |
| Martin, CA | 1 |
| Casey, B | 1 |
| Wong, CJ | 1 |
| Braillon, A | 1 |
| Robillart, H | 1 |
| Delcroix, M | 2 |
| Gomez, C | 1 |
| Delmas-Lanta, S | 1 |
| Dubois, G | 1 |
| Shiffman, S | 2 |
| Pierce, JP | 1 |
| Marshall, EC | 1 |
| Johnson, K | 1 |
| Bergman, J | 1 |
| Gibson, LE | 1 |
| Yeh, ML | 1 |
| Chang, CY | 1 |
| Chu, NF | 1 |
| Chen, HH | 1 |
| Bailey, SR | 1 |
| Goedeker, KC | 1 |
| Tiffany, ST | 2 |
| Weinberger, AH | 1 |
| Reutenauer, EL | 1 |
| Jatlow, PI | 1 |
| Potenza, MN | 1 |
| George, TP | 1 |
| Kozak, JT | 1 |
| Rasmussen, T | 4 |
| Gustavsson, G | 1 |
| Le Houezec, J | 1 |
| Ho, MK | 1 |
| Faseru, B | 1 |
| Choi, WS | 1 |
| Nollen, NL | 1 |
| Mayo, MS | 1 |
| Thomas, JL | 1 |
| Okuyemi, KS | 1 |
| Ahluwalia, JS | 2 |
| Tyndale, RF | 1 |
| Tang, KZ | 1 |
| Sanborn, PM | 1 |
| Zhou, JY | 1 |
| Kozlowski, LT | 2 |
| Leventhal, AM | 1 |
| Gwaltney, CJ | 1 |
| Kamarck, TW | 1 |
| Fraser, T | 1 |
| Whittaker, R | 1 |
| Barlow, D | 1 |
| Schnoll, RA | 1 |
| Martinez, E | 1 |
| Tatum, KL | 1 |
| Glass, M | 1 |
| Bernath, A | 1 |
| Ferris, D | 1 |
| Reynolds, P | 1 |
| Harakeh, Z | 1 |
| Engels, RC | 1 |
| Vohs, K | 1 |
| van Baaren, RB | 1 |
| Blank, MD | 1 |
| Allen, AM | 1 |
| Lunos, S | 1 |
| Pomerleau, CS | 1 |
| Fritz, M | 1 |
| Wallner, R | 1 |
| Grohs, U | 1 |
| Kemmler, G | 1 |
| Saria, A | 1 |
| Zernig, G | 1 |
| Kałucka, S | 1 |
| Geimer, N | 1 |
| Olson, CE | 1 |
| Baumgarten, D | 1 |
| Kepner, JL | 1 |
| Mahoney, MC | 1 |
| Sejourne, C | 1 |
| Parot-Schinckel, E | 1 |
| Rouquette, A | 1 |
| Pare, F | 1 |
| Fanello, S | 1 |
| Karatay, G | 1 |
| Kublay, G | 1 |
| Emiroğlu, ON | 1 |
| Martinet, Y | 2 |
| Wirth, N | 2 |
| Faix, C | 1 |
| Turturici, M | 1 |
| Kollins, SH | 1 |
| Van Voorhees, EE | 1 |
| Sood, A | 2 |
| Ebbert, JO | 2 |
| Prasad, K | 2 |
| Croghan, IT | 8 |
| Bauer, B | 1 |
| Schroeder, DR | 4 |
| Murphy, GM | 1 |
| Lowenthal, K | 1 |
| Bryson, SW | 1 |
| Killen, DT | 1 |
| Sen, S | 1 |
| Peltz, C | 1 |
| Beard, J | 1 |
| Zeno, B | 1 |
| Willi, C | 1 |
| Chiolero, A | 1 |
| Stoianov, R | 1 |
| Payot, S | 1 |
| Locatelli, I | 1 |
| Morse, EF | 1 |
| Smith, T | 1 |
| Edwards, A | 1 |
| Gonzales, D | 1 |
| Jorenby, DE | 4 |
| Brandon, TH | 2 |
| Arteaga, C | 1 |
| Lee, TC | 1 |
| Kotlyar, M | 1 |
| Hertsgaard, LA | 1 |
| Mann-Wrobel, MC | 1 |
| Bennett, ME | 1 |
| Weiner, EE | 1 |
| Ball, MP | 1 |
| Stapleton, JA | 3 |
| Sutherland, G | 3 |
| Martinasek, MP | 1 |
| McDermott, RJ | 1 |
| Martini, L | 1 |
| McNeill, A | 1 |
| Meredith, SE | 1 |
| Reid, N | 1 |
| de Carvalho, VF | 1 |
| De Micheli, G | 1 |
| Luijten, M | 1 |
| Littel, M | 1 |
| Franken, IH | 1 |
| De Toledo, AC | 1 |
| Fosco, LC | 1 |
| Vieira, RP | 1 |
| Jardim, JR | 1 |
| Cabezas, C | 1 |
| Advani, M | 1 |
| Puente, D | 1 |
| Rodriguez-Blanco, T | 1 |
| Gaalema, DE | 1 |
| Bradstreet, MP | 1 |
| Bernstein, IM | 2 |
| Lee, DC | 1 |
| Zimmerman, E | 1 |
| Robbins, G | 1 |
| Kelly, TH | 1 |
| Frei, M | 1 |
| Engel Brügger, O | 1 |
| Sendi, P | 1 |
| Reichart, PA | 1 |
| Ramseier, CA | 1 |
| Bornstein, MM | 1 |
| Brewer, JA | 1 |
| Mallik, S | 1 |
| Babuscio, TA | 1 |
| Nich, C | 1 |
| Johnson, HE | 1 |
| Deleone, CM | 1 |
| Minnix-Cotton, CA | 1 |
| Byrne, SA | 1 |
| Kober, H | 1 |
| Weinstein, AJ | 1 |
| Carroll, KM | 1 |
| Rounsaville, BJ | 1 |
| Freeman, TP | 1 |
| Morgan, CJ | 1 |
| Beesley, T | 1 |
| Curran, HV | 1 |
| Tröstl, A | 1 |
| Womastek, I | 1 |
| Wilcox, CS | 1 |
| Noble, EP | 1 |
| Oskooilar, N | 1 |
| Cooley, ME | 1 |
| Wang, Q | 1 |
| Johnson, BE | 1 |
| Catalano, P | 1 |
| Haddad, RI | 1 |
| Bueno, R | 1 |
| Emmons, KM | 2 |
| Carpagnano, GE | 1 |
| Lacedonia, D | 1 |
| Palladino, GP | 1 |
| Foschino Barbaro, MP | 1 |
| Brunner Frandsen, N | 1 |
| Sørensen, M | 1 |
| Hyldahl, TK | 1 |
| Henriksen, RM | 1 |
| Bak, S | 1 |
| Przewoźniak, K | 1 |
| Lobaszewski, J | 1 |
| Cedzyńska, M | 1 |
| Wojtyła, A | 1 |
| Paprzycki, P | 1 |
| Mańczuk, M | 1 |
| Zatoński, WA | 1 |
| Kotz, D | 1 |
| Williams, JM | 1 |
| Gandhi, KK | 1 |
| Lu, SE | 1 |
| Steinberg, ML | 1 |
| Tønnesen, P | 6 |
| Lauri, H | 1 |
| Mann, K | 1 |
| Leung, L | 1 |
| Neufeld, T | 1 |
| Marin, S | 1 |
| Ripoll, J | 1 |
| Girauta, H | 1 |
| Ramos, M | 1 |
| Medina-Bombardó, D | 1 |
| Pastor, A | 1 |
| Alvarez-Ossorio, C | 1 |
| Gorreto, L | 1 |
| Esteva, M | 1 |
| García, E | 1 |
| Uréndez, A | 1 |
| Buades, A | 1 |
| Torres, E | 1 |
| Whelton, H | 1 |
| Kingston, R | 1 |
| O'Mullane, D | 1 |
| Nilsson, F | 4 |
| Tuten, M | 1 |
| Fitzsimons, H | 1 |
| Chisolm, MS | 1 |
| Jones, HE | 1 |
| Cabriales, JA | 1 |
| Cooper, TV | 1 |
| Salgado-Garcia, F | 1 |
| Naylor, N | 1 |
| Gonzalez, E | 1 |
| El-Mohandes, AA | 1 |
| Windsor, R | 1 |
| Tan, S | 1 |
| Perry, DC | 1 |
| Gantz, MG | 1 |
| Kiely, M | 1 |
| Ward, KD | 2 |
| Asfar, T | 1 |
| Al Ali, R | 1 |
| Rastam, S | 1 |
| Weg, MW | 1 |
| Maziak, W | 1 |
| Ehlers, SL | 1 |
| Shi, Y | 1 |
| Ehlers, S | 1 |
| Hinds, R | 1 |
| Baumgartner, A | 1 |
| Warner, DO | 2 |
| Hackshaw, L | 1 |
| Ferguson, J | 1 |
| Taylor, G | 1 |
| Salway, R | 1 |
| Pai, A | 1 |
| Prasad, S | 1 |
| Bernard, PP | 1 |
| Esseul, EC | 1 |
| Raymond, L | 1 |
| Dandonneau, L | 1 |
| Xambo, JJ | 1 |
| Carayol, MS | 1 |
| Ninot, GJ | 1 |
| Auditore, R | 1 |
| Russo, C | 1 |
| Cappello, GC | 1 |
| Derlon, V | 1 |
| Martinet, PY | 1 |
| McNelis, U | 1 |
| Minary, L | 1 |
| Boileau, S | 1 |
| Bouaziz, H | 1 |
| Hand, S | 1 |
| Edwards, S | 1 |
| Campbell, IA | 1 |
| Cannings, R | 1 |
| Murray, RP | 3 |
| Connett, JE | 3 |
| Istvan, JA | 1 |
| Nides, MA | 2 |
| Rempel-Rossum, S | 1 |
| Myles, PS | 2 |
| Iacono, GA | 1 |
| Hunt, JO | 1 |
| Fletcher, H | 1 |
| Morris, J | 1 |
| McIlroy, D | 1 |
| Fritschi, L | 2 |
| Lagrue, G | 1 |
| Mautrait, C | 1 |
| Cormier, S | 1 |
| Dupont, P | 1 |
| Teneggi, V | 1 |
| Squassante, L | 1 |
| Milleri, S | 1 |
| Ziviani, L | 1 |
| Bye, A | 1 |
| Breland, AB | 2 |
| Evans, SE | 1 |
| Buchhalter, AR | 1 |
| Rand, CS | 1 |
| Pan, W | 1 |
| Anthonisen, NR | 1 |
| Mogg, K | 1 |
| Bradley, BP | 1 |
| Jiménez Ruiz, CA | 2 |
| Barrueco Ferrero, M | 2 |
| Solano Reina, S | 1 |
| Torrecilla García, M | 2 |
| Domínguez Grandal, F | 1 |
| Díaz-Maroto Muñoz, JL | 1 |
| Alonso Moreno, J | 1 |
| La Cruz Amorós Ed, Ed | 1 |
| Abengozar Muela, R | 1 |
| Rea, J | 1 |
| Williams, D | 1 |
| Cárdenas, L | 1 |
| MacDonald, A | 1 |
| Corrigall, WA | 1 |
| Holmes, HW | 1 |
| Bohadana, A | 1 |
| Hald, J | 1 |
| Overgaard, J | 1 |
| Grau, C | 1 |
| Clemente Jiménez, ML | 1 |
| Pérez-Trullén, A | 1 |
| Rubio Aranda, E | 1 |
| Marrón Tundidor, R | 1 |
| Herrero Labarga, I | 1 |
| Rose, JE | 4 |
| Behm, FM | 4 |
| Westman, EC | 3 |
| Bates, JE | 1 |
| Salley, A | 1 |
| Sato, S | 1 |
| Nishimura, K | 1 |
| Koyama, H | 1 |
| Tsukino, M | 1 |
| Oga, T | 1 |
| Hajiro, T | 1 |
| Mishima, M | 1 |
| Ivers, RG | 1 |
| Farrington, M | 1 |
| Burns, CB | 1 |
| Bailie, RS | 1 |
| D'Abbs, PH | 1 |
| Richmond, RL | 3 |
| Tipiloura, E | 1 |
| Orain-Pelissolo, S | 1 |
| Grillon, C | 1 |
| Perez-Diaz, F | 1 |
| Jouvent, R | 1 |
| Chou, KR | 1 |
| Chen, R | 1 |
| Lee, JF | 1 |
| Ku, CH | 1 |
| Lu, RB | 1 |
| Lee, EM | 1 |
| Malson, JL | 1 |
| Moolchan, ET | 3 |
| Pickworth, WB | 6 |
| Morozumi, T | 2 |
| Kubota, T | 2 |
| Sato, T | 1 |
| Okuda, K | 1 |
| Yoshie, H | 2 |
| Davis, GL | 2 |
| Wittmers, LE | 1 |
| Kirby, KC | 3 |
| Morral, AR | 3 |
| Galbicka, G | 3 |
| Iguchi, MY | 2 |
| Brimkulov, NN | 1 |
| Vinnikov, DV | 1 |
| Cholurova, RA | 1 |
| Lemmonds, C | 1 |
| Zhang, Y | 2 |
| Le, C | 2 |
| Haustein, KO | 1 |
| Krause, J | 1 |
| Haustein, H | 1 |
| Cort, N | 1 |
| Stevens, KR | 1 |
| Muñoz, LR | 1 |
| Acosta, M | 1 |
| Buchhalter, A | 1 |
| Breland, A | 1 |
| Hamilton, D | 1 |
| Leslie, K | 1 |
| Angliss, M | 1 |
| Mezzavia, P | 1 |
| Lee, L | 1 |
| Patterson, F | 1 |
| Underner, M | 1 |
| Ingrand, P | 1 |
| Favreau, M | 1 |
| Mura, P | 1 |
| Meurice, JC | 1 |
| Sugita, N | 1 |
| Itagaki, M | 1 |
| García-Vera, MP | 1 |
| Jackson, AA | 1 |
| Manan, WA | 1 |
| Gani, AS | 1 |
| Eldridge, S | 1 |
| Carter, YH | 1 |
| Ong, KC | 1 |
| Cheong, GN | 1 |
| Prabhakaran, L | 1 |
| Earnest, A | 1 |
| Wood, T | 1 |
| Wewers, ME | 3 |
| Groner, J | 1 |
| Ahijevych, K | 2 |
| Yang, X | 1 |
| Shoptaw, S | 1 |
| Barrueco, M | 1 |
| Jiménez Ruiz, C | 1 |
| Palomo, L | 1 |
| Torrecilla, M | 1 |
| Romero, P | 1 |
| Riesco, JA | 1 |
| Amodei, N | 1 |
| Zimmerman, D | 2 |
| Sehnert, SS | 1 |
| Huestis, MA | 1 |
| Epstein, DH | 1 |
| Keely, JP | 1 |
| Robles, E | 1 |
| Crone, CC | 1 |
| Whiteside-Mansell, L | 1 |
| Conners, NA | 1 |
| Bokony, PA | 1 |
| Worley, LL | 1 |
| McMillan, DE | 2 |
| Pisinger, C | 1 |
| Hvidberg, S | 1 |
| Wennike, P | 1 |
| Bremann, L | 1 |
| Westin, A | 4 |
| Thomsen, C | 1 |
| Katomeri, M | 1 |
| Eid, NC | 1 |
| Fant, RV | 4 |
| Wiseman, EJ | 1 |
| Williams, DK | 1 |
| Payne, TJ | 1 |
| Smith, PO | 1 |
| Adams, SG | 1 |
| Diefenbach, L | 1 |
| Hotham, ED | 1 |
| Gilbert, AL | 1 |
| Atkinson, ER | 1 |
| Ludvig, J | 1 |
| Miner, B | 1 |
| Mustonen, TK | 1 |
| Spencer, SM | 1 |
| Hoskinson, RA | 1 |
| Sachs, DP | 1 |
| Garvey, AJ | 2 |
| Alfonso, HS | 1 |
| de Klerk, NH | 1 |
| Olsen, N | 1 |
| Sleith, J | 1 |
| Musk, AB | 1 |
| Huang, CL | 1 |
| Wilkes, S | 1 |
| Evans, A | 1 |
| Henderson, M | 1 |
| Gibson, J | 1 |
| Klingler, K | 1 |
| Landfeldt, B | 2 |
| Friederich, HM | 1 |
| Hung, J | 1 |
| Lin, CH | 1 |
| Wang, JD | 1 |
| Chan, CC | 1 |
| Nasry, HA | 1 |
| Preshaw, PM | 1 |
| Stacey, F | 1 |
| Heasman, L | 1 |
| Swan, M | 1 |
| Heasman, PA | 1 |
| Whetzel, CA | 2 |
| Corwin, EJ | 1 |
| Klein, LC | 1 |
| Giovino, GA | 1 |
| Pauly, J | 1 |
| Cummings, KM | 1 |
| Benson, TA | 1 |
| van Biljon, X | 1 |
| Rennard, SI | 1 |
| Glover, ED | 1 |
| Daughton, DM | 1 |
| Glover, PN | 1 |
| Muramoto, M | 1 |
| Franzon, M | 1 |
| Sitkauskiene, B | 1 |
| Stravinskaite, K | 1 |
| Sakalauskas, R | 1 |
| Dicpinigaitis, PV | 1 |
| Werley, MS | 1 |
| Coggins, CR | 1 |
| Lee, PN | 1 |
| Tanaka, N | 1 |
| Minomi, Y | 1 |
| O'Connell, KA | 2 |
| Hosein, VL | 1 |
| Schwartz, JE | 1 |
| Kleykamp, BA | 1 |
| Nerín, I | 1 |
| Beamonte, A | 1 |
| Gargallo, P | 1 |
| Jiménez-Muro, A | 1 |
| Marqueta, A | 1 |
| Mooney, M | 1 |
| Murphy, S | 2 |
| LeSage, M | 1 |
| Babb, D | 1 |
| Hecht, S | 1 |
| Mongeon, JA | 1 |
| Solomon, LJ | 1 |
| McHale, L | 1 |
| Chatkin, J | 1 |
| Fritscher, L | 1 |
| de Abreu, C | 1 |
| Cavalet-Blanco, D | 1 |
| Chatkin, G | 1 |
| Wagner, M | 1 |
| Fritscher, C | 1 |
| Nagai, A | 1 |
| Hernández Mezquita, MA | 1 |
| Morales Sánchez, A | 1 |
| Alonso Díaz, A | 1 |
| Plaza Martín, D | 1 |
| Glenn, IM | 1 |
| Javors, MA | 1 |
| Iguchi, M | 1 |
| Culhane, MA | 1 |
| Birnbaum, A | 1 |
| Horowitz, J | 1 |
| Hsieh, E | 1 |
| Freudenreich, O | 1 |
| Henderson, DC | 1 |
| Schoenfeld, DA | 1 |
| Rigotti, NA | 1 |
| Goff, DC | 1 |
| Domier, CP | 1 |
| Monterosso, JR | 1 |
| Brody, AL | 1 |
| Simon, SL | 1 |
| Mendrek, A | 1 |
| Olmstead, R | 1 |
| Jarvik, ME | 3 |
| Cohen, MS | 1 |
| London, ED | 1 |
| Stead, LF | 1 |
| Daniel, JZ | 1 |
| Cropley, M | 1 |
| Fife-Schaw, C | 1 |
| Kim, TS | 1 |
| Kim, DJ | 1 |
| Lee, H | 1 |
| Kim, YK | 1 |
| Halvorsen, B | 1 |
| Lund Sagen, E | 1 |
| Ueland, T | 1 |
| Aukrust, P | 1 |
| Tonstad, S | 1 |
| Colligan, RC | 1 |
| Hurt, RD | 7 |
| Mendoza-Baumgart, MI | 1 |
| Tulunay, OE | 1 |
| Seo, NS | 1 |
| Kang, HY | 1 |
| Sharp, L | 1 |
| Johansson, H | 1 |
| Fagerström, K | 1 |
| Rutqvist, LE | 1 |
| Joseph, AM | 1 |
| Lando, H | 1 |
| Gross, M | 1 |
| Bliss, R | 1 |
| Offord, KP | 5 |
| Hays, JT | 2 |
| Lewis, SF | 1 |
| Uematsu, T | 1 |
| Mizuno, A | 1 |
| Nagashima, S | 1 |
| Oshima, A | 1 |
| Nakamura, M | 1 |
| Crowley, TJ | 2 |
| Macdonald, MJ | 2 |
| Walter, MI | 1 |
| Gross, TM | 1 |
| Rosenblatt, MR | 3 |
| Harris, K | 1 |
| de Almeida Neto, A | 1 |
| Levin, ED | 3 |
| Stein, RM | 2 |
| Ripka, GV | 1 |
| Hudzinski, LG | 1 |
| Sirois, PA | 1 |
| Carnahan, E | 1 |
| Sanchez, M | 1 |
| Herman, S | 1 |
| Bliss, RE | 1 |
| Vokonas, PS | 1 |
| Brutsche, M | 1 |
| Frey, JG | 1 |
| Tschopp, JM | 1 |
| Kenford, SL | 2 |
| Wetter, D | 1 |
| Dale, LC | 1 |
| Fredrickson, PA | 1 |
| Caldwell, CC | 1 |
| Lee, GA | 1 |
| Lauger, GG | 2 |
| Marŭsić, Z | 1 |
| Neese, LW | 1 |
| Lundberg, TG | 1 |
| Gilbert, DD | 1 |
| Voelker, HT | 1 |
| Schur, C | 1 |
| Tashkin, DP | 1 |
| Bendayan, R | 1 |
| Kennedy, G | 1 |
| Frecker, RC | 1 |
| Sellers, EM | 1 |
| Nørregaard, J | 3 |
| Mikkelsen, K | 1 |
| Jørgensen, S | 2 |
| Russell, MA | 2 |
| Feyerabend, C | 2 |
| Hartmann, KE | 1 |
| Thorp, JM | 1 |
| Pahel-Short, L | 1 |
| Koch, MA | 1 |
| García, MP | 1 |
| Stitzer, ML | 3 |
| Mikkelsen, KL | 2 |
| Iversen, E | 1 |
| Sørensen, T | 1 |
| Søeberg, B | 1 |
| Jakobsen, HB | 1 |
| Gold, K | 1 |
| Audrain, J | 1 |
| Lin, TH | 1 |
| Boyd, NR | 1 |
| Orleans, CT | 1 |
| Wilfond, B | 1 |
| Louben, G | 1 |
| Caporaso, N | 1 |
| Kottke, TE | 1 |
| Butschky, MF | 1 |
| Goffman, AL | 1 |
| Henningfield, JE | 3 |
| Valente, SN | 1 |
| Hill, AL | 1 |
| Otte, PS | 1 |
| Aickin, M | 1 |
| Holden, T | 1 |
| Kligman, E | 1 |
| Cook, G | 1 |
| Grobe, J | 1 |
| Akrawi, W | 1 |
| Benumof, JL | 1 |
| Roussel, G | 1 |
| Roche, D | 1 |
| Momas, I | 1 |
| Brahimi, N | 1 |
| Callais, F | 1 |
| Lequang, NT | 1 |
| Labrousse, F | 1 |
| Newton, TF | 1 |
| Cook, IA | 1 |
| Holschneider, DP | 1 |
| Lindholm, JE | 1 |
| Jarvik, MM | 1 |
| Fagerström, KO | 3 |
| Tejding, R | 1 |
| Lunell, E | 1 |
| Spiga, R | 1 |
| Schmitz, J | 1 |
| Day, J | 1 |
| Mitchell, SL | 1 |
| Jones, RL | 1 |
| Nguyen, A | 1 |
| Man, SF | 1 |
| Nelson, RA | 2 |
| Fulcher, SM | 1 |
| Koman, LA | 1 |
| Smith, BP | 1 |
| Holden, M | 1 |
| Vázquez, FL | 1 |
| Gerkovich, MM | 1 |
| Cook, MR | 1 |
| Hickcox, M | 1 |
| Kakolewski, KE | 1 |
| Zevin, S | 1 |
| Olmstead, RE | 1 |
| Iwamoto-Schaap, PN | 1 |
| Blauensteiner, D | 1 |
| Hansen, HH | 1 |
| Vammen, B | 1 |
| Jensen, MK | 1 |
| Woehlck, HJ | 1 |
| Connolly, LA | 1 |
| Cinquegrani, MP | 1 |
| Dunning, MB | 1 |
| Hoffmann, RG | 1 |
| Wolter, TD | 4 |
| Davidson, M | 1 |
| O'Neill, SC | 1 |
| Croghan, GA | 3 |
| Beede, SD | 1 |
| Patten, CA | 1 |
| Morgan, MJ | 1 |
| Davies, GM | 1 |
| Willner, P | 1 |
| Fowler, G | 1 |
| Snively, TA | 1 |
| Ahijevych, KL | 1 |
| Bernhard, LA | 1 |
| Hughes, EG | 1 |
| Lamont, DA | 1 |
| Beecroft, ML | 1 |
| Wilson, DM | 1 |
| Brennan, BG | 1 |
| Rice, SC | 1 |
| Corby, EA | 1 |
| Roll, JM | 1 |
| Schuster, CR | 1 |
| Rohrer, MS | 1 |
| Ahlskog, JE | 1 |
| Moyer, TP | 1 |
| Bayer, P | 1 |
| Galvin, K | 1 |
| Webb, C | 1 |
| Hillier, V | 1 |
| Williams, GM | 1 |
| Djordjevic, MV | 1 |
| Jeffrey, AM | 1 |
| Lee, A | 1 |
| Owen, L | 1 |
| Eiser, JR | 2 |
| Main, N | 1 |
| From Attebring, M | 1 |
| Herlitz, J | 1 |
| Berndt, AK | 1 |
| Karlsson, T | 1 |
| Hjalmarson, A | 1 |
| Stahl, MM | 1 |
| Wohlfart, B | 1 |
| Pahlm, O | 1 |
| Oncken, CA | 1 |
| White, WB | 1 |
| Cooney, JL | 1 |
| Van Kirk, JR | 1 |
| Giacco, S | 1 |
| Haug, NA | 1 |
| Svikis, DS | 1 |
| Gariti, P | 1 |
| Alterman, AI | 1 |
| Ehrman, R | 1 |
| Mulvaney, FD | 1 |
| O'Brien, CP | 1 |
| Kawane, H | 1 |
| Belcher, M | 1 |
| Pare, P | 1 |
| Abboud, RT | 1 |
| Velicer, WF | 1 |
| Redding, CA | 1 |
| Greeley, J | 1 |
| Swift, W | 1 |
| Simonsen, K | 1 |
| Petersen, L | 1 |
| Säwe, U | 1 |
| Bennett, RH | 1 |
| Cherek, DR | 1 |
| Roth, N | 1 |
| Lutiger, B | 1 |
| Hasenfratz, M | 1 |
| Bättig, K | 1 |
| Knye, M | 1 |
| Woodward, M | 1 |
| Tunstall-Pedoe, H | 1 |
| Rush, D | 1 |
| Orme, J | 1 |
| King, J | 1 |
| Butler, NR | 1 |
| Brigham, J | 1 |
| Felch, LJ | 1 |
| Millard, RW | 1 |
| Waranch, HR | 1 |
| McEntee, M | 1 |
| Ockene, JK | 1 |
| Hymowitz, N | 1 |
| Lagus, J | 1 |
| Shaten, BJ | 1 |
| Zerbe, GO | 1 |
| Petty, TL | 1 |
| Puścińska, E | 1 |
| Klimaszewski, A | 1 |
| Górecka, D | 1 |
| Zieliński, J | 1 |
| Emont, SL | 1 |
| Collins, RL | 1 |
| Weidner, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| UW Quitting Using Intensive Treatment Study[NCT03176784] | Phase 4 | 1,251 participants (Actual) | Interventional | 2017-11-11 | Completed | ||
| Take a Break (TAB): mHealth-assisted Skills Building Challenge for Unmotivated Smokers[NCT02973425] | 433 participants (Actual) | Interventional | 2016-11-07 | Completed | |||
| The Appeal and Impact of E-cigarettes in Smokers With Serious Mental Illness[NCT03050853] | 240 participants (Actual) | Interventional | 2017-03-01 | Completed | |||
| Pilot Randomized Controlled Trial of a Smart Phone-Based Smoking Cessation Program[NCT04955639] | 180 participants (Anticipated) | Interventional | 2021-06-03 | Recruiting | |||
| Does Abstinence From E-cigarettes Produce Withdrawal Symptoms?[NCT02825459] | 147 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| Effectiveness of a Brief, Self-determination Intervention for Smoking Cessation (Immediate or Progressive) Among People Attending Emergency Departments: a Randomised Controlled Trial[NCT02660957] | 1,571 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| Development and a Pilot Randomized Controlled Trial of a Brief Alcohol Intervention During Smoking Cessation Treatment Delivered by Healthcare Professionals[NCT05430529] | 100 participants (Actual) | Interventional | 2022-06-17 | Completed | |||
| SCH: INT: Harnessing the Power of Technology: MOMBA for Postpartum Smoking[NCT02237898] | Phase 1 | 26 participants (Actual) | Interventional | 2017-02-10 | Completed | ||
| Low-intensity Ecological Momentary Assessment (EMA) for Smoking Cessation Intervention and Tobacco Control Policy Evaluation: a Randomized Controlled Trial Nested Within an EMA-based Observational Study[NCT05212220] | 459 participants (Actual) | Interventional | 2022-03-21 | Active, not recruiting | |||
| Chat-based Instant Messaging Support for Preventing Smoking Relapse in the Context of COVID-19 Outbreak: a Pilot Randomised Clinical Trial[NCT04409496] | 108 participants (Actual) | Interventional | 2020-06-02 | Completed | |||
| Effectiveness of Mobile Chat Messaging for Preventing Relapse in Smokers Who Have Recently Quit Smoking: a Randomised Controlled Trial[NCT05370352] | 586 participants (Anticipated) | Interventional | 2023-03-14 | Recruiting | |||
| Optimizing Health Promotion Strategy to Increase Quitting Preparation in Cigarette Smokers: A Pragmatic Randomized Factorial Screening Experiment[NCT06077058] | 160 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| "Building Capacity and Promoting Smoking Cessation in the Community Via Quit to Win Contest 2017: a Single-blind Cluster Randomized Controlled Trial on a Combined Cocktail Intervention of Brief Advice, Instant Messaging and Active Referral (AIR) to Increa[NCT03182790] | 1,311 participants (Actual) | Interventional | 2017-06-18 | Completed | |||
| A Combined Cessation Intervention of Brief Advice, Nicotine Replacement Therapy Sampling and Active Referral (BANSAR) for Smoking Fathers: a Multicenter, Single-blinded, Pragmatic Randomised Controlled Trial[NCT03671707] | 1,053 participants (Actual) | Interventional | 2018-10-10 | Completed | |||
| Brief Mindfulness Cessation Training With EMA for Post-hospital Depressed Smokers[NCT02742610] | 60 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Effect of Smoking Reduction on Endothelial Glucocalyx and Arterial Wall Properites During Medically-aided Smoking Cessation Program.[NCT02307045] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-12-03 | Active, not recruiting | ||
| Smoking Reduction In Gravid Women With Substance Use Disorders (SIGS): A Randomized Controlled Trial[NCT04132232] | 74 participants (Anticipated) | Interventional | 2021-02-15 | Recruiting | |||
| Mobile Ecological Momentary Assessment-based Peer Counselling for Youth Smokers: a Pilot Randomised Controlled Trial[NCT05732220] | 105 participants (Actual) | Interventional | 2023-05-18 | Active, not recruiting | |||
| Project 2: Strategies for Reducing Nicotine Content in Cigarettes[NCT02139930] | 1,250 participants (Anticipated) | Interventional | 2014-09-30 | Completed | |||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Using a Naturalistic Clinical Model to Measure the Efficacy and Safety of a Novel Nicotine Replacement Therapy in Smokers Motivated to Quit[NCT02355665] | Phase 3 | 1,198 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers[NCT02148445] | Phase 3 | 398 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers[NCT00790569] | 315 participants (Actual) | Interventional | 2008-09-30 | Completed | |||
| Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation[NCT00289653] | 23 participants (Actual) | Interventional | 2005-09-30 | Completed | |||
| Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation (The ESTxENDS Trial)[NCT03589989] | 1,246 participants (Actual) | Interventional | 2018-07-16 | Completed | |||
| Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation (The ESTxENDS Trial)- Extension of Follow-up[NCT04236791] | 1,246 participants (Actual) | Interventional | 2018-07-16 | Completed | |||
| The Effects of Electronic Cigarettes on the Microcirculation of the Hand[NCT02206737] | 20 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | |||
| Let's STOP Now Trial: Smoking in Trauma Orthopaedic Patients. A Prospective Randomized Trial[NCT02428244] | 269 participants (Actual) | Interventional | 2014-11-30 | Completed | |||
| Wayne Warrior CAnnabis Research and Education: Naturalistic Observation and Harm Reduction[NCT05386862] | 215 participants (Anticipated) | Interventional | 2022-05-25 | Recruiting | |||
| Efficacy of a Short-bout Handgrip Exercise Intervention for Smoking Cessation: a Pilot Randomized Controlled Trial[NCT02844296] | 208 participants (Actual) | Interventional | 2016-10-31 | Completed | |||
| Use of Nicotine Replacement Therapy (NRT) Sample and Brief Smoking Cessation Advice for Recruiting Smokers to Smoking Cessation Services and Motivating Quit Attempts[NCT03717051] | 834 participants (Actual) | Interventional | 2018-10-13 | Completed | |||
| Smoking Cessation in Hospitalized Patients: Efficacy of an Intensive Intervention Program Using an App[NCT04502004] | 116 participants (Anticipated) | Interventional | 2019-11-14 | Recruiting | |||
| Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation[NCT02859142] | Phase 4 | 122 participants (Actual) | Interventional | 2018-03-29 | Completed | ||
| A 26-Week Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Varenicline in Combination With Nicotine Replacement Therapy for Smoking Cessation[NCT01444131] | Phase 2 | 446 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| RCT of an Internet Cessation Program Plus Online Social Network for HIV+ Smokers[NCT02781090] | 512 participants (Actual) | Interventional | 2016-07-06 | Completed | |||
| A Mobile Intervention to Promote Cessation in HIV-infected Smokers[NCT02432482] | 100 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| A Pilot Study of Positively Smoke Free on the Web (PSFW) for HIV-infected Smokers[NCT01570595] | Phase 1/Phase 2 | 138 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder[NCT05452772] | Phase 2 | 66 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| Effect of Smoking Cessation on Non-surgical Periodontal Therapy[NCT02493270] | 177 participants (Actual) | Interventional | 2007-05-31 | Completed | |||
| Encouraging Abstinence Behavior in a Drug Epidemic[NCT04927143] | Phase 2 | 600 participants (Anticipated) | Interventional | 2021-09-15 | Recruiting | ||
| Mindfulness Training for Smokers Online Feasibility Study[NCT02164656] | Phase 2 | 26 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| The Get Quit-Stay Quit Study: a Randomized Trial of Health Risk Feedback and Relapse Prevention for Treatment-seeking Smokers[NCT01980485] | 225 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Multicentric 5-year Follow-up Study to Assess the Efficacy of E-cigarettes as a Tool for Smoking Cessation and to Compare the Risk of Smoking-related Diseases Among Electronic and Traditional Cigarette Smokers, and Smokers of Both.[NCT01785537] | 1,050 participants (Anticipated) | Observational | 2013-10-31 | Active, not recruiting | |||
| Project 2: The Impact of Cigarette Nicotine Content, E-cigarette Nicotine Content, and E-cigarette Flavoring on Smoking Behavior[NCT03185546] | 156 participants (Actual) | Interventional | 2018-08-06 | Completed | |||
| Smoking Cessation Treatment for Substance Use Dependents[NCT03551704] | 120 participants (Anticipated) | Interventional | 2018-01-15 | Recruiting | |||
| Behavioral Activation and Voucher-based Contingency Management for Smokers With Depression[NCT03163056] | 180 participants (Actual) | Interventional | 2015-01-26 | Completed | |||
| Incentive-based Smoking Cessation for Methadone Patients[NCT00718835] | Phase 2 | 170 participants (Anticipated) | Interventional | 2007-06-30 | Completed | ||
| A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers[NCT01553084] | Phase 4 | 1,086 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Smoking Cessation on the Human Airway: Mucus Secretion, Inflammatory and Proteomic Profile in Nasal Lavage and miRNAs in Blood[NCT02136550] | 36 participants (Anticipated) | Interventional | 2013-02-28 | Active, not recruiting | |||
| Comparative Tobacco Interventions for Individuals With Severe and Persisting Behavioral Health Disorders[NCT04523948] | 100 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| Assessing the Effectiveness of Peer-Facilitated Versus Self-Navigated Tobacco Cessation Interventions for Youths[NCT06053762] | 630 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | |||
| Assessing the Effectiveness of Virtual Versus In-person Peer-motivation Smoking Cessation Interventions[NCT05181072] | 630 participants (Anticipated) | Interventional | 2022-01-05 | Recruiting | |||
| Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders[NCT01928758] | 245 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Piloting Deposit Contracts to Increase Accessibility of a Contingency Management Intervention to Reduce Problematic Drinking[NCT05837611] | 80 participants (Anticipated) | Interventional | 2022-06-10 | Recruiting | |||
| Behavioral Maintenance Treatment for Smoking Cessation[NCT00110825] | 304 participants (Actual) | Interventional | 2004-02-29 | Completed | |||
| Behavioral Maintenance Treatment for Smoking Cessation[NCT01615770] | 304 participants (Actual) | Interventional | 2004-02-29 | Completed | |||
| Randomized Clinical Trial About the Effectiveness of the Spirometry Test as a Motivational Tool for Quitting Tobacco in Primary Care[NCT03377738] | 90 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes[NCT01681875] | 839 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| Proactive Cessation Intervention With Biomarker Feedback[NCT00169260] | Phase 2/Phase 3 | 536 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Usefulness of Selegiline for Smoking Cessation[NCT00129311] | Phase 2 | 101 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Phase II Study to Measure Effectiveness and to Monitor Side Effects of Smoke-Break Nicotine Delivery Device[NCT00715871] | Phase 2 | 52 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| St. John's Wort for Tobacco Cessation[NCT00405912] | Phase 2 | 118 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Selegiline Patch for Treatment of Nicotine Dependence[NCT01330030] | Phase 2 | 243 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Physical Activity as an Aid for Smoking Cessation: a Randomized Controlled Trial[NCT00521391] | Phase 3 | 600 participants (Actual) | Interventional | 2003-04-30 | Terminated (stopped due to End of the recruitment) | ||
| A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation[NCT00143364] | Phase 3 | 1,005 participants | Interventional | 2003-06-30 | Completed | ||
| A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation[NCT00141206] | Phase 3 | 1,005 participants | Interventional | 2003-05-31 | Completed | ||
| Comparing the Health Effects of Smokeless Tobacco, Cigarette Smoking, and New Tobacco Products Advertised as Safer Alternatives Part of Tobacco Exposure Reduction[NCT00469079] | Phase 2 | 130 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Incentives Plus Bupropion for Smoking in Schizophrenics[NCT00136760] | Phase 2 | 57 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Effectiveness of a Stepped Primary Care Smoking Cessation Intervention Based on an Evidence Based Clinical Practice Guideline (ISTAPS Project)[NCT00125905] | 3,012 participants | Interventional | 2003-10-31 | Active, not recruiting | |||
| Regulation of Craving: Brief Neurocognitive Training and Neural Mechanisms[NCT02153749] | 92 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Assessing Mindfulness Training as a Mechanistic Probe for Stress-Induced Brain Activation and Relapse Prevention for Tobacco Addiction[NCT01144689] | 42 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| Feasibility and Efficacy of a Brief Mindfulness-Based Smoking Intervention Via the Internet[NCT04572126] | 80 participants (Actual) | Interventional | 2020-11-25 | Completed | |||
| Evaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events on a Prospective Cohort of Subjects Aged 65 Years[NCT00759304] | 1,011 participants (Actual) | Observational | 2000-01-02 | Active, not recruiting | |||
| Autonomic Nervous System Activity, Aging and Sleep Apnea/Hypopnea in a Prospective Cohort of Subjects Aged 67 Years[NCT00766584] | 852 participants (Actual) | Observational | 2003-01-15 | Active, not recruiting | |||
| Effect of Self-administered Auricular Acupressure on Smoking Cessation-a Pilot Study[NCT01389622] | Phase 2 | 60 participants (Anticipated) | Interventional | 2011-07-31 | Recruiting | ||
| A Randomized Cross-over Clinical Trial of Unfiltered Cigarettes[NCT03749876] | 37 participants (Actual) | Interventional | 2019-01-17 | Completed | |||
| An Evaluator-Blinded, Randomized, Parallel Controlled Study of Nicorette® Freshmint Gum Versus Nicorette® Microtab in Healthy Smokers Motivated to Quit Smoking With Visible Staining of Teeth[NCT01440985] | 200 participants (Actual) | Interventional | 2005-07-31 | Completed | |||
| Nicotine Replacement Therapy Methods for Pregnant Women[NCT00341432] | Phase 2 | 300 participants (Anticipated) | Interventional | 2005-08-16 | Completed | ||
| Transdermal Nicotine Therapy as an Adjunct to Behavioral Smoking Cessation Counseling in Syrian Primary Care Settings[NCT01085032] | Phase 2 | 269 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Monitoring of Exhaled Carbon Monoxide to Promote Pre-operative Smoking Cessation[NCT01014455] | 169 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Evaluating the Acute Effects of Electronic Nicotine Delivery Devices Marketed to Smokers.[NCT00932295] | Phase 1/Phase 2 | 32 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Phase 4 Study to Compare of the Effects of the Electronic Cigarette and Nicotine Inhalator on Tobacco Withdrawal Symptoms Over 24 Hours of Abstinence[NCT01454362] | 51 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| The Interplay Between Addiction to Tobacco Smoking and Sleep Quality Among Healthy Adults[NCT04265339] | 150 participants (Anticipated) | Interventional | 2018-10-15 | Recruiting | |||
| Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy - Transdisciplinary Tobacco Use Research Center (TTURC), Project 2[NCT00326781] | Phase 4 | 674 participants (Actual) | Interventional | 1999-12-31 | Completed | ||
| Smoking Topography Study 2018[NCT03498053] | 12 participants (Actual) | Interventional | 2017-12-12 | Completed | |||
| Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence[NCT01208935] | Phase 2/Phase 3 | 157 participants (Actual) | Interventional | 1999-08-31 | Completed | ||
| Brain Circuits in Schizophrenia and Smoking[NCT01369966] | 42 participants (Actual) | Observational | 2011-05-16 | Completed | |||
| The Effect of Exercise on Acute Nicotine Withdrawal: Human Study[NCT01047930] | 88 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Phase 2 Study of the Efficacy of Voucher-Based Incentives to Treat Pregnant Smokers[NCT01801384] | 166 participants (Actual) | Interventional | 2006-04-30 | Completed | |||
| Breath Carbon Monoxide and Cotinine as Biomarkers to Distinguish Smokers From Nonsmokers[NCT01031121] | 240 participants (Anticipated) | Observational | 2009-06-08 | Completed | |||
| Nicotine and Smoking Cessation in Schizophrenia[NCT00307203] | Phase 4 | 51 participants (Actual) | Interventional | 1998-08-31 | Completed | ||
| Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence[NCT00749658] | Phase 2/Phase 3 | 121 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Smoking Cessation Intervention for Head and Neck Cancer Patients: A Prospective Randomised Controlled Trial[NCT03786172] | 100 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | |||
| The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome: The STADIA Pilot Study[NCT00990197] | 30 participants (Anticipated) | Interventional | 2005-06-30 | Suspended (stopped due to Difficulties with enrollment.) | |||
| A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study of 100 or 250 μg of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation[NCT00633321] | Phase 2 | 522 participants (Anticipated) | Interventional | 2007-05-31 | Completed | ||
| Efficacy and Cost of State Quitline Policies[NCT00366977] | Phase 3 | 4,614 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
| Financial Incentive Structures for Smoking Cessation: A Pilot Randomized Trial[NCT01303081] | 63 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| Way to Quit - Comparative Efficacy, Acceptance and Effectiveness of Health Incentive Structures[NCT01526265] | 2,185 participants (Anticipated) | Interventional | 2012-02-29 | Completed | |||
| [NCT00000568] | Phase 3 | 0 participants | Interventional | 1984-09-30 | Completed | ||
| Enhancing Smoking Cessation in the Homeless Population[NCT01932996] | Phase 4 | 352 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| A Dyad-based Multiple Behavior Intervention for Reducing Lung Cancer Symptoms - a Pilot Randomized Control Trial (Breathe Easier II)[NCT05956782] | 60 participants (Anticipated) | Interventional | 2022-06-15 | Recruiting | |||
| Smoking Cessation for Low-Income Pregnant Women[NCT02211430] | 277 participants (Actual) | Interventional | 2002-10-31 | Completed | |||
| Smokers' Response to Nicotine Dependence Genotyping[NCT01780038] | 24 participants (Actual) | Interventional | 2012-11-14 | Completed | |||
| An Innovative Digital Smoking Cessation Intervention for Low-Income Adults With Substance Use Disorder[NCT04419922] | 100 participants (Actual) | Observational | 2020-04-02 | Active, not recruiting | |||
| [NCT00000487] | Phase 3 | 0 participants | Interventional | 1972-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Biochemically confirmed self-reported total abstinence from any cigarette use (even a single puff) for the seven days preceding the target follow-up day, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm. (NCT03176784)
Timeframe: Assessed 23 weeks after quit date
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline + Patch Standard Duration | 74 |
| Varenicline Only Standard Duration | 66 |
| Varenicline + Patch Extended Duration | 82 |
| Varenicline Only Extended Duration | 70 |
Biochemically confirmed self-reported total abstinence from any cigarette use (even a single puff) from week 2 post-quit through week 23 post-quit, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm. (NCT03176784)
Timeframe: Assessed 23 weeks after quit date
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline + Patch Standard Duration | 66 |
| Varenicline Only Standard Duration | 72 |
| Varenicline + Patch Extended Duration | 73 |
| Varenicline Only Extended Duration | 65 |
Biochemically-confirmed self-reported total abstinence from any cigarette use (even a single puff) for the seven days preceding the target follow-up day, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm. (NCT03176784)
Timeframe: Assessed 52 weeks after quit date
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline + Patch Standard Duration | 74 |
| Varenicline Only Standard Duration | 79 |
| Varenicline + Patch Extended Duration | 78 |
| Varenicline Only Extended Duration | 76 |
Biochemically confirmed self-reported total abstinence from any cigarette use (even a single puff) from week 2 post-quit through week 52 post-quit, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm. (NCT03176784)
Timeframe: Assessed 52 weeks after quit date
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline + Patch Standard Duration | 47 |
| Varenicline Only Standard Duration | 55 |
| Varenicline + Patch Extended Duration | 57 |
| Varenicline Only Extended Duration | 46 |
"Self Efficacy is measured by the Self-Efficacy Questionnaire (SEQ-12).The SEQ-12 is a 12-item instrument (two six-item subscales) that measures the confidence in ability to refrain from smoking when facing internal stimuli (e.g. feeling depressed) and external stimuli (e.g. being with smokers).~The scale varies from 1-5 [Not at all (1) Not very(2) Moderately(3) Very (4) Extremely (5)] A higher score indicates a higher level of confidence to refrain from smoking in certain social or emotional situations and a lower score indicates a lower level of confidence to refrain from smoking." (NCT02973425)
Timeframe: 6 months
| Intervention | SEQ-12 overall score (mean) (Mean) |
|---|---|
| NRT and mHealth Assessment Tool Without Feedback | 2.7 |
| Take a Break as an Augmentation to NRT in Motivation | 2.9 |
Measure the mean number of days abstinent as self-reported by participant via the mHealth assessment. (NCT02973425)
Timeframe: 3 Weeks
| Intervention | days (Mean) |
|---|---|
| NRT and mHealth Assessment Tool Without Feedback | 0.60 |
| Take a Break as an Augmentation to NRT in Motivation | 1.20 |
"Number of participants abstinent within the 3 week period as self-reported by participant via the mHealth assessment.~." (NCT02973425)
Timeframe: 3 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| NRT and mHealth Assessment Tool Without Feedback | 29 |
| Take a Break as an Augmentation to NRT in Motivation | 49 |
Participants in the Intervention group were asked to participate in a goal-setting call to establish a smoking abstinence goal (typically one to two days of abstinence from cigarettes). The outcome measures the number of participants who completed to goal-setting call. (NCT02973425)
Timeframe: 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Take a Break as an Augmentation to NRT in Motivation | 199 |
Participants were asked to complete daily challenge quizzes during the first 3 weeks of participation. The challenge quizzes contained daily self-assessment text messages and motivational replies (intervention only) (NCT02973425)
Timeframe: 3 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Take a Break as an Augmentation to NRT in Motivation | 112 |
TAB participants were encouraged to use mHealth apps that provide relaxation or distraction to help manage smoking cravings. The study team measured the number of participants used mHealth apps to manage nicotine cravings in a 3 week period. (NCT02973425)
Timeframe: 3 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Take a Break as an Augmentation to NRT in Motivation | 159 |
At one week TAB participants were asked to whether they would like to set an abstinence goal for the following 2-week challenge. The outcome measures the number of participants in the TAB group who set a brief abstinence goal (NCT02973425)
Timeframe: 2 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Take a Break as an Augmentation to NRT in Motivation | 145 |
Point prevalent cessation here is measured by the number of participants with a decreased carbon monoxide level as verified by carbon monoxide levels in blood. (NCT02973425)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| NRT and mHealth Assessment Tool Without Feedback | 17 |
| Take a Break as an Augmentation to NRT in Motivation | 28 |
Time to first quit attempt is measured by participant self-report of number of days from baseline to first quit attempt within a 6 month period. At the 6-month follow-up visit, the dates of all quit attempts were assessed using the Timeline Follow-Back Method and used to calculate time to first quit attempt. (NCT02973425)
Timeframe: 6 months
| Intervention | days (Mean) |
|---|---|
| NRT and mHealth Assessment Tool Without Feedback | 0.89 |
| Take a Break as an Augmentation to NRT in Motivation | 1.48 |
Primary Outcome - Feasibility of the delivery of financial incentives for smoking abstinence in postpartum women through a smartphone platform as compared to traditional, in office contingency management. Feasibility: participation rate of > 60% for eligible women between screening and enrollment. Number of women who were eligible from screening that completed an intake. (NCT02237898)
Timeframe: 15 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Eligible From Screening | 26 |
Primary Outcome - Feasibility of the delivery of financial incentives for smoking abstinence in postpartum women through a smartphone platform as compared to traditional, in office contingency management. Feasibility: retention set at 80% for the Momba Smoking group. Number of participants in the intervention group (MoMba Contingency Management) and number of participants in the control group (office contingency management) who remained in the study at the end of contingency management (12 weeks). (NCT02237898)
Timeframe: 15 months
| Intervention | Participants (Count of Participants) |
|---|---|
| MoMba Contingency Management | 7 |
| Office Contingency Management | 2 |
"Primary Outcome - Feasibility of the delivery of financial incentives for smoking abstinence in postpartum women through a smartphone platform as compared to traditional, in office contingency management. Feasibility: challenge completion and in-office visit attendance to assess compliance.~MoMba Contingency Management: Number of breath tests completed among participants who remained enrolled at the end of 12 weeks.~Office Contingency Management: Number of breath tests (corresponds to office visits) completed among participants who remained enrolled at the end of 12 weeks." (NCT02237898)
Timeframe: 15 months
| Intervention | breath tests (Median) |
|---|---|
| MoMba Contingency Management | 16 |
| Office Contingency Management | 21.5 |
Secondary outcome - Long term abstinence from smoking equals 7-day point prevalence determined through # of negative breath tests and self-reports based on the Timeline Follow Back. (NCT02237898)
Timeframe: 15 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Number of negative breath tests using Sensordrone | Number of negative breath tests using the piCO | Last 7 days no smoking (from timeline followback) | |
| MoMba Contingency Management | 3 | 3 | 1 |
| Office Contingency Management | 4 | 4 | 0 |
Secondary outcome - Long term abstinence from smoking equals 7-day point prevalence determined through # of negative breath tests and self-reports based on the Timeline Follow Back. (NCT02237898)
Timeframe: 9 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Number of negative breath tests using Sensordrone | Number of negative breath tests using the piCO | Last 7 days no smoking (from timeline followback) | |
| MoMba Contingency Management | 2 | 3 | 1 |
| Office Contingency Management | 2 | 3 | 0 |
Secondary outcome - Short term abstinence from smoking. Immediate smoking prevalence as determined by # of negative breath tests and self-reports; the pilot will also utilize urine tests to measure negative cotinine levels. (NCT02237898)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Number of negative breath tests using Sensordrone | Number of negative breath tests using piCO | Self-report (no smoking cigs in past 7 days) | Urine test (<50ng) | |
| MoMba Contingency Management | 2 | 3 | 3 | 3 |
| Office Contingency Management | 2 | 2 | 1 | 1 |
Primary outcome is the correlation coefficient. The correlation coefficient was calculated between the piCO+™ and the Sensordrone™ specific to expired CO measurement and verified through urine cotinine levels. Data for all three instruments was collected during week 1 visits 1-5, 3 month, 9 month and 15 month assessments. (NCT02237898)
Timeframe: 15 months
| Intervention | correlation (Number) | ||
|---|---|---|---|
| Sensordrone and Pico | Sensordrone and Urine | Pico and Urine | |
| MoMba Contingency Management | 0.93 | 0.76 | 0.81 |
| Office Contingency Management | 0.87 | 0.66 | 0.67 |
"Primary Outcome - Acceptability of the delivery of financial incentives for smoking abstinence in postpartum women through a smartphone platform as compared to traditional, in office contingency management. Acceptability of the smartphone application to low-income, pregnant women defined by the percentage of women who would recommend the site to a friend.~Question: How likely is it that you would recommend MoMba LiveLong to a friend who wants to stop smoking?" (NCT02237898)
Timeframe: 3 and 9 months
| Intervention | Participants (Count of Participants) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 month follow-up assessment72254305 | 3 month follow-up assessment72254304 | 9-month follow-up assessment72254304 | 9-month follow-up assessment72254305 | |||||||||||||||||
| Unlikely | Highly Unlikely | Neutral | Likely | Highly Likely | ||||||||||||||||
| Office Contingency Management | 0 | |||||||||||||||||||
| MoMba Contingency Management | 1 | |||||||||||||||||||
| Office Contingency Management | 1 | |||||||||||||||||||
| MoMba Contingency Management | 0 | |||||||||||||||||||
| Office Contingency Management | 2 | |||||||||||||||||||
| MoMba Contingency Management | 5 | |||||||||||||||||||
| Office Contingency Management | 4 | |||||||||||||||||||
Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28. (NCT02355665)
Timeframe: Week 1
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 5.1 |
| Nicotine | 4.5 |
Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28. (NCT02355665)
Timeframe: Week 2
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 6.3 |
| Nicotine | 4.5 |
Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28. (NCT02355665)
Timeframe: Week 4
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 4.2 |
| Nicotine | 3.7 |
Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28. (NCT02355665)
Timeframe: Week 6
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 4.8 |
| Nicotine | 3.8 |
Change from baseline in body weight (NCT02355665)
Timeframe: Baseline to Week 12
| Intervention | pounds (Mean) |
|---|---|
| Placebo | -0.3 |
| Nicotine | 0.4 |
Change from baseline in body weight (NCT02355665)
Timeframe: Baseline to Week 12
| Intervention | pounds (Mean) |
|---|---|
| Placebo | 4.2 |
| Nicotine | 6.4 |
Change from baseline in body weight (NCT02355665)
Timeframe: Baseline to Week 26
| Intervention | pounds (Mean) |
|---|---|
| Placebo | -0.2 |
| Nicotine | 1.0 |
Change from baseline in body weight (NCT02355665)
Timeframe: Baseline to Week 26
| Intervention | pounds (Mean) |
|---|---|
| Placebo | 2.5 |
| Nicotine | 9.3 |
Change from baseline in body weight (NCT02355665)
Timeframe: Baseline to Week 6
| Intervention | pounds (Mean) |
|---|---|
| Placebo | 0.5 |
| Nicotine | 0.7 |
Change from baseline in body weight (NCT02355665)
Timeframe: Baseline to Week 6
| Intervention | pounds (Mean) |
|---|---|
| Placebo | 3.6 |
| Nicotine | 3.7 |
Change from baseline in diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 1
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 0.1 |
| Nicotine | 0.5 |
Change from baseline in diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 12
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -0.4 |
| Nicotine | -0.4 |
Change from baseline in diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 16
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -0.6 |
| Nicotine | -0.8 |
Change from baseline in diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 2
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -0.4 |
| Nicotine | 0.4 |
Change from baseline in diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 20
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -0.8 |
| Nicotine | -0.5 |
Change from baseline in diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 26
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -0.1 |
| Nicotine | 0.7 |
Change from baseline in diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 4
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -0.3 |
| Nicotine | -0.1 |
Change from baseline in diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 6
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -0.6 |
| Nicotine | -1.0 |
Change from baseline in diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 8
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -0.4 |
| Nicotine | -0.1 |
Change from baseline in pulse (beats per minute) (NCT02355665)
Timeframe: Baseline to Week 1
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 1.4 |
| Nicotine | 2.0 |
Change from baseline in pulse (beats per minute) (NCT02355665)
Timeframe: Baseline to Week 12
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 0.9 |
| Nicotine | 1.8 |
Change from baseline in pulse (beats per minute) (NCT02355665)
Timeframe: Baseline to Week 16
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 2.8 |
| Nicotine | 1.9 |
Change from baseline in pulse (beats per minute) (NCT02355665)
Timeframe: Baseline to Week 2
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 1.2 |
| Nicotine | 1.8 |
Change from baseline in pulse (beats per minute) (NCT02355665)
Timeframe: Baseline to Week 20
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 2.7 |
| Nicotine | 2.0 |
Change from baseline in pulse (beats per minute) (NCT02355665)
Timeframe: Baseline to Week 26
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 3.2 |
| Nicotine | 1.8 |
Change from baseline in pulse (beats per minute) (NCT02355665)
Timeframe: Baseline to Week 4
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 1.3 |
| Nicotine | 2.4 |
Change from baseline in pulse (beats per minute) (NCT02355665)
Timeframe: Baseline to Week 6
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 1.0 |
| Nicotine | 0.7 |
Change from baseline in pulse (beats per minute) (NCT02355665)
Timeframe: Baseline to Week 8
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 1.2 |
| Nicotine | 2.7 |
Change from baseline in systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 1
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -0.2 |
| Nicotine | 0.2 |
Change from baseline in systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 12
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -2.2 |
| Nicotine | -2.4 |
Change from baseline in systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 16
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -1.8 |
| Nicotine | -2.8 |
Change from baseline in systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 2
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -0.7 |
| Nicotine | -0.7 |
Change from baseline in systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 20
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -1.7 |
| Nicotine | -2.0 |
Change from baseline in systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 26
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -0.6 |
| Nicotine | -0.6 |
Change from baseline in systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 4
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -1.8 |
| Nicotine | -1.9 |
Change from baseline in systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 6
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -2.0 |
| Nicotine | -2.2 |
Change from baseline in systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Baseline to Week 8
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | -1.8 |
| Nicotine | -2.2 |
Diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 1
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 77.3 |
| Nicotine | 78.0 |
Diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 12
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 76.6 |
| Nicotine | 77.4 |
Diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 16
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 76.4 |
| Nicotine | 77.0 |
Diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 2
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 76.7 |
| Nicotine | 78.0 |
Diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 20
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 76.3 |
| Nicotine | 76.8 |
Diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 26
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 76.9 |
| Nicotine | 78.1 |
Diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 4
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 76.9 |
| Nicotine | 77.6 |
Diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 6
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 76.6 |
| Nicotine | 76.5 |
Diastolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 8
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 76.5 |
| Nicotine | 77.3 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 1
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 6.0 |
| Nicotine | 4.8 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 10
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 3.2 |
| Nicotine | 2.3 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 11
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 3.0 |
| Nicotine | 2.2 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 12
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.8 |
| Nicotine | 2.0 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 13
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.7 |
| Nicotine | 2.2 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 14
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.9 |
| Nicotine | 2.2 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 15
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.6 |
| Nicotine | 2.4 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 16
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.7 |
| Nicotine | 2.1 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 17
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.5 |
| Nicotine | 2.1 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 18
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.4 |
| Nicotine | 2.3 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 19
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.6 |
| Nicotine | 2.3 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 2
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 4.8 |
| Nicotine | 3.4 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 20
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.4 |
| Nicotine | 2.0 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 21
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.3 |
| Nicotine | 2.1 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 22
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.3 |
| Nicotine | 2.0 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 23
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.1 |
| Nicotine | 2.0 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 24
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.4 |
| Nicotine | 1.9 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 25
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.0 |
| Nicotine | 1.8 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 26
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 2.1 |
| Nicotine | 1.8 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 3
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 4.3 |
| Nicotine | 3.1 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 4
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 4.1 |
| Nicotine | 3.0 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 5
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 3.7 |
| Nicotine | 2.8 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 6
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 3.7 |
| Nicotine | 2.7 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 7
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 3.6 |
| Nicotine | 2.9 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 8
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 3.3 |
| Nicotine | 2.6 |
Maximum Hourly Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 9
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 3.3 |
| Nicotine | 2.3 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 1
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 22.1 |
| Nicotine | 17.2 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 10
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 14.7 |
| Nicotine | 11.4 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 11
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 15.1 |
| Nicotine | 11.2 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 12
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 12.6 |
| Nicotine | 9.8 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 13
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 12.9 |
| Nicotine | 10.5 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 14
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 13.1 |
| Nicotine | 13.6 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 15
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 15.3 |
| Nicotine | 10.8 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 16
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 12.4 |
| Nicotine | 10.0 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 17
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 11.5 |
| Nicotine | 10.5 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 18
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 12.3 |
| Nicotine | 10.3 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 19
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 11.2 |
| Nicotine | 10.3 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 2
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 21.2 |
| Nicotine | 15.4 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 20
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 10.5 |
| Nicotine | 10.5 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 21
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 10.0 |
| Nicotine | 11.0 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 22
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 9.4 |
| Nicotine | 10.8 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 23
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 10.5 |
| Nicotine | 9.1 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 24
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 9.2 |
| Nicotine | 8.8 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 25
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 8.5 |
| Nicotine | 8.4 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 26
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 8.1 |
| Nicotine | 7.9 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 3
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 19.2 |
| Nicotine | 15.2 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 4
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 17.9 |
| Nicotine | 15.8 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 5
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 19.2 |
| Nicotine | 15.1 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 6
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 17.5 |
| Nicotine | 14.6 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 7
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 16.0 |
| Nicotine | 12.8 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 8
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 16.0 |
| Nicotine | 13.6 |
Maximum Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 9
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 15.4 |
| Nicotine | 12.2 |
Number of Cigarettes Smoked Per Day (NCT02355665)
Timeframe: Week 12
| Intervention | Number of cigarettes (Mean) |
|---|---|
| Placebo | 7.1 |
| Nicotine | 7.5 |
Number of Cigarettes Smoked Per Day (NCT02355665)
Timeframe: Week 16
| Intervention | Number of cigarettes (Mean) |
|---|---|
| Placebo | 7.7 |
| Nicotine | 7.3 |
Number of Cigarettes Smoked Per Day (NCT02355665)
Timeframe: Week 20
| Intervention | Number of cigarettes (Mean) |
|---|---|
| Placebo | 7.0 |
| Nicotine | 7.2 |
Number of Cigarettes Smoked Per Day (NCT02355665)
Timeframe: Week 26
| Intervention | Number of cigarettes (Mean) |
|---|---|
| Placebo | 7.2 |
| Nicotine | 7.5 |
Number of Cigarettes Smoked Per Day (NCT02355665)
Timeframe: Week 4
| Intervention | Number of cigarettes (Mean) |
|---|---|
| Placebo | 7.3 |
| Nicotine | 6.6 |
Number of Cigarettes Smoked Per Day (NCT02355665)
Timeframe: Week 6
| Intervention | Number of cigarettes (Mean) |
|---|---|
| Placebo | 7.0 |
| Nicotine | 6.6 |
Number of Cigarettes Smoked Per Day (NCT02355665)
Timeframe: Week 8
| Intervention | Number of cigarettes (Mean) |
|---|---|
| Placebo | 6.8 |
| Nicotine | 6.3 |
Number of Cigarettes Smoked Since Last Visit (NCT02355665)
Timeframe: Week 1
| Intervention | Number of cigarettes (Mean) |
|---|---|
| Placebo | 36.2 |
| Nicotine | 34.0 |
Number of Cigarettes Smoked Since Last Visit (NCT02355665)
Timeframe: Week 2
| Intervention | Number of cigarettes (Mean) |
|---|---|
| Placebo | 38.9 |
| Nicotine | 35.8 |
Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking (NCT02355665)
Timeframe: Week 2 to Week 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 1.3 |
| Nicotine | 4.0 |
Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking (NCT02355665)
Timeframe: Week 2 to Week 16
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 1.3 |
| Nicotine | 3.9 |
Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking (NCT02355665)
Timeframe: Week 2 to Week 20
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 1.3 |
| Nicotine | 3.5 |
Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking (NCT02355665)
Timeframe: Week 2 to Week 26
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 1.2 |
| Nicotine | 3.4 |
Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking (NCT02355665)
Timeframe: Week 2 to Week 4
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 4.0 |
| Nicotine | 6.7 |
Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking (NCT02355665)
Timeframe: Week 2 to Week 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 2.5 |
| Nicotine | 5.0 |
Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking (NCT02355665)
Timeframe: Week 2 to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 2.2 |
| Nicotine | 4.5 |
Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings. (NCT02355665)
Timeframe: Week 6 or when withdrawn from study
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 1.2 |
| Nicotine | 1.6 |
Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings. (NCT02355665)
Timeframe: Week 6 or when withdrawn from study
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 0.2 |
| Nicotine | 1.0 |
Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings. (NCT02355665)
Timeframe: Week 6 or when withdrawn from study
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 0.4 |
| Nicotine | 1.0 |
Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings. (NCT02355665)
Timeframe: Week 6 or when withdrawn from study
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 0.4 |
| Nicotine | 1.0 |
Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings. (NCT02355665)
Timeframe: Week 6 or when withdrawn from study
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 0.2 |
| Nicotine | 0.0 |
Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings. (NCT02355665)
Timeframe: Week 6 or when withdrawn from study
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 0.0 |
| Nicotine | 0.0 |
Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings. (NCT02355665)
Timeframe: Week 6 or when withdrawn from study
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 0.8 |
| Nicotine | 0.8 |
Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings. (NCT02355665)
Timeframe: Week 6 or when withdrawn from study
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 0.4 |
| Nicotine | 0.2 |
Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings. (NCT02355665)
Timeframe: Week 6 or when withdrawn from study
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 1.8 |
| Nicotine | 3.6 |
Pulse (beats per minute) (NCT02355665)
Timeframe: Week 1
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 76.1 |
| Nicotine | 76.8 |
Pulse (beats per minute) (NCT02355665)
Timeframe: Week 12
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 75.1 |
| Nicotine | 76.1 |
Pulse (beats per minute) (NCT02355665)
Timeframe: Week 16
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 76.9 |
| Nicotine | 76.2 |
Pulse (beats per minute) (NCT02355665)
Timeframe: Week 2
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 75.9 |
| Nicotine | 76.5 |
Pulse (beats per minute) (NCT02355665)
Timeframe: Week 20
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 76.4 |
| Nicotine | 76.2 |
Pulse (beats per minute) (NCT02355665)
Timeframe: Week 26
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 76.9 |
| Nicotine | 76.0 |
Pulse (beats per minute) (NCT02355665)
Timeframe: Week 4
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 75.6 |
| Nicotine | 77.0 |
Pulse (beats per minute) (NCT02355665)
Timeframe: Week 6
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 75.3 |
| Nicotine | 75.2 |
Pulse (beats per minute) (NCT02355665)
Timeframe: Week 8
| Intervention | beats per minute (Mean) |
|---|---|
| Placebo | 75.4 |
| Nicotine | 77.3 |
Systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 1
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 123.7 |
| Nicotine | 124.7 |
Systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 12
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 121.8 |
| Nicotine | 122.7 |
Systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 16
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 122.3 |
| Nicotine | 122.8 |
Systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 2
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 123.3 |
| Nicotine | 123.7 |
Systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 20
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 122.4 |
| Nicotine | 123.2 |
Systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 26
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 123.2 |
| Nicotine | 124.8 |
Systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 4
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 122.5 |
| Nicotine | 122.9 |
Systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 6
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 122.3 |
| Nicotine | 122.4 |
Systolic blood pressure (mm Hg) (NCT02355665)
Timeframe: Week 8
| Intervention | mm Hg (Mean) |
|---|---|
| Placebo | 122.0 |
| Nicotine | 122.7 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 1
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 15.6 |
| Nicotine | 12.3 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 10
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 11.6 |
| Nicotine | 9.3 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 11
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 11.3 |
| Nicotine | 8.8 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 12
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 9.7 |
| Nicotine | 7.9 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 13
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 10.2 |
| Nicotine | 8.4 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 14
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 10.3 |
| Nicotine | 9.2 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 15
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 10.5 |
| Nicotine | 8.2 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 16
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 9.2 |
| Nicotine | 8.0 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 17
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 9.2 |
| Nicotine | 8.0 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 18
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 9.4 |
| Nicotine | 8.2 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 19
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 9.1 |
| Nicotine | 8.3 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 2
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 15.7 |
| Nicotine | 11.8 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 20
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 7.8 |
| Nicotine | 8.2 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 21
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 7.8 |
| Nicotine | 8.2 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 22
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 7.5 |
| Nicotine | 7.8 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 23
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 7.7 |
| Nicotine | 7.4 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 24
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 7.2 |
| Nicotine | 7.2 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 25
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 6.6 |
| Nicotine | 6.7 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 26
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 6.3 |
| Nicotine | 6.3 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 3
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 14.6 |
| Nicotine | 11.6 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 4
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 13.8 |
| Nicotine | 11.3 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 5
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 14.2 |
| Nicotine | 10.9 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 6
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 13.1 |
| Nicotine | 10.5 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 7
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 12.3 |
| Nicotine | 9.9 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 8
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 12.1 |
| Nicotine | 10.1 |
Total Daily Number of Self-Reported Spray Doses (NCT02355665)
Timeframe: Week 9
| Intervention | Number of sprays (Mean) |
|---|---|
| Placebo | 11.8 |
| Nicotine | 9.7 |
Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now). (NCT02355665)
Timeframe: Week 1
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| I like it much less now (1) | I like it slightly less now (2) | I like it about the same (3) | I like it slightly more now (4) | I like it much more now (5) | |
| Nicotine | 1.7 | 4.8 | 44.8 | 28.9 | 19.9 |
| Placebo | 2.5 | 4.3 | 50.9 | 26.4 | 15.9 |
Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now). (NCT02355665)
Timeframe: Week 12
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| I like it much less now (1) | I like it slightly less now (2) | I like it about the same (3) | I like it slightly more now (4) | I like it much more now (5) | |
| Nicotine | 6.5 | 8.4 | 44.6 | 20.1 | 20.3 |
| Placebo | 9.0 | 9.0 | 46.0 | 18.7 | 17.4 |
Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now). (NCT02355665)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| I like it much less now (1) | I like it slightly less now (2) | I like it about the same (3) | I like it slightly more now (4) | I like it much more now (5) | |
| Nicotine | 4.3 | 7.7 | 46.9 | 22.9 | 18.2 |
| Placebo | 4.7 | 11.9 | 47.9 | 22.3 | 13.2 |
Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent). (NCT02355665)
Timeframe: Week 1
| Intervention | Percentage of Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 (Very Poor) | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Excellent) | |
| Nicotine | 1.8 | 2.6 | 3.9 | 5.2 | 16.0 | 8.5 | 18.8 | 21.2 | 7.9 | 14.2 |
| Placebo | 3.2 | 3.1 | 2.7 | 6.0 | 18.6 | 9.2 | 18.6 | 20.0 | 6.7 | 11.9 |
Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent). (NCT02355665)
Timeframe: Week 12
| Intervention | Percentage of Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 (Very Poor) | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Excellent) | |
| Nicotine | 3.5 | 2.3 | 3.3 | 2.1 | 12.4 | 6.8 | 14.0 | 23.6 | 11.0 | 21.0 |
| Placebo | 5.5 | 3.5 | 3.7 | 3.7 | 11.4 | 10.0 | 16.7 | 20.4 | 10.9 | 14.2 |
Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent). (NCT02355665)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 (Very Poor) | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Excellent) | |
| Nicotine | 2.4 | 3.0 | 3.4 | 3.2 | 12.6 | 10.3 | 17.8 | 21.4 | 10.3 | 15.6 |
| Placebo | 5.3 | 2.1 | 4.5 | 5.1 | 14.9 | 8.9 | 18.7 | 22.3 | 8.3 | 9.8 |
Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient). (NCT02355665)
Timeframe: Week 1
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all convenient (1) | Somewhat convenient (2) | Moderately convenient (3) | Very convenient (4) | Extremely convenient (5) | |
| Nicotine | 0.2 | 3.7 | 10.1 | 41.6 | 44.4 |
| Placebo | 0.9 | 3.2 | 10.1 | 45.1 | 40.6 |
Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient). (NCT02355665)
Timeframe: Week 12
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all convenient (1) | Somewhat convenient (2) | Moderately convenient (3) | Very convenient (4) | Extremely convenient (5) | |
| Nicotine | 0.2 | 4.0 | 9.1 | 44.2 | 42.5 |
| Placebo | 1.5 | 3.0 | 9.0 | 48.0 | 38.6 |
Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient). (NCT02355665)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all convenient (1) | Somewhat convenient (2) | Moderately convenient (3) | Very convenient (4) | Extremely convenient (5) | |
| Nicotine | 0.4 | 3.4 | 8.4 | 50.1 | 37.7 |
| Placebo | 0.9 | 4.7 | 8.7 | 46.2 | 39.6 |
Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective). (NCT02355665)
Timeframe: Week 1
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all effective (1) | Somewhat effective (2) | Moderately effective (3) | Very effective (4) | Extremely effective (5) | |
| Nicotine | 4.2 | 20.8 | 32.4 | 29.8 | 12.7 |
| Placebo | 8.7 | 27.8 | 34.5 | 23.3 | 5.8 |
Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective). (NCT02355665)
Timeframe: Week 12
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all effective (1) | Somewhat effective (2) | Moderately effective (3) | Very effective (4) | Extremely effective (5) | |
| Nicotine | 6.8 | 17.1 | 29.7 | 28.7 | 17.8 |
| Placebo | 12.7 | 20.1 | 32.1 | 25.6 | 9.5 |
Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective). (NCT02355665)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all effective (1) | Somewhat effective (2) | Moderately effective (3) | Very effective (4) | Extremely effective (5) | |
| Nicotine | 5.4 | 19.5 | 32.5 | 31.0 | 11.6 |
| Placebo | 11.7 | 26.8 | 31.7 | 23.0 | 6.8 |
Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast). (NCT02355665)
Timeframe: Week 1
| Intervention | Percentage of Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Extremely slow (1) | Very slow (2) | Moderately slow (3) | Slightly slow (4) | Neither fast nor slow (5) | Sightly fast (6) | Moderately fast (7) | Very fast (8) | Extremely fast (9) | |
| Nicotine | 1.8 | 1.5 | 2.0 | 2.8 | 14.9 | 11.8 | 24.7 | 24.9 | 15.7 |
| Placebo | 4.7 | 2.7 | 4.0 | 6.0 | 21.8 | 10.5 | 24.2 | 17.9 | 8.3 |
Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast). (NCT02355665)
Timeframe: Week 12
| Intervention | Percentage of Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Extremely slow (1) | Very slow (2) | Moderately slow (3) | Slightly slow (4) | Neither fast nor slow (5) | Sightly fast (6) | Moderately fast (7) | Very fast (8) | Extremely fast (9) | |
| Nicotine | 4.0 | 1.6 | 2.6 | 3.3 | 14.7 | 8.6 | 21.7 | 28.3 | 15.2 |
| Placebo | 5.5 | 3.5 | 4.2 | 4.7 | 19.4 | 8.5 | 28.4 | 17.9 | 8.0 |
Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast). (NCT02355665)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Extremely slow (1) | Very slow (2) | Moderately slow (3) | Slightly slow (4) | Neither fast nor slow (5) | Sightly fast (6) | Moderately fast (7) | Very fast (8) | Extremely fast (9) | |
| Nicotine | 2.8 | 2.4 | 3.9 | 3.6 | 13.3 | 9.2 | 25.3 | 25.1 | 14.6 |
| Placebo | 5.5 | 4.9 | 4.7 | 4.7 | 20.2 | 11.9 | 24.3 | 18.3 | 5.5 |
Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 1
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 59.0 | 28.2 | 7.7 | 0.0 | 5.1 |
| Placebo | 52.4 | 28.6 | 19.0 | 0.0 | 0.0 |
Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 2
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 72.4 | 12.1 | 8.6 | 3.4 | 3.4 |
| Placebo | 44.0 | 24.0 | 12.0 | 12.0 | 8.0 |
Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 4
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 65.1 | 23.3 | 11.6 | 0.0 | 0.0 |
| Placebo | 65.4 | 26.9 | 7.7 | 0.0 | 0.0 |
Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 66.7 | 20.4 | 9.3 | 3.7 | 0.0 |
| Placebo | 62.5 | 25.0 | 6.3 | 6.3 | 0.0 |
Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 1
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 12.8 | 35.9 | 25.6 | 15.4 | 10.3 |
| Placebo | 9.5 | 33.3 | 33.3 | 19.0 | 4.8 |
Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 2
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 15.5 | 36.2 | 34.5 | 10.3 | 3.4 |
| Placebo | 24.0 | 28.0 | 20.0 | 20.0 | 8.0 |
Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 4
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 37.2 | 39.5 | 16.3 | 7.0 | 0.0 |
| Placebo | 19.2 | 53.8 | 23.1 | 3.8 | 0.0 |
Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 31.5 | 42.6 | 18.5 | 3.7 | 3.7 |
| Placebo | 43.8 | 31.3 | 12.5 | 9.4 | 3.1 |
Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 1
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 69.2 | 17.9 | 7.7 | 5.1 | 0.0 |
| Placebo | 66.7 | 23.8 | 4.8 | 4.8 | 0.0 |
Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 2
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 63.8 | 24.1 | 6.9 | 3.4 | 1.7 |
| Placebo | 52.0 | 32.0 | 8.0 | 4.0 | 4.0 |
Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 4
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 74.4 | 11.6 | 9.3 | 4.7 | 0.0 |
| Placebo | 73.1 | 23.1 | 3.8 | 0.0 | 0.0 |
Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 74.1 | 16.7 | 5.6 | 3.7 | 0.0 |
| Placebo | 71.9 | 12.5 | 9.4 | 6.3 | 0.0 |
Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 1
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 87.2 | 5.1 | 5.1 | 2.6 | 0.0 |
| Placebo | 81.0 | 19.0 | 0.0 | 0.0 | 0.0 |
Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 2
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 84.5 | 5.2 | 6.9 | 1.7 | 1.7 |
| Placebo | 72.0 | 20.0 | 8.0 | 0.0 | 0.0 |
Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 4
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 86.0 | 9.3 | 2.3 | 2.3 | 0.0 |
| Placebo | 84.6 | 11.5 | 0.0 | 0.0 | 3.8 |
Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 75.9 | 16.7 | 5.6 | 1.9 | 0.0 |
| Placebo | 78.1 | 15.6 | 3.1 | 3.1 | 0.0 |
Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 1
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 43.6 | 28.2 | 5.1 | 17.9 | 5.1 |
| Placebo | 9.5 | 52.4 | 23.8 | 14.3 | 0.0 |
Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 2
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 41.4 | 25.9 | 12.1 | 17.2 | 3.4 |
| Placebo | 28.0 | 36.0 | 24.0 | 12.0 | 0.0 |
Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 4
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 44.2 | 30.2 | 11.6 | 9.3 | 4.7 |
| Placebo | 30.8 | 26.9 | 23.1 | 15.4 | 3.8 |
Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 35.2 | 31.5 | 14.8 | 14.8 | 3.7 |
| Placebo | 21.9 | 43.8 | 18.8 | 12.5 | 3.1 |
Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 1
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 79.5 | 12.8 | 2.6 | 5.1 | 0.0 |
| Placebo | 76.2 | 14.3 | 9.5 | 0.0 | 0.0 |
Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 2
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 67.2 | 20.7 | 5.2 | 5.2 | 1.7 |
| Placebo | 76.0 | 16.0 | 0.0 | 8.0 | 0.0 |
Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 4
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 69.8 | 20.9 | 7.0 | 2.3 | 0.0 |
| Placebo | 61.5 | 26.9 | 11.5 | 0.0 | 0.0 |
Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 83.3 | 11.1 | 3.7 | 1.9 | 0.0 |
| Placebo | 62.5 | 21.9 | 6.3 | 6.3 | 3.1 |
Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 1
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 51.3 | 28.2 | 15.4 | 0.0 | 5.1 |
| Placebo | 38.1 | 38.1 | 19.0 | 4.8 | 0.0 |
Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 2
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 56.9 | 24.1 | 8.6 | 5.2 | 5.2 |
| Placebo | 28.0 | 40.0 | 12.0 | 8.0 | 12.0 |
Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 4
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 55.8 | 23.3 | 11.6 | 7.0 | 2.3 |
| Placebo | 46.2 | 34.6 | 15.4 | 3.8 | 0.0 |
Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 61.1 | 20.4 | 13.0 | 3.7 | 1.9 |
| Placebo | 43.8 | 43.8 | 6.3 | 6.3 | 0.0 |
Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 1
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 43.6 | 30.8 | 17.9 | 5.1 | 2.6 |
| Placebo | 47.6 | 14.3 | 23.8 | 9.5 | 4.8 |
Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 2
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 58.6 | 20.7 | 17.2 | 1.7 | 1.7 |
| Placebo | 40.0 | 32.0 | 12.0 | 12.0 | 4.0 |
Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 4
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 62.8 | 32.6 | 2.3 | 2.3 | 0.0 |
| Placebo | 53.8 | 34.6 | 11.5 | 0.0 | 0.0 |
Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). (NCT02355665)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Not at all (0) | Somewhat (1) | Moderately so (2) | Very much so (3) | Extremely so (4) | |
| Nicotine | 63.0 | 24.1 | 11.1 | 1.9 | 0.0 |
| Placebo | 46.9 | 37.5 | 9.4 | 6.3 | 0.0 |
Change in respiratory function, as measured by spirometry (FEV1), at 12 months post-randomization. (NCT02148445)
Timeframe: Month 12
| Intervention | % of predicted (Mean) |
|---|---|
| Standard Smoking Cessation | 55.4 |
| Extended Nicotine Replacement Therapy | 56.8 |
7-day point prevalent abstinence at 12 months, confirmed by exhaled CO <=10 (NCT02148445)
Timeframe: Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Smoking Cessation | 23 |
| Extended Nicotine Replacement Therapy | 24 |
"6 month sustained abstinence as measured by self-report at 6 and 12 months and confirmed by CO at 6 and 12 months. Participants who were confirmed as non-smokers by carbon monoxide (CO) at both Month 6 and Month 12 were considered to have 6-month sustained abstinence." (NCT02148445)
Timeframe: Month 6 through Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Smoking Cessation | 15 |
| Extended Nicotine Replacement Therapy | 12 |
"Self-reported and biochemically verified 7-day abstinence. Participants were asked at Month 3, Month 6, and Month 12, Have you smoked any cigarettes or little cigars, even a puff, in the past 7 days? They also completed an exhaled carbon monoxide lab test at Month 3, 6 and 12. Biochemical verification= exhaled CO <=10 ppm. Month 12 biochemically verified abstinence is the primary outcome, and is not reported in this table." (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Month 3, self-report | Month 3, biochemically verified | Month 6, self-report | Month 6, biochemically verified | Month 12, self-report | |
| Extended Nicotine Replacement Therapy | 16 | 14 | 20 | 19 | 28 |
| Standard Smoking Cessation | 27 | 25 | 28 | 25 | 25 |
"Average number of cigarettes per day over one year. Participants were asked at Month 3, Month 6, and Month 12 During the past 7 days, on those days that you smoked, what was the average number of cigarettes or little cigars smoked per day?" (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | cigarettes per day (Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 10.5 | 9.1 | 8.1 |
| Standard Smoking Cessation | 7.9 | 8.1 | 8.5 |
"Average number of cigarettes per day over one year, among continued smokers. All participants were asked During the past 7 days, on those days that you smoked, what was the average number of cigarettes smoked per day? at Month 3, Month 6, and Month 12. This analysis looks at the number of cigarettes per day among participants who were still smoking." (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | cigarettes per day (Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 11.4 | 9.9 | 9.3 |
| Standard Smoking Cessation | 8.7 | 9.1 | 9.7 |
Carbon monoxide (CO) exposure over 12 months. At Month 3, Month 6, and Month 12, participants completed an expired carbon monoxide laboratory test, which measured CO in parts per million. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | parts per million (ppm) (Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 17.4 | 15.4 | 13.8 |
| Standard Smoking Cessation | 15.0 | 14.6 | 15.5 |
Carbon monoxide (CO) exposure over 12 months. At Month 3, Month 6, and Month 12, participants completed an expired carbon monoxide laboratory test, which measured CO in parts per million. This analysis looks at CO among those continuing to smoke. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | parts per million (ppm) (Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 18.8 | 17.0 | 15.8 |
| Standard Smoking Cessation | 16.4 | 16.0 | 17.4 |
Creatinine-adjusted NNAL (4-(methylnitrosamino)-1-(3)pyridyl-1-butanol)) exposure over 12 months. At Month 3, Month 6, and Month 12, participants provided a urine sample that was used to assess their level of urinary creatinine and NNAL. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | pg/mg creatinine (Geometric Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 320.1 | 186.0 | 183.5 |
| Standard Smoking Cessation | 279.0 | 178.2 | 190.4 |
Creatinine-adjusted NNAL (4-(methylnitrosamino)-1-(3)pyridyl-1-butanol)) exposure over 12 months. At Month 3, Month 6, and Month 12, participants provided a urine sample that was used to assess their level of urinary creatinine and NNAL. This analysis looks at NNAL among continuing smokers only. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | pg/mg creatinine (Geometric Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 337.6 | 217.1 | 247.5 |
| Standard Smoking Cessation | 314.6 | 219.8 | 257.0 |
Cotinine over 12 months, adjusted for creatinine. At Month 3, Month 6, and Month 12, participants provided a urine sample that was used to assess their level of urinary creatinine and cotinine. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | ng/mg creatinine (Geometric Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 3378.1 | 3342.3 | 2363.7 |
| Standard Smoking Cessation | 2652.5 | 2390.7 | 2159.0 |
Cotinine over 12 months, adjusted for creatinine. At Month 3, Month 6, and Month 12, participants provided a urine sample that was used to assess their level of urinary creatinine and cotinine. This analysis looks at NNAL among continuing smokers only. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | ng/mg creatinine (Geometric Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 3305.8 | 3502.2 | 2782.7 |
| Standard Smoking Cessation | 2771.2 | 2850.7 | 2733.9 |
Number of self-reported quit attempts over one year. At Month 3 and Month 6, participants reported the number of quit attempts in the last 3 months. At Month 12, participants reported the number of quit attempts in the last 6 months. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | number of quit attempts (Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 3.7 | 4.8 | 6.2 |
| Standard Smoking Cessation | 4.6 | 4.5 | 5.7 |
Respiratory symptoms as measured by the COPD Assessment Test (CAT) respiratory questionnaire. Participants completed this 8-item assessment at Month 3, Month 6, and Month 12. Scores range from 0 to 40, with higher levels indicating higher impact of COPD on well-being and daily life. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 19.3 | 18.1 | 18.2 |
| Standard Smoking Cessation | 17.8 | 17.9 | 17.5 |
Number of cardiac-related hospital admissions and emergency room visits. Participants were asked how many times they had visited the ED or were admitted to the hospital for cardiac-related problems at Month 3, Month 6, and Month 12. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month 371962791 | Month 371962792 | Month 671962791 | Month 671962792 | Month 1271962791 | Month 1271962792 | |||||||||||||
| 0 Visits | 2 or more Visits | 1 Visit | ||||||||||||||||
| Standard Smoking Cessation | 181 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 185 | |||||||||||||||||
| Standard Smoking Cessation | 7 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 6 | |||||||||||||||||
| Standard Smoking Cessation | 1 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 0 | |||||||||||||||||
| Standard Smoking Cessation | 171 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 180 | |||||||||||||||||
| Standard Smoking Cessation | 10 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 4 | |||||||||||||||||
| Standard Smoking Cessation | 0 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 1 | |||||||||||||||||
| Standard Smoking Cessation | 175 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 167 | |||||||||||||||||
| Standard Smoking Cessation | 8 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 12 | |||||||||||||||||
| Standard Smoking Cessation | 2 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 3 | |||||||||||||||||
Number of respiratory-related hospital admissions and emergency room visits. Participants were asked how many times they had visited the ED or were admitted to the hospital for respiratory-related problems at Month 3, Month 6, and Month 12 (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month 371962791 | Month 371962792 | Month 671962792 | Month 671962791 | Month 1271962791 | Month 1271962792 | |||||||||||||
| 0 Visits | 1 Visit | 2 or more Visits | ||||||||||||||||
| Standard Smoking Cessation | 176 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 169 | |||||||||||||||||
| Standard Smoking Cessation | 11 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 15 | |||||||||||||||||
| Standard Smoking Cessation | 2 | |||||||||||||||||
| Standard Smoking Cessation | 152 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 154 | |||||||||||||||||
| Standard Smoking Cessation | 22 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 24 | |||||||||||||||||
| Standard Smoking Cessation | 7 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 7 | |||||||||||||||||
| Standard Smoking Cessation | 157 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 153 | |||||||||||||||||
| Standard Smoking Cessation | 18 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 20 | |||||||||||||||||
| Standard Smoking Cessation | 10 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 10 | |||||||||||||||||
Number of participants reporting 7-day abstinence at 6-months, confirmed with CO measurement. (NCT00790569)
Timeframe: 6-Months
| Intervention | participants (Number) |
|---|---|
| Arm I | 5 |
| Arm II | 1 |
| Arm III | 11 |
Change in mean cigarettes per day (NCT00790569)
Timeframe: 6-Months
| Intervention | cigarettes/day (Mean) |
|---|---|
| Arm I | -8.7 |
| Arm II | -8.5 |
| Arm III | -7.8 |
Smoking urges was measured on a 0 (not at all) - 100 (strongest feeling possible) scale. Higher values represent greater urge to smoke. Change in smoking urges was calculated as Follow-up score (6 month) - Baseline Score. (NCT00790569)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I | -29.971 |
| Arm II | -25.015 |
| Arm III | -24.177 |
Number of participants reporting 7-day abstinence at 12-months, confirmed with CO measurement. (NCT00790569)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Arm I | 4 |
| Arm II | 1 |
| Arm III | 8 |
Number of participants who self-reported continuous abstinence from their initial quit day (study day 14) to 6 Months (NCT00790569)
Timeframe: 6-Months
| Intervention | participants (Number) |
|---|---|
| Arm I | 2 |
| Arm II | 0 |
| Arm III | 2 |
Reinforcing effects of smoking was measured using the modified version of the Cigarette Evaluation Questionnaire. Participants were asked to indicate on a 12-item scale how smoking made them feel in the prior 30 days on a scale from 1 (Not at all) to 7 (Extremely). Higher values indicated that smoking was a more positive experience for 10 of 12 items. Two items were reverse coded. Change in reinforcing effects of smoking was calculated as Follow-up score (6 month) - Baseline Score. (NCT00790569)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I | -1.005 |
| Arm II | -.683 |
| Arm III | -.761 |
Number of participants with self-reported, 7-day abstinence at 6-months (NCT00790569)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Arm I | 11 |
| Arm II | 3 |
| Arm III | 16 |
Number of participants with self-reported 7-day abstinence at 12-months (NCT00790569)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Arm I | 4 |
| Arm II | 3 |
| Arm III | 11 |
Withdrawal Symptoms were measured using a modified version of the Minnesota Behavior Rating Scale. The scale asked subjects to rate their smoking withdrawal symptoms over the previous 24 hours on a scale from 0 (none) to 4 (severe). Higher values indicate more severe withdrawal symptoms. Change in withdrawal symptoms was calculated as Follow-up score (6 month) - Baseline Score. (NCT00790569)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I | -.222 |
| Arm II | -.163 |
| Arm III | -.113 |
Expired Co levels were measured to confirm smoking status (NCT00289653)
Timeframe: measured at week 10
| Intervention | parts per million (Mean) |
|---|---|
| Enrolled Participants | 9.2 |
self reported # cigarettes per day (NCT00289653)
Timeframe: Week 10
| Intervention | cigarettes per day (Mean) |
|---|---|
| Enrolled Participants | 3.7 |
measurement of exhaled carbon monoxide using a Smokerlyzer, and a saliva cotinine test (NCT03717051)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 22 |
| Control | 10 |
Number of participants who enroll in any smoking cessation service in Hong Kong (NCT03717051)
Timeframe: 1 month
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 156 |
| Control | 158 |
Number of participants who enroll in any smoking cessation service in Hong Kong (NCT03717051)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 247 |
| Control | 213 |
No smoking for at least 24 hours in the past month (NCT03717051)
Timeframe: 1 month
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 214 |
| Control | 153 |
No smoking for at least 24 hours in the past month (NCT03717051)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 300 |
| Control | 243 |
self-reported tobacco abstinence in past 30 days (NCT03717051)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 68 |
| Control | 52 |
self-reported tobacco abstinence in past 30 days (NCT03717051)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 93 |
| Control | 77 |
self-reported tobacco abstinence in past 7 days (NCT03717051)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 95 |
| Control | 79 |
self-reported tobacco abstinence in past 7 days (NCT03717051)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 104 |
| Control | 92 |
self-reported use of NRT in past week/month (NCT03717051)
Timeframe: 1 month
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 192 |
| Control | 121 |
self-reported use of NRT in past week/month (NCT03717051)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 92 |
| Control | 86 |
progression towards smoking cessation as measured by Incremental Behavior Change toward Smoking cessation (IBC-S). The minimum value is 3 and the maximum value is 27. Higher scores mean a better outcome. (NCT03717051)
Timeframe: 1 month
| Intervention | score on a scale (Mean) |
|---|---|
| Intervention | 16.04 |
| Control | 15.12 |
progression towards smoking cessation as measured by Incremental Behavior Change toward Smoking cessation (IBC-S). The minimum value is 3 and the maximum value is 27. Higher scores mean a better outcome. (NCT03717051)
Timeframe: 3 months
| Intervention | score on a scale (Mean) |
|---|---|
| Intervention | 14.60 |
| Control | 14.42 |
progression towards smoking cessation as measured by Incremental Behavior Change toward Smoking cessation (IBC-S). The minimum value is 3 and the maximum value is 27. Higher scores mean a better outcome. (NCT03717051)
Timeframe: 6 months
| Intervention | score on a scale (Mean) |
|---|---|
| Intervention | 13.94 |
| Control | 14.58 |
Self-efficacy will be evaluated according to the importance of quitting on a scale of 0 to 10 (0, least important; 10, most important), difficulty of quitting on a scale of 0 to 10 (0, least difficult; 10, most difficult), and confidence in quitting on a scale of 0 to 10 (0, least confident; 10, most confident) (NCT03717051)
Timeframe: 3 months
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Importance | Difficulty | Confidence | |
| Control | 7.53 | 7.34 | 6.47 |
| Intervention | 7.80 | 7.25 | 6.58 |
Self-efficacy will be evaluated according to the importance of quitting on a scale of 0 to 10 (0, least important; 10, most important), difficulty of quitting on a scale of 0 to 10 (0, least difficult; 10, most difficult), and confidence in quitting on a scale of 0 to 10 (0, least confident; 10, most confident) (NCT03717051)
Timeframe: 6 months
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Importance | Difficulty | Confidence | |
| Control | 8.09 | 7.22 | 6.47 |
| Intervention | 7.36 | 7.53 | 6.02 |
Self-efficacy will be evaluated according to the importance of quitting on a scale of 0 to 10 (0, least important; 10, most important), the difficulty of quitting on a scale of 0 to 10 (0, least difficult; 10, most difficult), and confidence in quitting on a scale of 0 to 10 (0, least confident; 10, most confident). For the scale of measuring quitting importance and confidence, higher scores mean a better outcome and for the scale of measuring difficulty, higher scores mean a worse outcome. (NCT03717051)
Timeframe: 1 month
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Importance | Difficulty | Confidence | |
| Control | 7.88 | 7.38 | 6.97 |
| Intervention | 7.60 | 7.02 | 6.39 |
Self-reported alcohol drinking days obtained via a past month Timeline Followback Calendar at 12 weeks (NCT02859142)
Timeframe: 12 weeks
| Intervention | days (Mean) |
|---|---|
| Augmented Treatment | 12.25 |
| Standard Treatment | 11.96 |
Self reported monthly alcohol drinking days obtained via a past month Timeline Followback Calendar at 26 weeks (NCT02859142)
Timeframe: 26 weeks
| Intervention | days (Mean) |
|---|---|
| Augmented Treatment | 12.73 |
| Standard Treatment | 11.44 |
Self reported heavy drinking (5+ drinks/day for men, 4+ drinks/day for women) days obtained via a past month Timeline Followback Calendar at 12 weeks (NCT02859142)
Timeframe: 12 weeks
| Intervention | days (Mean) |
|---|---|
| Augmented Treatment | 5.02 |
| Standard Treatment | 5.58 |
Self reported heavy drinking (5+ drinks/day for men, 4+ drinks/day for women) days obtained via a past month Timeline Followback Calendar at 26 weeks (NCT02859142)
Timeframe: 26 weeks
| Intervention | days (Mean) |
|---|---|
| Augmented Treatment | 4.79 |
| Standard Treatment | 5.56 |
Number of participants reporting smoking abstinence at 12 weeks from baseline (smoking quit date) via subjective and biologically verified reports. (NCT02859142)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Augmented Treatment | 27 |
| Standard Treatment | 17 |
Number of participants reporting smoking abstinence at 26 weeks from quit date via subjective and biologically verified reports. (NCT02859142)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Augmented Treatment | 15 |
| Standard Treatment | 16 |
Questionnaires were administered to all study participants at 6 months to assess participant satisfaction with the PSFW+ and AHA 'Getting Healthy' website and online tools. Participants were asked to provide feedback regarding their level of satisfaction with the online platform using the following response options: Not at all Satisfied, A little Satisfied, Moderately Satisfied, Very Satisfied, or Extremely Satisfied. Participants responses were aggregated and tabulated. (NCT02781090)
Timeframe: Up to 6 months
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Not at all satisfied | A little satisfied | Moderately satisfied | Very satisfied | Extremely satisfied | Refused or missing | |
| American Heart Association Getting Healthy (AHA) | 16 | 45 | 50 | 63 | 24 | 6 |
| Positively Smoke Free on the Web (PSFW+) | 16 | 34 | 62 | 68 | 25 | 1 |
Exhaled CO <10 ppm and no tobacco use in the past 7 days (NCT01980485)
Timeframe: 28 days post quit date
| Intervention | Participants (Count of Participants) |
|---|---|
| Feedback on Lung Age and Exhaled Carbon Monoxide | 61 |
| No Lung Age Feedback | 55 |
Among those who have not smoked in the previous week at visit 7, sustained tobacco abstinence (including no tobacco use in prior 7 days), validated by exhaled CO < 10 ppm at the 6 month visit(8) AND not smoking for any 7 consecutive days during the prior 5 months (definition of a relapse in this study) (NCT01980485)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Forever Free Relapse Materials | 24 |
| Surgeon General Brochure | 25 |
Measure of cigarette smoke exposure using data on expired breath CO. CO was captured using Covita Smokelyzer devices and standard exhalation procedures. The unit of measurement is parts per million (ppm). (NCT03185546)
Timeframe: Baseline - Week 12
| Intervention | parts per million (ppm) (Mean) |
|---|---|
| NNC Cigarette + Moderate Nicotine E-liquid + Tobacco Flavors | 31 |
| VLNC Cigarette + Moderate Nicotine E-liquid + Variety Flavors | 7.2 |
| VLNC Cigarette + Low Nicotine E-liquid +Tobacco Flavors | 18 |
| VLNC Cigarette + Moderate Nicotine E-liquid + Tobacco Flavor | 12 |
| NNC Cigarette + Low Nicotine E-liquid + Variety Flavors | 18.2 |
| NNC Cigarette + Moderate Nicotine E-liquid + Variety Flavors | 21 |
| NNC Cigarette + Low Nicotine E-liquid + Tobacco Flavors | 18.3 |
| VLNC Cigarette + Low Nicotine E-liquid + Variety Flavors | 32.5 |
The average number of cigarettes (study and non-study, summed) smoked per day between the Week 10 and Week 12 visits (the end of the study). (NCT03185546)
Timeframe: Week 10 through Week 12
| Intervention | number of cigarettes (Mean) |
|---|---|
| NNC Cigarette + Moderate Nicotine E-liquid + Tobacco Flavors | 21.6 |
| VLNC Cigarette + Moderate Nicotine E-liquid + Variety Flavors | 7.7 |
| VLNC Cigarette + Low Nicotine E-liquid +Tobacco Flavors | 18.4 |
| VLNC Cigarette + Moderate Nicotine E-liquid + Tobacco Flavor | 12.5 |
| NNC Cigarette + Low Nicotine E-liquid + Variety Flavors | 34 |
| NNC Cigarette + Moderate Nicotine E-liquid + Variety Flavors | 18.7 |
| NNC Cigarette + Low Nicotine E-liquid + Tobacco Flavors | 17.7 |
| VLNC Cigarette + Low Nicotine E-liquid + Variety Flavors | 15.8 |
"Study team generates the smoke free days outcome by counting days where no cigarettes and no other forms of combusted tobacco products are used. Days where participants use no nicotine products and days where participants only vape are smoke free. Percentage of smoke free days = the number days that participants reported smoking 0 cigarettes (0 study cigarettes and 0 non-study cigarettes) divided by the total number of days between their randomization and Week 12 visits. Due to the distribution of the data, statisticians grouped participants according to whether they had 0 smoke-free days or more than 0 smoke free days during the study." (NCT03185546)
Timeframe: Baseline-Week 12
| Intervention | participants (Number) | |
|---|---|---|
| Subjects with 0% smoke free days | Subjects with more than 0% smoke free days | |
| NNC Cigarette + Low Nicotine E-liquid + Tobacco Flavors | 6 | 1 |
| NNC Cigarette + Low Nicotine E-liquid + Variety Flavors | 4 | 0 |
| NNC Cigarette + Moderate Nicotine E-liquid + Tobacco Flavors | 1 | 1 |
| NNC Cigarette + Moderate Nicotine E-liquid + Variety Flavors | 3 | 1 |
| VLNC Cigarette + Low Nicotine E-liquid + Variety Flavors | 0 | 2 |
| VLNC Cigarette + Low Nicotine E-liquid +Tobacco Flavors | 3 | 1 |
| VLNC Cigarette + Moderate Nicotine E-liquid + Tobacco Flavor | 3 | 2 |
| VLNC Cigarette + Moderate Nicotine E-liquid + Variety Flavors | 1 | 3 |
Self-reported total abstinence from any tobacco use (even a single puff) for the seven days preceding the target follow-up day, confirmed with an exhaled carbon monoxide reading of <10 ppm.. (NCT01553084)
Timeframe: Assessed 26 weeks after the target quit day.
| Intervention | Participants (Count of Participants) |
|---|---|
| Effectiveness of Nicotine Patch Only | 63 |
| Effectiveness of Combination NRT | 124 |
| Effectiveness of Varenicline [Chantix] | 108 |
The number of days to relapse is defined as the number of days from the target quit day until the first of seven consecutive days of smoking. (NCT01553084)
Timeframe: Assessed from the target quit day through 26 weeks.
| Intervention | Days (Mean) |
|---|---|
| Effectiveness of Nicotine Patch Only | 29.3 |
| Effectiveness of Combination NRT | 37.4 |
| Effectiveness of Varenicline [Chantix] | 31.7 |
Defined as at least 1 day of abstinence during the first 7 days after the target quit day. (NCT01553084)
Timeframe: Assessed for the first seven days after the target quit date.
| Intervention | Participants (Count of Participants) |
|---|---|
| Effectiveness of Nicotine Patch Only | 176 |
| Effectiveness of Combination NRT | 339 |
| Effectiveness of Varenicline [Chantix] | 289 |
Change in carotid intima-media thickness (CIMT) from Baseline to Year 3 as a function of smoking status (abstinent versus smoking) at Year 3. Change is calculated as Baseline CIMT score minus Year 3 CIMT score. CIMT score is thickness of the carotid intima-media in millimeters (mm). Lower CIMT values indicate a better outcome. (NCT01553084)
Timeframe: Assessed at Baseline and Year 3
| Intervention | millimeters (mm) (Mean) |
|---|---|
| Abstinent at Year 3 | -0.0682 |
| Smoking at Year 3 | -0.0620 |
Smokers assigned to reduced nicotine content cigarettes will be more likely to successfully abstain from smoking at the end of the trial, based on all randomized participants, defined as no cigarette use in past 7 days, verified by exhaled carbon monoxide <10ppm. (NCT01928758)
Timeframe: Follow-up appointment 30 weeks after randomization (12 weeks after last visit of randomized trial phase).
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Nicotine Content Cigarettes | 17 |
| Usual Nicotine Content Cigarettes | 4 |
Smokers assigned to the reduced nicotine content cigarette group may have lower perceived dependence and be more likely to report intention to quit smoking (NCT01928758)
Timeframe: At end of 18-week randomized trial phase
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Nicotine Content Cigarettes | 33 |
| Usual Nicotine Content Cigarettes | 25 |
This 8-item scale measures nicotine withdrawal symptoms and the scale range is from 0-32. Higher scores indicate higher severity. (NCT01928758)
Timeframe: Measured at the end of the last 3 weeks of randomization trial phase
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Nicotine Content Cigarettes | 8.1 |
| Usual Nicotine Content Cigarettes | 9.0 |
10-item questionnaire measuring the degree to which life situations are appraised stressful. Scale range is 0-40. Higher scores indicate more stress. (NCT01928758)
Timeframe: Measured at the end of the last 3 weeks of randomization trial phase
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Nicotine Content Cigarettes | 15.0 |
| Usual Nicotine Content Cigarettes | 15.1 |
Plasma cotinine is a measure of daily nicotine exposure. Samples were measured in ng/mL. (NCT01928758)
Timeframe: Measured at the end of the last 3 weeks of randomization trial phase
| Intervention | ng/mL (Mean) |
|---|---|
| Reduced Nicotine Content Cigarettes | 82.8 |
| Usual Nicotine Content Cigarettes | 259.0 |
A 16-item scale on depression symptoms. The scale range is 0-27 where 0 = Least Severe and 27 = Most Severe. (NCT01928758)
Timeframe: Measured at the end of the last 3 weeks of randomization trial phase
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Nicotine Content Cigarettes | 5.5 |
| Usual Nicotine Content Cigarettes | 5.3 |
(NCT00129311)
Timeframe: 6-month follow up
| Intervention | participants (Number) |
|---|---|
| Selegiline | 6 |
| Placebo | 8 |
(NCT00129311)
Timeframe: Week 8
| Intervention | participants (Number) |
|---|---|
| Selegiline | 8 |
| Placebo | 10 |
"Point prevalence tobacco abstinence was adjudicated if the following conditions were met:(a) self-reported tobacco abstinence for the previous 7 days with a negative response to the question Have you used any type of tobacco,even a puff, in the past 7 days? and (b) Expired Carbon Monoxide equal or less then 8 parts per million." (NCT00405912)
Timeframe: 12 weeks following start of medication
| Intervention | participants (Number) |
|---|---|
| Placebo | 7 |
| St. John's Wort - 900 mg /Day | 8 |
| St. John's Wort - 1800 mg /Day | 6 |
tobacco abstience during the 12-week course of SJW in two different oral doses of 300-mg three times a day or 600-mg three times a day compared to placebo at six months. (NCT00405912)
Timeframe: 24 weeks after the start of medication
| Intervention | participants (Number) |
|---|---|
| Placebo | 0 |
| St. John's Wort - 900 mg /Day | 1 |
| St. John's Wort - 1800 mg /Day | 2 |
expired-air carbon monoxide confirmed smoking abstinence at 52 weeks (NCT01330030)
Timeframe: 52 weeks
| Intervention | participants not smoking (Number) |
|---|---|
| Drug Selegiline | 24 |
| Matching Placebo | 25 |
Self-reported daily use of the assigned study product. Range of scores is from 0 to about 20. Higher scores do not represent either a better or a worse outcome. Higher number of product used per day may indicate higher abuse liability of the product but may lead to a greater suppression in usual brand cigarette smoking. Lower number of product use per day may indicate lower abuse liability but may lead to lower suppression of usual brand smoking. (NCT00469079)
Timeframe: 4 weeks
| Intervention | uses per day (Least Squares Mean) |
|---|---|
| Medicinal Nicotine | 7.27 |
| Taboka | 5.27 |
| Snus | 6.76 |
This study was not powered to detect differences in smoking cessation rates between groups; however, smoking status was collected at each visit to obtain preliminary data. Point prevalence (no smoking during the previous 7 days) cigarette abstinence rates were calculated at the end of treatment and at each of the 2 follow-up visits (week 1 and 11 post-intervention). Continuous abstinence rates were calculated for the 4 week period between the week 1 and week 4 visits. Abstinence at all visits was assessed by self-report (i.e., no cigarettes smoked) and confirmed by an exhaled CO of less than 8 ppm. At the follow-up visits, abstinence was also confirmed by both exhaled CO concentrations and urinary cotinine concentration (<35 ng/mL). (NCT00469079)
Timeframe: 12 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| End of intervention continuous abstinence | 1 week post-intervention point prevalence | 11 weeks post intervention point prevalence | |
| Camel Snus | 22 | 24 | 16 |
| Medicinal Nicotine | 11 | 15 | 9 |
| Taboka | 17 | 22 | 12 |
Changes in craving and withdrawal symptoms were assessed at the time of discontinuation of usual brand cigarettes (i.e., baseline compared to week 1). Assessments were made using the Minnesota Nicotine Withdrawal Scale, which measures abstinence effects from usual brand cigarettes. Total Score: Range of scores is from 0 to 28. All items with the exclusion of craving are summed. Craving Score: Range of score is from 0 to 4. A higher score would indicate more severe withdrawal. (NCT00469079)
Timeframe: Baseline and 1 week
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Craving Scores | Nicotine Withdrawal Scores | |
| Medicinal Nicotine | 2.55 | 8.15 |
| Snus | 2.62 | 8.61 |
| Taboka | 2.76 | 8.89 |
Levels of carcinogen biomarkers (NNAL) reported as difference between baseline and week 4 scores. (NCT00469079)
Timeframe: Baseline, 4 weeks
| Intervention | ng/ml (Geometric Mean) | ||
|---|---|---|---|
| Cotinine | Total NNAL | Total NNN | |
| Medicinal Nicotine | 835.3 | 0.157 | 0.010 |
| Snus | 726.8 | 0.296 | 0.026 |
| Taboka | 782.1 | 0.281 | 0.011 |
(NCT00136760)
Timeframe: 3 weeks
| Intervention | cigarettes per day (Mean) |
|---|---|
| CM + BUP | 12.7 |
| CM + PLA | 13.9 |
| NR + BUP | 18.8 |
| NR + PLA | 21.0 |
Urinary Cotinine levels at Week 4 (average of last 3 study visits) (NCT00136760)
Timeframe: 3 weeks
| Intervention | ng/ml (Mean) |
|---|---|
| CM + BUP | 755 |
| CM + PLA | 1102 |
| NR + BUP | 1534 |
| NR + PLA | 1408 |
On the morning of surgery, as matter of clinical routine all patients receiving surgery requiring anesthesia services at one of the two main surgical facilities at Mayo Clinic Rochester and who self-report as a current smoker are asked about their typical cigarette consumption (cigarettes per day), if they have smoked cigarettes today, and have their exhaled CO levels measured (Micro Smokerlyzer; Bedfont, United Kingdom). This information is entered into the clinical record. The CO monitors are maintained by the Division of Respiratory Therapy, including regular calibration. (NCT01014455)
Timeframe: The median time from study assessment at POE to surgery was 1 day with an interquartile range of 1 to 3 days.
| Intervention | ppm (Mean) |
|---|---|
| CO Reminder | 9.7 |
| no CO Reminder | 9.3 |
Sensory effects: Measure of airway sensations (throat and chest). Mean enjoyment score (rating 0-4), higher the score indicating increased enjoyment. (NCT01454362)
Timeframe: 24 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Electronic Cigarette | 1.65 |
| Nicotine Inhalator | 0.51 |
"Cotinine is a measure sensitive enough to detect effects of a switch to different nicotine products and salivary cotinine was shown to be dependent on nicotine mouth exposure.~The results show the mean change in salivary cotinine in each study arm (all study participants)." (NCT01454362)
Timeframe: 24 hours
| Intervention | ng/ml (Mean) |
|---|---|
| Electronic Cigarette | -66.32 |
| Nicotine Inhalator | -53.8 |
"Mood and Physical Symptoms Scale (MPSS): Measure of severity of urges to smoke and tobacco withdrawal symptoms.~A five-point scale is used to rate 'How much of the time have you felt the urge to smoke in the past week?' ((1) 'not at all' to (5) 'almost all of the time') and 'How strong have the urges been?' ('no urges' to 'very strong'). Clients also rate depression, irritability, restlessness, hunger, poor concentration, poor sleep at night, and anxiety during the past week ((1)=not at all to (5)=extremely). The combined score to questions on depression, irritability, restlessness, hunger, and poor concentration are averaged to give the MPSS score. A higher score means a more severe rating of withdrawal.~The primary outcome is a change in MPSS score between baseline and 24 hours (value at 24 hours minus value at baseline). Therefore, a smaller change in MPSS score represents a smaller increase in tobacco withdrawal symptoms." (NCT01454362)
Timeframe: 24 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Electronic Cigarette | 0.73 |
| Nicotine Inhalator | 0.86 |
Product satisfaction: Ratings of product satisfaction (when compared to cigarettes). Rating 0-4, with higher value indicating higher satisfaction ratings. (NCT01454362)
Timeframe: 24 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Electronic Cigarette | 1.18 |
| Nicotine Inhalator | 0.59 |
Modified Cigarette Evaluation Questionnaire (mCEQ): Measure of reinforcing effects of smoking (pleasant feeling). Mean pleasant feeling from using product (rating 0-4). Higher value indicating the higher rating of pleasure. (NCT01454362)
Timeframe: 24 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Electronic Cigarette | 2 |
| Nicotine Inhalator | 0.67 |
A self-report measure of continuous abstinence at end of treatment. It is defined as the number of consecutive days without smoking a cigarette for each subject, as determined by the Timeline Followback (TLFB), completed by research staff. The TLFB is an assessment tool that obtains estimates of daily smoking. Using a calendar, people provide retrospective estimates of their daily smoking over a specified time period that can vary up to 12 months from the interview date. The TLFB has also been used to assess other forms of substance abuse (e.g., alcohol, drugs, etc.). (NCT00326781)
Timeframe: End of Treatment (8-weeks after quit date)
| Intervention | Participants (Number) |
|---|---|
| Transdermal Nicotine | 83 |
| Nicotine Nasal Spray | 75 |
"End-of-Treatment (EOT) is defined as the phone survey that takes place at the end of each subject's nicotine replacement therapy treatment. The EOT took place up to 8 weeks after participants began the study and also utilized the Timeline Followback. It is a 7-day point prevalence measure describing a subject's ability to remain abstinent from smoking for the 7 previous days occurring before a subject's EOT phone survey.~This was verified by a Carbon Monoxide breath reading taking place within a week of a subject's End of Treatment phone survey." (NCT00326781)
Timeframe: End of Treatment
| Intervention | participants (Number) |
|---|---|
| Transdermal Nicotine | 112 |
| Nicotine Nasal Spray | 95 |
Smoking status is verified by measuring the concentration of carbon monoxide (CO) in expired air. Participants with a breath CO content less than or equal to 8 parts per million are characterized as abstinent from smoking for at least 7 days. (NCT01932996)
Timeframe: at weeks 12
| Intervention | percentage of participants (Number) |
|---|---|
| Integrated Intensive Smoking + Alcohol | 21.6 |
| Usual Care | 14 |
Smoking status is verified by measuring the concentration of carbon monoxide (CO) in expired air. Participants with a breath CO content less than or equal to 8 parts per million are characterized as abstinent from smoking for at least 7 days. (NCT01932996)
Timeframe: 7-day smoking abstinence at week 26 follow-up
| Intervention | percentage of participants (Number) |
|---|---|
| Integrated Intensive Smoking + Alcohol | 16.3 |
| Usual Care | 12.6 |
Participants will use a self-administered timeline-followback instrument, which asks them to retrospectively estimate their alcohol use in the 30 days prior to the report date. Outcome is reported as the mean number of continuous alcohol-free days over the past 30 day period. (NCT01932996)
Timeframe: at week 26
| Intervention | days (Mean) |
|---|---|
| Integrated Intensive Smoking + Alcohol | 3.4 |
| Usual Care | 3.9 |
25 reviews available for carbon monoxide and Smoking Cessation
| Article | Year |
|---|---|
Effect of menthol on nicotine reduction: Pooled results from two double-blind randomized controlled trials.
Topics: Carbon Monoxide; Cotinine; Humans; Menthol; Nicotine; Randomized Controlled Trials as Topic; Recepto | 2022 |
Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT.
Topics: Carbon Monoxide; Cost-Benefit Analysis; Exercise; Humans; Middle Aged; Multicenter Studies as Topic; | 2023 |
Biochemical Verification of Tobacco Use and Abstinence: 2019 Update.
Topics: Biomarkers; Carbon Monoxide; Cigarette Smoking; Cotinine; Humans; Nicotine; Smoking Cessation; Tobac | 2020 |
Interventions to reduce tobacco use in people experiencing homelessness.
Topics: Adult; Bias; Carbon Monoxide; Cognitive Behavioral Therapy; Cotinine; Counseling; Electronic Nicotin | 2020 |
Cessation classification likelihood increases with higher expired-air carbon monoxide cutoffs: a meta-analysis.
Topics: Adult; Carbon Monoxide; Humans; Male; Probability; Smokers; Smoking; Smoking Cessation | 2021 |
Use of Expired Air Carbon Monoxide Testing in Clinical Tobacco Treatment Settings.
Topics: Breath Tests; Carbon Monoxide; Humans; Patient Care Planning; Smoking Cessation; Smoking Prevention | 2018 |
Biomedical risk assessment as an aid for smoking cessation.
Topics: Adult; Biofeedback, Psychology; Breath Tests; Carbon Monoxide; Female; Genetic Predisposition to Dis | 2019 |
'Hubble-bubble leads to trouble'--waterpipe smoking and oral health.
Topics: Attitude to Health; Carbon Monoxide; Humans; Nicotine; Oral Health; Smoking; Smoking Cessation; Toba | 2013 |
The pathophysiology of smoking during pregnancy: a systems biology approach.
Topics: Biomarkers; Calcinosis; Carbon Monoxide; Dinoprost; Female; Humans; Oxidative Stress; Placenta; Preg | 2014 |
Does the Magnitude of Reduction in Cigarettes Per Day Predict Smoking Cessation? A Qualitative Review.
Topics: Adult; Carbon Monoxide; Female; Humans; Motivation; Smoking Cessation; Smoking Prevention; Tobacco P | 2016 |
Patients with lung cancer: Are electronic cigarettes harmful or useful?
Topics: Carbon Monoxide; Electronic Nicotine Delivery Systems; Humans; Lung Neoplasms; Nitrosamines; Smoking | 2017 |
Interventions to reduce harm from continued tobacco use.
Topics: Biomarkers; Bupropion; Carbon Monoxide; Cotinine; Electronic Nicotine Delivery Systems; Humans; Nico | 2016 |
Smoking and smoking cessation -- the relationship between cardiovascular disease and lipoprotein metabolism: a review.
Topics: Carbon Monoxide; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Humans; Lipids; | 2008 |
Biomedical risk assessment as an aid for smoking cessation.
Topics: Biofeedback, Psychology; Breath Tests; Carbon Monoxide; Genetic Predisposition to Disease; Humans; R | 2009 |
Biomedical risk assessment as an aid for smoking cessation.
Topics: Biofeedback, Psychology; Breath Tests; Carbon Monoxide; Genetic Predisposition to Disease; Humans; R | 2012 |
Cigarette smoking: Evidence to guide measurement.
Topics: Adolescent; Adolescent Behavior; Biomarkers; Carbon Monoxide; Cotinine; Female; Half-Life; Humans; M | 2004 |
Recent marijuana blunt smoking impacts carbon monoxide as a measure of adolescent tobacco abstinence.
Topics: Adolescent; Breath Tests; Carbon Monoxide; Cognitive Behavioral Therapy; Female; Humans; Male; Marij | 2005 |
Smoking cessation in patients with coronary artery disease.
Topics: Administration, Cutaneous; Administration, Inhalation; Administration, Oral; Atherosclerosis; Behavi | 2005 |
Biomedical risk assessment as an aid for smoking cessation.
Topics: Biofeedback, Psychology; Breath Tests; Carbon Monoxide; Genetic Predisposition to Disease; Humans; R | 2005 |
Possible effects on smokers of cigarette mentholation: a review of the evidence relating to key research questions.
Topics: Adult; Black or African American; Blood Pressure; Carbon Monoxide; Cotinine; Female; Health Behavior | 2007 |
Interventions to reduce harm from continued tobacco use.
Topics: Biomarkers; Bupropion; Carbon Monoxide; Cotinine; Humans; Nicotine; Nicotinic Agonists; Smoking; Smo | 2007 |
Chemical analyses as validators in smoking cessation programs.
Topics: Biomarkers; Biotransformation; Breath Tests; Carbon Monoxide; Cotinine; Follow-Up Studies; Humans; M | 1993 |
A pathophysiological basis for informed preoperative smoking cessation counseling.
Topics: Carbon Monoxide; Counseling; Humans; Nicotine; Nitric Oxide; Smoke; Smoking; Smoking Cessation; Tars | 1997 |
Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials.
Topics: Administration, Cutaneous; Adult; Carbon Monoxide; Double-Blind Method; Female; Humans; Male; Middle | 1999 |
Helping smokers to stop: an evidence-based approach.
Topics: Algorithms; Carbon Monoxide; Evidence-Based Medicine; Family Practice; Humans; Smoking Cessation; To | 2000 |
216 trials available for carbon monoxide and Smoking Cessation
| Article | Year |
|---|---|
Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial.
Topics: Carbon Monoxide; Combined Modality Therapy; Confidence Intervals; Double-Blind Method; Female; Human | 2021 |
Effect of Technology-Assisted Brief Abstinence Game on Long-term Smoking Cessation in Individuals Not Yet Ready to Quit: A Randomized Clinical Trial.
Topics: Carbon Monoxide; Delivery of Health Care; Female; Humans; Male; Middle Aged; Smoking Cessation; Tech | 2022 |
E-Cigarette Provision to Promote Switching in Cigarette Smokers With Serious Mental Illness-A Randomized Trial.
Topics: Carbon Monoxide; Electronic Nicotine Delivery Systems; Humans; Prospective Studies; Smokers; Smoking | 2022 |
Long-Term Effectiveness of a Clinician-Assisted Digital Cognitive Behavioral Therapy Intervention for Smoking Cessation: Secondary Outcomes From a Randomized Controlled Trial.
Topics: Adult; Carbon Monoxide; Cognitive Behavioral Therapy; Humans; Smoking Cessation; Tobacco Use Cessati | 2022 |
Varenicline Treatment for Waterpipe Smoking Cessation.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Humans; Male; Nicotinic Agonists; Smoking Cessation; Varen | 2023 |
Outcomes of a Comprehensive Mobile Smoking Cessation Program With Nicotine Replacement Therapy in Adult Smokers: Pilot Randomized Controlled Trial.
Topics: Adult; Carbon Monoxide; Female; Humans; Male; Middle Aged; Pilot Projects; Smokers; Smoking Cessatio | 2022 |
A Secondary Analysis of a Preliminary Contingency Management Intervention for Presurgical Cancer Patients: Evaluating Individual Participant Data.
Topics: Carbon Monoxide; Humans; Motivation; Neoplasms; Recurrence; Smoking Cessation; Tobacco Use Cessation | 2023 |
Comparison of the Bluetooth iCOquit, piCO, and Vitalograph for the assessment of breath carbon monoxide among adults initiating smoking cessation and standardized canisters.
Topics: Adult; Breath Tests; Carbon Monoxide; Humans; Smoking; Smoking Cessation; Tobacco Smoking; Tobacco U | 2023 |
Evaluating the impact of varying expired carbon monoxide thresholds on smoking relapse identification: insights from the E3 trial on e-cigarette efficacy for smoking cessation.
Topics: Adult; Canada; Carbon Monoxide; Electronic Nicotine Delivery Systems; Humans; Smoking Cessation; Vap | 2023 |
Withdrawal Symptoms From E-Cigarette Abstinence Among Adult Never-Smokers: A Pilot Experimental Study.
Topics: Adult; Behavior, Addictive; Carbon Monoxide; Electronic Nicotine Delivery Systems; Female; Health Be | 2020 |
Effectiveness of a Brief Self-determination Theory-Based Smoking Cessation Intervention for Smokers at Emergency Departments in Hong Kong: A Randomized Clinical Trial.
Topics: Adult; Breath Tests; Carbon Monoxide; Cigarette Smoking; Cost-Benefit Analysis; Cotinine; Counseling | 2020 |
Effectiveness of a Brief Self-determination Theory-Based Smoking Cessation Intervention for Smokers at Emergency Departments in Hong Kong: A Randomized Clinical Trial.
Topics: Adult; Breath Tests; Carbon Monoxide; Cigarette Smoking; Cost-Benefit Analysis; Cotinine; Counseling | 2020 |
Effectiveness of a Brief Self-determination Theory-Based Smoking Cessation Intervention for Smokers at Emergency Departments in Hong Kong: A Randomized Clinical Trial.
Topics: Adult; Breath Tests; Carbon Monoxide; Cigarette Smoking; Cost-Benefit Analysis; Cotinine; Counseling | 2020 |
Effectiveness of a Brief Self-determination Theory-Based Smoking Cessation Intervention for Smokers at Emergency Departments in Hong Kong: A Randomized Clinical Trial.
Topics: Adult; Breath Tests; Carbon Monoxide; Cigarette Smoking; Cost-Benefit Analysis; Cotinine; Counseling | 2020 |
A Randomized Clinical Trial Examining the Effects of Instructions for Electronic Cigarette Use on Smoking-Related Behaviors and Biomarkers of Exposure.
Topics: Adult; Aged; Biomarkers; Carbon Monoxide; Carcinogens; Cigarette Smoking; Electronic Nicotine Delive | 2020 |
Smartphone App and Carbon Monoxide Self-Monitoring Support for Smoking Cessation: A Randomized Controlled Trial Nested into the Swiss HIV Cohort Study.
Topics: Adult; Carbon Monoxide; Cohort Studies; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mo | 2020 |
Randomized clinical trial to determine the effectiveness of CO-oximetry and anti-smoking brief advice in a cohort of kidney transplant patients who smoke.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Follow-Up Studies; Graft Rejection; Humans; Kidney Transpl | 2020 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Chat-based instant messaging support integrated with brief interventions for smoking cessation: a community-based, pragmatic, cluster-randomised controlled trial.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Hong Kong; Humans; Intention; Male; Mobile Applications; R | 2019 |
Comparison of Interventional Methods to Motivate and Change the Behavioural Stage of Smokers to Quit Smoking- A Hospital Based Randomised Controlled Trial.
Topics: Adolescent; Adult; Breath Tests; Carbon Monoxide; Cheilitis; Counseling; Female; Humans; Leukoplakia | 2021 |
Brief Advice, Nicotine Replacement Therapy Sampling, and Active Referral for Expectant Fathers Who Smoke Cigarettes: A Randomized Clinical Trial.
Topics: Adult; Behavior Therapy; Breath Tests; Carbon Monoxide; Cigarette Smoking; Family Health; Fathers; F | 2021 |
A pilot randomized controlled trial of smartphone-assisted mindfulness-based intervention with contingency management for smokers with mood disorders.
Topics: Adult; Carbon Monoxide; Humans; Mindfulness; Mood Disorders; Pilot Projects; Smartphone; Smokers; Sm | 2022 |
Effects of varenicline and nicotine replacement therapy on arterial elasticity, endothelial glycocalyx and oxidative stress during a 3-month smoking cessation program.
Topics: Adult; Aged; Breath Tests; Carbon Monoxide; Endothelial Cells; Female; Glycocalyx; Greece; Humans; M | 2017 |
Predictors of treatment success in smoking cessation with varenicline combined with nicotine replacement therapy v. varenicline alone.
Topics: Adult; Age Factors; Breath Tests; Carbon Monoxide; Female; Humans; Male; Middle Aged; Nicotinic Agon | 2017 |
Contingency management for college student smokers: The role of drinking as a moderator and mediator of smoking abstinence during treatment.
Topics: Adolescent; Alcohol Drinking in College; Behavior Therapy; Breath Tests; Carbon Monoxide; Cigarette | 2018 |
Adolescent smokers' response to reducing the nicotine content of cigarettes: Acute effects on withdrawal symptoms and subjective evaluations.
Topics: Adolescent; Affect; Breath Tests; Carbon Monoxide; Craving; Dose-Response Relationship, Drug; Female | 2018 |
Smoking outcome expectancies predict smoking during voucher-based treatment for smokers with substance use disorders.
Topics: Adult; Carbon Monoxide; Counseling; Female; Humans; Male; Motivation; Residential Treatment; Reward; | 2018 |
Effects of nicotine deprivation on current pain intensity among daily cigarette smokers.
Topics: Adult; Carbon Monoxide; Chronic Pain; Cigarette Smoking; Cross-Sectional Studies; Female; Humans; Ma | 2018 |
COach2Quit: A Pilot Randomized Controlled Trial of a Personal Carbon Monoxide Monitor for Smoking Cessation.
Topics: Baltimore; Biofeedback, Psychology; Biomarkers; Carbon Monoxide; Cell Phone; Female; Humans; Male; M | 2019 |
Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial.
Topics: Acetylcysteine; Adult; Area Under Curve; Biomarkers; Breath Tests; Carbon Monoxide; Creatinine; Doub | 2018 |
Biomarkers of Exposure Among "Dual Users" of Tobacco Cigarettes and Electronic Cigarettes in Canada.
Topics: Adult; Biomarkers; Breath Tests; Carbon Monoxide; Cigarette Smoking; Cross-Over Studies; Electronic | 2019 |
Web-Based Contingency Management for Adolescent Tobacco Smokers: A Clinical Trial.
Topics: Adolescent; Behavior Therapy; Biomarkers; Carbon Monoxide; Female; Humans; Internet; Male; Self Repo | 2020 |
Efficacy and Safety of a Nicotine Mouth Spray for Smoking Cessation: A Randomized, Multicenter, Controlled Study in a Naturalistic Setting.
Topics: Carbon Monoxide; Counseling; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nicot | 2020 |
Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease: A Randomized Clinical Trial.
Topics: Adult; Aged; Carbon Monoxide; Chronic Disease; Counseling; Female; Humans; Lung Diseases; Male; Midd | 2018 |
A cluster randomised controlled trial on effectiveness of carbon monoxide measurement feedback among college smoker : A study protocol.
Topics: Adolescent; Carbon Monoxide; Feedback; Female; Humans; Male; Motivation; Single-Blind Method; Smokin | 2019 |
Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population.
Topics: Adult; Body Weight; Carbon Monoxide; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosy | 2019 |
A Pilot Study of E-Cigarette Naïve Cigarette Smokers and the Effects on Craving After Acute Exposure to E-Cigarettes in the Laboratory.
Topics: Adult; Carbon Monoxide; Cigarette Smoking; Craving; Double-Blind Method; Electronic Nicotine Deliver | 2019 |
Enhanced smoking cessation support for newly abstinent smokers discharged from hospital (the Hospital to Home trial): a randomized controlled trial.
Topics: Adult; Aged; Air Pollution, Indoor; Breath Tests; Carbon Monoxide; Counseling; Feedback; Female; Hos | 2019 |
A Randomized Clinical Trial of Snus Examining the Effect of Complete Versus Partial Cigarette Substitution on Smoking-Related Behaviors, and Biomarkers of Exposure.
Topics: Adolescent; Adult; Biomarkers; Carbon Monoxide; Female; Humans; Male; Middle Aged; Minnesota; New Yo | 2020 |
Withdrawal Symptoms From E-Cigarette Abstinence Among Former Smokers: A Pre-Post Clinical Trial.
Topics: Adolescent; Adult; Aged; Carbon Monoxide; Electronic Nicotine Delivery Systems; Female; Health Behav | 2020 |
A pharmacist-led system-change smoking cessation intervention for smokers admitted to Australian public hospitals (GIVE UP FOR GOOD): study protocol for a randomised controlled trial.
Topics: Biomarkers; Breath Tests; Carbon Monoxide; Clinical Protocols; Hospitals, Public; Humans; Inpatients | 2013 |
Carbon monoxide feedback in a motivational decision support system for nicotine dependence among smokers with severe mental illnesses.
Topics: Adult; Behavior Therapy; Carbon Monoxide; Decision Support Techniques; Feedback; Female; Humans; Mal | 2013 |
Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial.
Topics: Adult; Benzazepines; Carbon Monoxide; Female; Follow-Up Studies; Guideline Adherence; Heroin Depende | 2013 |
Electronic cigarettes for smoking cessation: a randomised controlled trial.
Topics: Adult; Breath Tests; Carbon Monoxide; Counseling; Female; Humans; Male; Middle Aged; New Zealand; Ni | 2013 |
Electronic cigarettes for smoking cessation: a randomised controlled trial.
Topics: Adult; Breath Tests; Carbon Monoxide; Counseling; Female; Humans; Male; Middle Aged; New Zealand; Ni | 2013 |
Electronic cigarettes for smoking cessation: a randomised controlled trial.
Topics: Adult; Breath Tests; Carbon Monoxide; Counseling; Female; Humans; Male; Middle Aged; New Zealand; Ni | 2013 |
Electronic cigarettes for smoking cessation: a randomised controlled trial.
Topics: Adult; Breath Tests; Carbon Monoxide; Counseling; Female; Humans; Male; Middle Aged; New Zealand; Ni | 2013 |
Electronic cigarettes for smoking cessation: a randomised controlled trial.
Topics: Adult; Breath Tests; Carbon Monoxide; Counseling; Female; Humans; Male; Middle Aged; New Zealand; Ni | 2013 |
Electronic cigarettes for smoking cessation: a randomised controlled trial.
Topics: Adult; Breath Tests; Carbon Monoxide; Counseling; Female; Humans; Male; Middle Aged; New Zealand; Ni | 2013 |
Electronic cigarettes for smoking cessation: a randomised controlled trial.
Topics: Adult; Breath Tests; Carbon Monoxide; Counseling; Female; Humans; Male; Middle Aged; New Zealand; Ni | 2013 |
Electronic cigarettes for smoking cessation: a randomised controlled trial.
Topics: Adult; Breath Tests; Carbon Monoxide; Counseling; Female; Humans; Male; Middle Aged; New Zealand; Ni | 2013 |
Electronic cigarettes for smoking cessation: a randomised controlled trial.
Topics: Adult; Breath Tests; Carbon Monoxide; Counseling; Female; Humans; Male; Middle Aged; New Zealand; Ni | 2013 |
[Effects of a smoking cessation program including telephone counseling and text messaging using stages of change for outpatients after a myocardial infarction].
Topics: Adult; Carbon Monoxide; Counseling; Female; Hospitals, University; Humans; Male; Middle Aged; Myocar | 2013 |
Internet-based contingency management to promote smoking cessation: a randomized controlled study.
Topics: Adolescent; Adult; Behavior Therapy; Breath Tests; Carbon Monoxide; Female; Follow-Up Studies; Healt | 2013 |
The effect of successful and unsuccessful smoking cessation on short-term anxiety, depression, and suicidality.
Topics: Adolescent; Adult; Aged; Anxiety; Breath Tests; Carbon Monoxide; Depression; Female; Humans; Male; M | 2014 |
Prize contingency management for smoking cessation: a randomized trial.
Topics: Adult; Behavior Therapy; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Reinforcement | 2014 |
The effects of percentile versus fixed criterion schedules on smoking with equal incentive magnitude for initial abstinence.
Topics: Adult; Breath Tests; Carbon Monoxide; Female; Humans; Male; Middle Aged; Motivation; Reinforcement S | 2014 |
Smoking reductions and increased self-efficacy in a randomized controlled trial of smoking abstinence-contingent incentives in residential substance abuse treatment patients.
Topics: Adult; Behavior Therapy; Carbon Monoxide; Cotinine; Female; Follow-Up Studies; Humans; Male; Middle | 2014 |
Effect on smoking quit rate of telling smokers their health risk appraisal in terms of health age: a randomized control trial.
Topics: Adult; Aged; Carbon Monoxide; Cotinine; Counseling; Follow-Up Studies; Health Status Indicators; Hum | 2014 |
Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial.
Topics: Adult; Benzazepines; Breath Tests; Carbon Monoxide; Cholinergic Agents; Double-Blind Method; Drug Th | 2014 |
Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial.
Topics: Adult; Benzazepines; Breath Tests; Carbon Monoxide; Cholinergic Agents; Double-Blind Method; Drug Th | 2014 |
Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial.
Topics: Adult; Benzazepines; Breath Tests; Carbon Monoxide; Cholinergic Agents; Double-Blind Method; Drug Th | 2014 |
Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial.
Topics: Adult; Benzazepines; Breath Tests; Carbon Monoxide; Cholinergic Agents; Double-Blind Method; Drug Th | 2014 |
Beyond cigarettes per day. A genome-wide association study of the biomarker carbon monoxide.
Topics: Adult; Biomarkers; Black or African American; Carbon Monoxide; Confidence Intervals; Cytochrome P-45 | 2014 |
Feasibility and preliminary efficacy of a web-based smoking cessation intervention for HIV-infected smokers: a randomized controlled trial.
Topics: Breath Tests; Carbon Monoxide; Female; HIV Infections; HIV-1; Humans; Internet; Logistic Models; Mal | 2014 |
Feasibility and preliminary efficacy of a web-based smoking cessation intervention for HIV-infected smokers: a randomized controlled trial.
Topics: Breath Tests; Carbon Monoxide; Female; HIV Infections; HIV-1; Humans; Internet; Logistic Models; Mal | 2014 |
Feasibility and preliminary efficacy of a web-based smoking cessation intervention for HIV-infected smokers: a randomized controlled trial.
Topics: Breath Tests; Carbon Monoxide; Female; HIV Infections; HIV-1; Humans; Internet; Logistic Models; Mal | 2014 |
Feasibility and preliminary efficacy of a web-based smoking cessation intervention for HIV-infected smokers: a randomized controlled trial.
Topics: Breath Tests; Carbon Monoxide; Female; HIV Infections; HIV-1; Humans; Internet; Logistic Models; Mal | 2014 |
Feasibility and preliminary efficacy of a web-based smoking cessation intervention for HIV-infected smokers: a randomized controlled trial.
Topics: Breath Tests; Carbon Monoxide; Female; HIV Infections; HIV-1; Humans; Internet; Logistic Models; Mal | 2014 |
Feasibility and preliminary efficacy of a web-based smoking cessation intervention for HIV-infected smokers: a randomized controlled trial.
Topics: Breath Tests; Carbon Monoxide; Female; HIV Infections; HIV-1; Humans; Internet; Logistic Models; Mal | 2014 |
Feasibility and preliminary efficacy of a web-based smoking cessation intervention for HIV-infected smokers: a randomized controlled trial.
Topics: Breath Tests; Carbon Monoxide; Female; HIV Infections; HIV-1; Humans; Internet; Logistic Models; Mal | 2014 |
Feasibility and preliminary efficacy of a web-based smoking cessation intervention for HIV-infected smokers: a randomized controlled trial.
Topics: Breath Tests; Carbon Monoxide; Female; HIV Infections; HIV-1; Humans; Internet; Logistic Models; Mal | 2014 |
Feasibility and preliminary efficacy of a web-based smoking cessation intervention for HIV-infected smokers: a randomized controlled trial.
Topics: Breath Tests; Carbon Monoxide; Female; HIV Infections; HIV-1; Humans; Internet; Logistic Models; Mal | 2014 |
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
Topics: Attitude; Behavior, Addictive; Biomarkers; Carbon Monoxide; Cognitive Behavioral Therapy; Combined M | 2014 |
Intolerance for withdrawal discomfort and motivation predict voucher-based smoking treatment outcomes for smokers with substance use disorders.
Topics: Adolescent; Adult; Carbon Monoxide; Counseling; Female; Humans; Male; Middle Aged; Motivation; Patie | 2015 |
Financial incentives for smoking cessation in pregnancy: randomised controlled trial.
Topics: Adolescent; Adult; Birth Weight; Breath Tests; Carbon Monoxide; Cotinine; Female; Health Promotion; | 2015 |
The effects of fixed versus escalating reinforcement schedules on smoking abstinence.
Topics: Adult; Breath Tests; Carbon Monoxide; Female; Humans; Male; Middle Aged; Motivation; Reinforcement S | 2015 |
Mindfulness training for smokers via web-based video instruction with phone support: a prospective observational study.
Topics: Adult; Audiovisual Aids; Carbon Monoxide; Counseling; Female; Humans; Internet; Male; Meditation; Mi | 2015 |
Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence.
Topics: Adult; Carbon Monoxide; Cross-Over Studies; Double-Blind Method; Female; Fenofibrate; Humans; Male; | 2016 |
The effect of motivational lung age feedback on short-term quit rates in smokers seeking intensive group treatment: A randomized controlled pilot study.
Topics: Adult; Carbon Monoxide; Combined Modality Therapy; Counseling; Feedback, Psychological; Female; Huma | 2015 |
Electronic Cigarettes Efficacy and Safety at 12 Months: Cohort Study.
Topics: Adult; Aged; Carbon Monoxide; Electronic Nicotine Delivery Systems; Female; Humans; Male; Middle Age | 2015 |
One-Year Effects of Project EX in Spain: A Classroom-Based Smoking Prevention and Cessation Intervention Program.
Topics: Adolescent; Carbon Monoxide; Curriculum; Female; Follow-Up Studies; Health Education; Humans; Male; | 2015 |
Effect of reducing the nicotine content of cigarettes on cigarette smoking behavior and tobacco smoke toxicant exposure: 2-year follow up.
Topics: Adult; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Nicotiana; Nicotine; Nicotinic | 2015 |
Contingency management for cigarette smokers with depressive symptoms.
Topics: Adult; Carbon Monoxide; Cognitive Behavioral Therapy; Cotinine; Depression; Female; Follow-Up Studie | 2015 |
Contingency management for cigarette smokers with depressive symptoms.
Topics: Adult; Carbon Monoxide; Cognitive Behavioral Therapy; Cotinine; Depression; Female; Follow-Up Studie | 2015 |
Contingency management for cigarette smokers with depressive symptoms.
Topics: Adult; Carbon Monoxide; Cognitive Behavioral Therapy; Cotinine; Depression; Female; Follow-Up Studie | 2015 |
Contingency management for cigarette smokers with depressive symptoms.
Topics: Adult; Carbon Monoxide; Cognitive Behavioral Therapy; Cotinine; Depression; Female; Follow-Up Studie | 2015 |
A feasibility study of home-based contingency management with adolescent smokers of rural Appalachia.
Topics: Adolescent; Appalachian Region; Behavior Therapy; Breath Tests; Carbon Monoxide; Feasibility Studies | 2015 |
A comparative study of different modalities of treatment in nicotine dependence syndrome.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Behavior Control; Breath Tests; Brief P | 2015 |
Financial incentives to promote extended smoking abstinence in opioid-maintained patients: a randomized trial.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Analgesics, Opioid; Breath Tests; Bupropion; Carbon Monoxi | 2016 |
A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part B: Safety and subjective effects.
Topics: Administration, Inhalation; Adult; Aged; Breath Tests; Carbon Monoxide; Consumer Product Safety; Cro | 2016 |
Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial.
Topics: Adult; Carbon Monoxide; Counseling; Female; Humans; Intention to Treat Analysis; Male; Medication Ad | 2016 |
Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial.
Topics: Adult; Carbon Monoxide; Counseling; Female; Humans; Intention to Treat Analysis; Male; Medication Ad | 2016 |
Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial.
Topics: Adult; Carbon Monoxide; Counseling; Female; Humans; Intention to Treat Analysis; Male; Medication Ad | 2016 |
Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial.
Topics: Adult; Carbon Monoxide; Counseling; Female; Humans; Intention to Treat Analysis; Male; Medication Ad | 2016 |
Self-reported smoking effects and comparative value between cigarettes and high dose e-cigarettes in nicotine-dependent cigarette smokers.
Topics: Adult; Carbon Monoxide; Choice Behavior; Cross-Over Studies; Electronic Nicotine Delivery Systems; F | 2016 |
A randomized clinical trial to determine the effectiveness of CO-oximetry and anti-smoking brief advice in a cohort of kidney transplant patients who smoke: study protocol for a randomized controlled trial.
Topics: Biomarkers; Breath Tests; Carbon Monoxide; Clinical Protocols; Health Behavior; Health Knowledge, At | 2016 |
Elimination of Cigarette Smoke-derived Acetaldehyde in Saliva by Slow-release L-Cysteine Lozenge Is a Potential New Method to Assist Smoking Cessation. A Randomised, Double-blind, Placebo-controlled Intervention.
Topics: Acetaldehyde; Administration, Oral; Adult; Breath Tests; Carbon Monoxide; Cysteine; Delayed-Action P | 2016 |
Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes.
Topics: Adolescent; Adult; Aged; Breath Tests; Carbon Monoxide; Electronic Nicotine Delivery Systems; Exhala | 2016 |
Twelve Weeks of Successful Smoking Cessation Therapy with Varenicline Reduces Spirometric Lung Age.
Topics: Adult; Carbon Monoxide; Female; Humans; Lung; Male; Middle Aged; Nicotinic Agonists; Smoking; Smokin | 2016 |
A Randomized Trial of Adjunct mHealth Abstinence Reinforcement With Transdermal Nicotine and Counseling for Smoking Cessation.
Topics: Carbon Monoxide; Counseling; Humans; Smoking Cessation; Telemedicine; Tobacco Use Cessation Devices | 2017 |
A Community-Based Participatory Research on Smoking Cessation Intervention for Urban Communities.
Topics: Adult; Breath Tests; Carbon Monoxide; Community-Based Participatory Research; Counseling; Female; Hu | 2016 |
A Community-Based Participatory Research on Smoking Cessation Intervention for Urban Communities.
Topics: Adult; Breath Tests; Carbon Monoxide; Community-Based Participatory Research; Counseling; Female; Hu | 2016 |
A Community-Based Participatory Research on Smoking Cessation Intervention for Urban Communities.
Topics: Adult; Breath Tests; Carbon Monoxide; Community-Based Participatory Research; Counseling; Female; Hu | 2016 |
A Community-Based Participatory Research on Smoking Cessation Intervention for Urban Communities.
Topics: Adult; Breath Tests; Carbon Monoxide; Community-Based Participatory Research; Counseling; Female; Hu | 2016 |
Nationwide access to an internet-based contingency management intervention to promote smoking cessation: a randomized controlled trial.
Topics: Adult; Behavior Therapy; Breath Tests; Carbon Monoxide; Female; Health Services Accessibility; Human | 2017 |
A two-site, two-arm, 34-week, double-blind, parallel-group, randomized controlled trial of reduced nicotine cigarettes in smokers with mood and/or anxiety disorders: trial design and protocol.
Topics: Adult; Anxiety Disorders; Biomarkers; Carbon Monoxide; Clinical Protocols; Cotinine; Double-Blind Me | 2017 |
Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
Topics: Adult; alpha7 Nicotinic Acetylcholine Receptor; Antipsychotic Agents; Breath Tests; Carbon Monoxide; | 2008 |
Abstinence from smoking ten years after participation in a randomized controlled trial of a self-help program.
Topics: Adult; Breath Tests; Carbon Monoxide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Postal S | 2008 |
Comparison of expired carbon monoxide and plasma cotinine as markers of cigarette abstinence.
Topics: Adult; Antidepressive Agents, Second-Generation; Breath Tests; Bupropion; Carbon Monoxide; Cotinine; | 2008 |
A randomized trial of nicotine nasal spray in adolescent smokers.
Topics: Administration, Intranasal; Adolescent; Air; Breath Tests; California; Carbon Monoxide; Cotinine; Co | 2008 |
Extended cognitive behavior therapy for cigarette smoking cessation.
Topics: Adult; Bupropion; Carbon Monoxide; Cognitive Behavioral Therapy; Counseling; Dopamine Uptake Inhibit | 2008 |
Extended cognitive behavior therapy for cigarette smoking cessation.
Topics: Adult; Bupropion; Carbon Monoxide; Cognitive Behavioral Therapy; Counseling; Dopamine Uptake Inhibit | 2008 |
Extended cognitive behavior therapy for cigarette smoking cessation.
Topics: Adult; Bupropion; Carbon Monoxide; Cognitive Behavioral Therapy; Counseling; Dopamine Uptake Inhibit | 2008 |
Extended cognitive behavior therapy for cigarette smoking cessation.
Topics: Adult; Bupropion; Carbon Monoxide; Cognitive Behavioral Therapy; Counseling; Dopamine Uptake Inhibit | 2008 |
Contingency management for smoking cessation: enhancing feasibility through use of immunoassay test strips measuring cotinine.
Topics: Adolescent; Adult; Biomarkers; Carbon Monoxide; Cotinine; Feasibility Studies; Female; Gas Chromatog | 2008 |
Long-term results of a smoking reduction program.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Biomarkers; Carbon Monoxide; Colorado; Diagnostic | 2009 |
Severity of tobacco abstinence symptoms varies by time of day.
Topics: Administration, Cutaneous; Adult; Carbon Monoxide; Cross-Over Studies; Dose-Response Relationship, D | 2009 |
Immediate and short-term impact of a brief motivational smoking intervention using a biomedical risk assessment: the Get PHIT trial.
Topics: Carbon Monoxide; Female; Humans; Male; Middle Aged; Motivation; Program Evaluation; Respiratory Func | 2009 |
Prolonged exposure to denicotinized cigarettes with or without transdermal nicotine.
Topics: Administration, Cutaneous; Adolescent; Adult; Affect; Aged; Carbon Monoxide; Double-Blind Method; Ex | 2009 |
Family support and employment as predictors of smoking cessation success: a randomized, double-blind, placebo-controlled trial of nicotine sublingual tablets in chinese smokers.
Topics: Administration, Sublingual; Adult; Carbon Monoxide; China; Cotinine; Double-Blind Method; Family Rel | 2009 |
Impact of a brief motivational smoking cessation intervention the Get PHIT randomized controlled trial.
Topics: Adult; Carbon Monoxide; Directive Counseling; Female; Follow-Up Studies; Humans; Male; Middle Aged; | 2009 |
An internet-based abstinence reinforcement smoking cessation intervention in rural smokers.
Topics: Adolescent; Adult; Black People; Breath Tests; Carbon Monoxide; Data Collection; Female; Humans; Int | 2009 |
A six-week acupoint stimulation intervention for quitting smoking.
Topics: Acupuncture Points; Acupuncture Therapy; Adult; Carbon Monoxide; Cotinine; Exhalation; Humans; Smoki | 2009 |
The impact of cigarette deprivation and cigarette availability on cue-reactivity in smokers.
Topics: Adolescent; Adult; Affect; Behavior, Addictive; Carbon Monoxide; Conditioning, Psychological; Cues; | 2010 |
A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers.
Topics: Administration, Oral; Adolescent; Adult; Aged; Carbon Monoxide; Cotinine; Dizziness; Double-Blind Me | 2010 |
Smoking cessation or reduction with nicotine replacement therapy: a placebo-controlled double blind trial with nicotine gum and inhaler.
Topics: Adult; Aged; Breath Tests; Carbon Monoxide; Chewing Gum; Cotinine; Double-Blind Method; Female; Huma | 2009 |
Utility and relationships of biomarkers of smoking in African-American light smokers.
Topics: Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Biomarkers, Pharmacological; Black or | 2009 |
Nicotine patch vs. nicotine lozenge for smoking cessation: an effectiveness trial coordinated by the Community Clinical Oncology Program.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Breath Tests; Carbon Monoxide; Cognition; Fe | 2010 |
Exposure to movie smoking, antismoking ads and smoking intensity: an experimental study with a factorial design.
Topics: Adolescent; Adult; Advertising; Carbon Monoxide; Female; Health Promotion; Humans; Male; Motion Pict | 2010 |
Evaluating oral noncombustible potential-reduced exposure products for smokers.
Topics: Administration, Oral; Adolescent; Adult; Carbon Monoxide; Female; Humans; Male; Middle Aged; Nicotin | 2010 |
Severity of withdrawal symptomatology in follicular versus luteal quitters: The combined effects of menstrual phase and withdrawal on smoking cessation outcome.
Topics: Adolescent; Adult; Biomarkers; Carbon Monoxide; Cotinine; Female; Follicular Phase; Humans; Luteal P | 2010 |
Comparable sensitivities of urine cotinine and breath carbon monoxide at follow-up time points of three months or more in a smoking cessation trial.
Topics: Breath Tests; Carbon Monoxide; Cotinine; False Negative Reactions; Humans; Patient Compliance; Sensi | 2010 |
Use of a liquid nicotine delivery product to promote smoking cessation.
Topics: Adult; Carbon Monoxide; Female; Humans; Male; Middle Aged; Nicotine; Pharmaceutical Solutions; Smoki | 2010 |
[Impact of exhaled CO measurement. A randomised study among 578 smoking patients in general practice].
Topics: Adult; Breath Tests; Carbon Monoxide; Family Practice; Female; Humans; Male; Prospective Studies; Sm | 2010 |
Monetary incentives promote smoking abstinence in adults with attention deficit hyperactivity disorder (ADHD).
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Carbon Monoxide; | 2010 |
A randomized clinical trial of St. John's wort for smoking cessation.
Topics: Adolescent; Adult; Aged; Carbon Monoxide; Female; Flowers; Humans; Hypericum; Intention to Treat Ana | 2010 |
Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Behavior Therapy; Breath Tests; Carbon Monoxide; | 2010 |
Participation in a population-based physical activity programme as an aid for smoking cessation: a randomised trial.
Topics: Adult; Carbon Monoxide; Combined Modality Therapy; Counseling; Exercise; Female; Health Education; H | 2010 |
Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.
Topics: Adolescent; Adult; Aged; Benzazepines; Breath Tests; Bupropion; Carbon Monoxide; Delayed-Action Prep | 2010 |
Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.
Topics: Adolescent; Adult; Aged; Benzazepines; Breath Tests; Bupropion; Carbon Monoxide; Delayed-Action Prep | 2010 |
Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.
Topics: Adolescent; Adult; Aged; Benzazepines; Breath Tests; Bupropion; Carbon Monoxide; Delayed-Action Prep | 2010 |
Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.
Topics: Adolescent; Adult; Aged; Benzazepines; Breath Tests; Bupropion; Carbon Monoxide; Delayed-Action Prep | 2010 |
Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study.
Topics: Adolescent; Adult; Aged; Carbon Monoxide; Cotinine; Feasibility Studies; Humans; Middle Aged; Nicoti | 2011 |
Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program.
Topics: Adult; Carbon Monoxide; Double-Blind Method; Female; Humans; Male; Middle Aged; Motivation; Psychiat | 2011 |
Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial.
Topics: Administration, Intranasal; Adult; Breath Tests; Carbon Monoxide; Cotinine; Double-Blind Method; Eng | 2011 |
A randomized, controlled trial of adding expired carbon monoxide feedback to brief stop smoking advice: evaluation of cognitive and behavioral effects.
Topics: Adolescent; Adult; Biomarkers; Breath Tests; Carbon Monoxide; Exhalation; Feedback; Female; Humans; | 2011 |
Effects of escalating and descending schedules of incentives on cigarette smoking in smokers without plans to quit.
Topics: Adult; Breath Tests; Carbon Monoxide; Female; Humans; Male; Middle Aged; Motivation; Reinforcement S | 2010 |
Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia.
Topics: Adult; Behavior Therapy; Behavior, Addictive; Breath Tests; Bupropion; Carbon Monoxide; Combined Mod | 2011 |
A prospective 12-month study of the effect of smoking cessation on periodontal clinical parameters.
Topics: Adult; Analysis of Variance; Breath Tests; Carbon Monoxide; Chi-Square Distribution; Chronic Periodo | 2011 |
Effectiveness of a stepped primary care smoking cessation intervention: cluster randomized clinical trial (ISTAPS study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Breath Tests; | 2011 |
Effects of 24 hours of tobacco withdrawal and subsequent tobacco smoking among low and high sensation seekers.
Topics: Adolescent; Adult; Affect; Blood Pressure; Carbon Monoxide; Dose-Response Relationship, Drug; Double | 2011 |
Mindfulness training for smoking cessation: results from a randomized controlled trial.
Topics: Adult; Carbon Monoxide; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Ma | 2011 |
Mindfulness training for smoking cessation: results from a randomized controlled trial.
Topics: Adult; Carbon Monoxide; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Ma | 2011 |
Mindfulness training for smoking cessation: results from a randomized controlled trial.
Topics: Adult; Carbon Monoxide; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Ma | 2011 |
Mindfulness training for smoking cessation: results from a randomized controlled trial.
Topics: Adult; Carbon Monoxide; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Ma | 2011 |
Mindfulness training for smoking cessation: results from a randomized controlled trial.
Topics: Adult; Carbon Monoxide; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Ma | 2011 |
Mindfulness training for smoking cessation: results from a randomized controlled trial.
Topics: Adult; Carbon Monoxide; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Ma | 2011 |
Mindfulness training for smoking cessation: results from a randomized controlled trial.
Topics: Adult; Carbon Monoxide; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Ma | 2011 |
Mindfulness training for smoking cessation: results from a randomized controlled trial.
Topics: Adult; Carbon Monoxide; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Ma | 2011 |
Mindfulness training for smoking cessation: results from a randomized controlled trial.
Topics: Adult; Carbon Monoxide; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Ma | 2011 |
Drug cue induced overshadowing: selective disruption of natural reward processing by cigarette cues amongst abstinent but not satiated smokers.
Topics: Adult; Analysis of Variance; Association Learning; Attention; Behavior, Addictive; Breath Tests; Car | 2012 |
ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data.
Topics: Carbon Monoxide; Genetic Loci; Humans; Pilot Projects; Piperidines; Polymorphism, Single Nucleotide; | 2011 |
Smoking cessation intervention after ischemic stroke or transient ischemic attack. A randomized controlled pilot trial.
Topics: Adult; Aged; Carbon Monoxide; Counseling; Female; Follow-Up Studies; Humans; Ischemic Attack, Transi | 2012 |
Rapid smoking may not be aversive in schizophrenia.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Schizophrenia; Schizophrenic Ps | 2013 |
Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial.
Topics: Administration, Inhalation; Adult; Breath Tests; Carbon Monoxide; Counseling; Double-Blind Method; F | 2012 |
Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial.
Topics: Administration, Inhalation; Adult; Breath Tests; Carbon Monoxide; Counseling; Double-Blind Method; F | 2012 |
Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial.
Topics: Administration, Inhalation; Adult; Breath Tests; Carbon Monoxide; Counseling; Double-Blind Method; F | 2012 |
Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial.
Topics: Administration, Inhalation; Adult; Breath Tests; Carbon Monoxide; Counseling; Double-Blind Method; F | 2012 |
Effect of self-administered auricular acupressure on smoking cessation--a pilot study.
Topics: Acupressure; Acupuncture Points; Acupuncture, Ear; Adolescent; Adult; Aged; Carbon Monoxide; Ear; Ev | 2012 |
Clinical trial on the efficacy of exhaled carbon monoxide measurement in smoking cessation in primary health care.
Topics: Adolescent; Adult; Breath Tests; Carbon Monoxide; Exhalation; Female; Health Promotion; Humans; Male | 2012 |
Randomized controlled trial to evaluate tooth stain reduction with nicotine replacement gum during a smoking cessation program.
Topics: Carbon Monoxide; Chewing Gum; Cuspid; Gastrointestinal Diseases; Headache; Humans; Incisor; Single-B | 2012 |
Contingent incentives reduce cigarette smoking among pregnant, methadone-maintained women: results of an initial feasibility and efficacy randomized clinical trial.
Topics: Adult; Behavior Therapy; Carbon Monoxide; Feasibility Studies; Female; Humans; Methadone; Motivation | 2012 |
A randomized trial of a brief smoking cessation intervention in a light and intermittent Hispanic sample.
Topics: Adolescent; Adult; Aged; Carbon Monoxide; Female; Follow-Up Studies; Hispanic or Latino; Humans; Lin | 2012 |
A randomized clinical trial of trans-dermal nicotine replacement in pregnant African-American smokers.
Topics: Administration, Cutaneous; Adult; Black or African American; Carbon Monoxide; Cognitive Behavioral T | 2013 |
Randomized trial of the effectiveness of combined behavioral/pharmacological smoking cessation treatment in Syrian primary care clinics.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Ambulatory Care Facilities; Behavior, Addictive; | 2013 |
S-adenosyl-L-methionine (SAMe) for smoking abstinence: a randomized clinical trial.
Topics: Adult; Antidepressive Agents; Breath Tests; Carbon Monoxide; Dietary Supplements; Double-Blind Metho | 2012 |
Monitoring of exhaled carbon monoxide to promote preoperative smoking abstinence.
Topics: Adult; Aged; Carbon Monoxide; Directive Counseling; Exhalation; Female; Health Promotion; Humans; Ma | 2013 |
Optimal carbon monoxide criteria to confirm 24-hr smoking abstinence.
Topics: Adult; Benzazepines; Carbon Monoxide; Cross-Over Studies; Female; Humans; Male; Nicotinic Agonists; | 2013 |
Attempting tobacco cessation--an oral physician's perspective.
Topics: Adolescent; Adult; Breath Tests; Carbon Monoxide; Counseling; Female; Follow-Up Studies; Humans; Mal | 2012 |
Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study.
Topics: Adult; Carbon Monoxide; Female; Humans; Male; Middle Aged; Prospective Studies; Schizophrenia; Smoki | 2013 |
Controlled trial of three weeks nicotine replacement treatment in hospital patients also given advice and support.
Topics: Administration, Cutaneous; Administration, Inhalation; Adult; Aged; Breath Tests; Carbon Monoxide; C | 2002 |
Relations of cotinine and carbon monoxide to self-reported smoking in a cohort of smokers and ex-smokers followed over 5 years.
Topics: Adult; Carbon Monoxide; Cohort Studies; Cotinine; Female; Follow-Up Studies; Humans; Male; Middle Ag | 2002 |
Risk of respiratory complications and wound infection in patients undergoing ambulatory surgery: smokers versus nonsmokers.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia Recovery Period; Carbon Monoxide; Cohort Studies; | 2002 |
Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal.
Topics: Administration, Cutaneous; Adult; Blood Pressure; Carbon Monoxide; Cotinine; Cross-Over Studies; Dou | 2002 |
Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years.
Topics: Adult; Breath Tests; Canada; Carbon Monoxide; Cross-Sectional Studies; Female; Humans; Lung Neoplasm | 2002 |
Selective processing of smoking-related cues in smokers: manipulation of deprivation level and comparison of three measures of processing bias.
Topics: Adult; Affect; Analysis of Variance; Arousal; Attention; Carbon Monoxide; Conflict, Psychological; C | 2002 |
Nicotine patches and the subjective effects of cigarette smoking: a pilot study.
Topics: Administration, Cutaneous; Adult; Blood Pressure; Carbon Monoxide; Cotinine; Double-Blind Method; Fe | 2002 |
A contingent payment model of smoking cessation: effects on abstinence and withdrawal.
Topics: Adolescent; Adult; Carbon Monoxide; Female; Humans; Incidence; Male; Nicotine; Nicotinic Agonists; S | 2003 |
Gender differences in quit rates following smoking cessation with combination nicotine therapy: influence of baseline smoking behavior.
Topics: Administration, Inhalation; Adult; Carbon Monoxide; Female; Humans; Male; Nicotine; Sex Distribution | 2003 |
Pharmacologic and sensorimotor components of satiation in cigarette smoking.
Topics: Adolescent; Adult; Arousal; Carbon Monoxide; Cross-Over Studies; Female; Humans; Injections, Intrave | 2003 |
The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia.
Topics: Administration, Cutaneous; Adult; Carbon Monoxide; Female; Ganglionic Stimulants; Humans; Longitudin | 2004 |
Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products.
Topics: Administration, Cutaneous; Adult; Biomarkers; Carbon Monoxide; Carcinogens; Humans; Inhalation Expos | 2004 |
Changes in hemorheological and biochemical parameters following short-term and long-term smoking cessation induced by nicotine replacement therapy (NRT).
Topics: Administration, Cutaneous; Administration, Oral; Adult; Blood Viscosity; Carbon Monoxide; Cotinine; | 2004 |
Urine cotinine as an index of smoking status in smokers during 96-hr abstinence: comparison between gas chromatography/mass spectrometry and immunoassay test strips.
Topics: Adult; Biomarkers; Carbon Monoxide; Cotinine; Double-Blind Method; Female; Gas Chromatography-Mass S | 2004 |
Effectiveness of bupropion as an aid to stopping smoking before elective surgery: a randomised controlled trial.
Topics: Adult; Bupropion; Carbon Monoxide; Double-Blind Method; Elective Surgical Procedures; Female; Follow | 2004 |
Smoking topography predicts abstinence following treatment with nicotine replacement therapy.
Topics: Adult; Aged; Carbon Monoxide; Female; Humans; Logistic Models; Male; Middle Aged; Nicotine; Predicti | 2004 |
Clinical utility of the combination of cognitive-behavioral techniques with nicotine patches as a smoking-cessation treatment: five-year results of the "Ex-Moker" program.
Topics: Administration, Cutaneous; Adult; Carbon Monoxide; Cognitive Behavioral Therapy; Female; Follow-Up S | 2004 |
Beliefs and behavior of deceivers in a randomized, controlled trial of anti-smoking advice at a primary care clinic in Kelantan, Malaysia.
Topics: Adolescent; Adult; Carbon Monoxide; Child; Counseling; Deception; Health Behavior; Health Knowledge, | 2004 |
The effect of a novel smoking system--Accord--on ongoing smoking and toxin exposure.
Topics: Adult; Carbon Monoxide; Female; Humans; Male; Nicotine; Smoking Cessation; Smoking Prevention; Subst | 2004 |
Effects of smoking cessation and reduction in asthmatics.
Topics: Administration, Inhalation; Adult; Anti-Asthmatic Agents; Asthma; Carbon Monoxide; Chewing Gum; Chi- | 2005 |
Attenuated adrenocorticotropic responses to psychological stress are associated with early smoking relapse.
Topics: Adrenocorticotropic Hormone; Adult; Blood Pressure; Breath Tests; Carbon Monoxide; Female; Humans; H | 2005 |
Acute effects of self-paced walking on urges to smoke during temporary smoking abstinence.
Topics: Adolescent; Adult; Analysis of Variance; Behavior, Addictive; Breath Tests; Carbon Monoxide; Cross-O | 2005 |
Shaping reduced smoking in smokers without cessation plans.
Topics: Adolescent; Adult; Carbon Monoxide; Education; Employment; Female; Humans; Income; Male; Marriage; P | 2005 |
Effectiveness of payment for reduced carbon monoxide levels and noncontingent payments on smoking behaviors in cocaine-abusing outpatients wearing nicotine or placebo patches.
Topics: Administration, Cutaneous; Adult; Aged; Carbon Monoxide; Cocaine-Related Disorders; Cross-Over Studi | 2005 |
A randomised-controlled pilot study using nicotine patches with pregnant women.
Topics: Administration, Cutaneous; Adult; Carbon Monoxide; Cotinine; Feasibility Studies; Female; Humans; Ni | 2006 |
Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study.
Topics: Administration, Oral; Adult; Breath Tests; Carbon Dioxide; Carbon Monoxide; Chewing Gum; Cotinine; D | 2005 |
The early time course of smoking withdrawal effects.
Topics: Adult; Breath Tests; Carbon Monoxide; Emotions; Female; Heart Rate; Humans; Male; Smoking Cessation; | 2006 |
The use of contingency management to reduce cigarette smoking among college students.
Topics: Adult; Breath Tests; Carbon Monoxide; Female; Humans; Male; Reinforcement Schedule; Smoking; Smoking | 2006 |
Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial.
Topics: Administration, Inhalation; Adult; Carbon Monoxide; Double-Blind Method; Female; Ganglionic Stimulan | 2006 |
Changes in cough reflex sensitivity after cessation and resumption of cigarette smoking.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Analgesics, Non-Narcotic; Breath Tests; Caps | 2007 |
Effects of internet-based voucher reinforcement and a transdermal nicotine patch on cigarette smoking.
Topics: Administration, Cutaneous; Adult; Behavior Therapy; Breath Tests; Carbon Monoxide; Computer Peripher | 2007 |
Contingencies for change in complacent smokers.
Topics: Adult; Aged; Breath Tests; Carbon Monoxide; Female; Humans; Male; Middle Aged; Motivation; Reinforce | 2007 |
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Carbon Monoxide; Delayed-Action Preparat | 2007 |
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Carbon Monoxide; Delayed-Action Preparat | 2007 |
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Carbon Monoxide; Delayed-Action Preparat | 2007 |
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Carbon Monoxide; Delayed-Action Preparat | 2007 |
Effects of cigarette smoking and abstinence on Stroop task performance.
Topics: Adult; Analysis of Variance; Breath Tests; Carbon Monoxide; Cognition Disorders; Exhalation; Female; | 2007 |
Acute exercise effects on smoking withdrawal symptoms and desire to smoke are not related to expectation.
Topics: Adaptation, Psychological; Adult; Affect; Analysis of Variance; Aspirations, Psychological; Carbon M | 2007 |
Increased plasma brain-derived neurotrophic factor levels in chronic smokers following unaided smoking cessation.
Topics: Adult; Brain-Derived Neurotrophic Factor; Carbon Monoxide; Chronic Disease; Enzyme-Linked Immunosorb | 2007 |
Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine.
Topics: Adult; Biomarkers; Carbon Monoxide; Central Nervous System Stimulants; Cotinine; Cross-Over Studies; | 2007 |
[The effects of a group smoking cessation program among adult smokers in a rural community].
Topics: Adult; Aged; Breath Tests; Carbon Monoxide; Cotinine; Female; Follow-Up Studies; Humans; Male; Middl | 2007 |
Smoking reduction fails to improve clinical and biological markers of cardiac disease: a randomized controlled trial.
Topics: Adult; Aged; Biomarkers; C-Reactive Protein; Carbon Monoxide; Cotinine; F2-Isoprostanes; Female; Fib | 2008 |
Varying nicotine patch dose and type of smoking cessation counseling.
Topics: Administration, Cutaneous; Adult; Analysis of Variance; Carbon Monoxide; Combined Modality Therapy; | 1995 |
Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients.
Topics: Behavior Therapy; Breath Tests; Carbon Monoxide; Chewing Gum; Follow-Up Studies; Humans; Lung Diseas | 1995 |
Nicotine abstinence produces content-specific Stroop interference.
Topics: Adult; Breath Tests; Carbon Monoxide; Color Perception Tests; Humans; Male; Mental Processes; Nicoti | 1993 |
The transdermal nicotine patch: results of a randomised placebo-controlled trial.
Topics: Administration, Cutaneous; Adult; Age Factors; Attitude to Health; Behavior Therapy; Carbon Monoxide | 1994 |
Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone.
Topics: Administration, Cutaneous; Adult; Affect; Blood Pressure; Breath Tests; Carbon Monoxide; Double-Blin | 1994 |
Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking.
Topics: Administration, Cutaneous; Adult; Arousal; Breath Tests; Carbon Monoxide; Double-Blind Method; Femal | 1994 |
Predicting smoking cessation. Who will quit with and without the nicotine patch.
Topics: Administration, Cutaneous; Adult; Aged; Breath Tests; Carbon Monoxide; Confidence Intervals; Cotinin | 1994 |
Predicting smoking cessation. Who will quit with and without the nicotine patch.
Topics: Administration, Cutaneous; Adult; Aged; Breath Tests; Carbon Monoxide; Confidence Intervals; Cotinin | 1994 |
Predicting smoking cessation. Who will quit with and without the nicotine patch.
Topics: Administration, Cutaneous; Adult; Aged; Breath Tests; Carbon Monoxide; Confidence Intervals; Cotinin | 1994 |
Predicting smoking cessation. Who will quit with and without the nicotine patch.
Topics: Administration, Cutaneous; Adult; Aged; Breath Tests; Carbon Monoxide; Confidence Intervals; Cotinin | 1994 |
Predicting smoking cessation. Who will quit with and without the nicotine patch.
Topics: Administration, Cutaneous; Adult; Aged; Breath Tests; Carbon Monoxide; Confidence Intervals; Cotinin | 1994 |
Predicting smoking cessation. Who will quit with and without the nicotine patch.
Topics: Administration, Cutaneous; Adult; Aged; Breath Tests; Carbon Monoxide; Confidence Intervals; Cotinin | 1994 |
Predicting smoking cessation. Who will quit with and without the nicotine patch.
Topics: Administration, Cutaneous; Adult; Aged; Breath Tests; Carbon Monoxide; Confidence Intervals; Cotinin | 1994 |
Predicting smoking cessation. Who will quit with and without the nicotine patch.
Topics: Administration, Cutaneous; Adult; Aged; Breath Tests; Carbon Monoxide; Confidence Intervals; Cotinin | 1994 |
Predicting smoking cessation. Who will quit with and without the nicotine patch.
Topics: Administration, Cutaneous; Adult; Aged; Breath Tests; Carbon Monoxide; Confidence Intervals; Cotinin | 1994 |
Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement.
Topics: Administration, Cutaneous; Adult; Aged; Breath Tests; Carbon Monoxide; Cotinine; Counseling; Double- | 1994 |
Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments.
Topics: Administration, Cutaneous; Adult; Aged; Body Weight; Carbon Monoxide; Combined Modality Therapy; Cot | 1994 |
Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group.
Topics: Adult; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Saliva; Self Disc | 1993 |
Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group.
Topics: Adult; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Saliva; Self Disc | 1993 |
Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group.
Topics: Adult; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Saliva; Self Disc | 1993 |
Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group.
Topics: Adult; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Saliva; Self Disc | 1993 |
Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group.
Topics: Adult; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Saliva; Self Disc | 1993 |
Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group.
Topics: Adult; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Saliva; Self Disc | 1993 |
Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group.
Topics: Adult; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Saliva; Self Disc | 1993 |
Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group.
Topics: Adult; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Saliva; Self Disc | 1993 |
Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group.
Topics: Adult; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Saliva; Self Disc | 1993 |
Clinical evaluation of a citric acid inhaler for smoking cessation.
Topics: Adult; Aerosols; Affect; Behavior Therapy; Breath Tests; Carbon Monoxide; Citrates; Citric Acid; Dou | 1993 |
Lack of effect of cimetidine on cigarette smoking.
Topics: Carbon Monoxide; Cimetidine; Cotinine; Double-Blind Method; Female; Humans; Male; Nicotine; Smoking; | 1993 |
A double-blind trial of a nicotine inhaler for smoking cessation.
Topics: Adult; Carbon Monoxide; Double-Blind Method; Female; Humans; Male; Nebulizers and Vaporizers; Nicoti | 1993 |
A randomized controlled trial of smoking cessation intervention in pregnancy in an academic clinic.
Topics: Adult; Breath Tests; Carbon Monoxide; Female; Humans; Outpatient Clinics, Hospital; Pregnancy; Prena | 1996 |
Mecamylamine does not precipitate withdrawal in cigarette smokers.
Topics: Adult; Blood Pressure; Carbon Monoxide; Female; Heart Rate; Humans; Male; Mecamylamine; Middle Aged; | 1996 |
The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain.
Topics: Adult; Appetite Depressants; Blood Glucose; Breath Tests; Caffeine; Carbon Monoxide; Central Nervous | 1996 |
Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking-related cognitions, emotions, and behavior change.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Attitude to Health; Biomarkers; Breath Tests; Carbon | 1997 |
Evaluation of cranial electrostimulation therapy on short-term smoking cessation.
Topics: Adult; Brain; Carbon Monoxide; Double-Blind Method; Electric Stimulation Therapy; Female; Humans; Ma | 1997 |
Effects of nicotine dose and administration method on withdrawal symptoms and side effects during short-term smoking abstinence.
Topics: Administration, Cutaneous; Adult; Affect; Blood Pressure; Carbon Monoxide; Central Nervous System St | 1997 |
Influence of acute smoking exposure on the subsequent reinforcing value of smoking.
Topics: Adult; Breath Tests; Carbon Monoxide; Female; Humans; Male; Recurrence; Reinforcement Schedule; Rewa | 1997 |
Quantitative EEG effects of nicotine replacement by cigarette smoking.
Topics: Adult; Carbon Monoxide; Electroencephalography; Functional Laterality; Humans; Middle Aged; Nicotine | 1998 |
Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker?
Topics: Adult; Carbon Monoxide; Cotinine; Cross-Over Studies; Female; Humans; Infant; Male; Middle Aged; Nic | 1997 |
Effects of nicotine on methadone self-administration in humans.
Topics: Adult; Analysis of Variance; Behavior, Addictive; Carbon Monoxide; Drug Interactions; Female; Heroin | 1998 |
Interaction of stress, smoking, and dietary restraint in women.
Topics: Adolescent; Adult; Affect; Analysis of Variance; Appetite; Appetite Regulation; Body Weight; Breath | 1998 |
Nicotine and cotinine replacement when nicotine nasal spray is used to quit smoking.
Topics: Administration, Intranasal; Adult; Aerosols; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle | 1998 |
Effects of cigarette smoking through a partially occluded filter.
Topics: Adult; Carbon Monoxide; Cross-Over Studies; Double-Blind Method; Electroencephalography; Female; Fil | 1998 |
The effect of transdermal nicotine on digital perfusion in reformed habitual smokers.
Topics: Administration, Cutaneous; Adult; Analysis of Variance; Body Temperature Regulation; Carbon Monoxide | 1998 |
Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine.
Topics: Administration, Cutaneous; Adult; Carbon Monoxide; Carboxyhemoglobin; Cross-Over Studies; Humans; Ma | 1998 |
Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials.
Topics: Administration, Cutaneous; Adult; Carbon Monoxide; Double-Blind Method; Female; Humans; Male; Middle | 1999 |
Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels.
Topics: Administration, Cutaneous; Adolescent; Carbon Monoxide; Cotinine; Female; Follow-Up Studies; Humans; | 2000 |
The Questionnaire of Smoking Urges is sensitive to abstinence and exposure to smoking-related cues.
Topics: Carbon Monoxide; Cues; Data Interpretation, Statistical; Female; Humans; Male; Smoking; Smoking Cess | 1999 |
Smoking behavior, dysphoric states and the menstrual cycle: results from single smoking sessions and the natural environment.
Topics: Adult; Breath Tests; Carbon Monoxide; Depression; Female; Humans; Menstrual Cycle; Smoking; Smoking | 2000 |
Randomized trial of a "stage-of-change" oriented smoking cessation intervention in infertile and pregnant women.
Topics: Adult; Breath Tests; Carbon Monoxide; Female; Humans; Infertility, Female; Pregnancy; Smoking Cessat | 2000 |
Contingency management interventions for treating the substance abuse of adolescents: a feasibility study.
Topics: Adolescent; Adult; Affect; Carbon Monoxide; Feasibility Studies; Female; Humans; Male; Prospective S | 2000 |
Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit.
Topics: Administration, Inhalation; Adult; Aged; Carbon Monoxide; Female; Humans; Male; Middle Aged; Motivat | 2000 |
Carbidopa/levodopa for smoking cessation: a pilot study with negative results.
Topics: Adult; Carbidopa; Carbon Monoxide; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levod | 2000 |
Smoking cessation with four nicotine replacement regimes in a lung clinic.
Topics: Adult; Aged; Analysis of Variance; Carbon Monoxide; Central Nervous System Stimulants; Cotinine; Fem | 2000 |
Assessing the impact of a nurse-led health education intervention for people with peripheral vascular disease who smoke: the use of physiological markers, nicotine dependence and withdrawal.
Topics: Aged; Biomarkers; Breath Tests; Carbon Monoxide; Cotinine; Female; Follow-Up Studies; Health Knowled | 2001 |
Randomized controlled trial of a midwife-delivered brief smoking cessation intervention in pregnancy.
Topics: Birth Weight; Carbon Monoxide; Chi-Square Distribution; Female; Humans; Logistic Models; Midwifery; | 2001 |
Tolerability of concurrent use of nicotine gum and smoking in healthy volunteers.
Topics: Adult; Blood Pressure; Carbon Monoxide; Chewing Gum; Cross-Over Studies; Drug Administration Schedul | 2001 |
Impact of smoking cessation on ambulatory blood pressure and heart rate in postmenopausal women.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carbon Monoxid | 2001 |
Detecting smoking following smoking cessation treatment.
Topics: Adult; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Indicators and Reagents; Male; Self- | 2002 |
Randomised controlled trial of nasal nicotine spray in smoking cessation.
Topics: Administration, Intranasal; Adult; Breath Tests; Carbon Monoxide; Combined Modality Therapy; Cotinin | 1992 |
Reinforcing breath carbon monoxide reductions in chronic obstructive pulmonary disease.
Topics: Breath Tests; Carbon Monoxide; Chewing Gum; Follow-Up Studies; Forced Expiratory Volume; Humans; Lun | 1991 |
Relapse prevention versus broad spectrum treatment for smoking cessation: a comparison of efficacy.
Topics: Adult; Behavior Therapy; Carbon Monoxide; Chewing Gum; Cognitive Behavioral Therapy; Female; Follow- | 1988 |
200 other studies available for carbon monoxide and Smoking Cessation
| Article | Year |
|---|---|
Effects of smoking cessation using varenicline on the serum concentrations of oxidized high-density lipoprotein: Comparison with high-density lipoprotein cholesterol.
Topics: Adult; Carbon Monoxide; Cholesterol, HDL; Humans; Lipoproteins, HDL; Smoking; Smoking Cessation; Var | 2022 |
Effects of smoking cessation using varenicline on the serum concentrations of oxidized high-density lipoprotein: Comparison with high-density lipoprotein cholesterol.
Topics: Adult; Carbon Monoxide; Cholesterol, HDL; Humans; Lipoproteins, HDL; Smoking; Smoking Cessation; Var | 2022 |
Effects of smoking cessation using varenicline on the serum concentrations of oxidized high-density lipoprotein: Comparison with high-density lipoprotein cholesterol.
Topics: Adult; Carbon Monoxide; Cholesterol, HDL; Humans; Lipoproteins, HDL; Smoking; Smoking Cessation; Var | 2022 |
Effects of smoking cessation using varenicline on the serum concentrations of oxidized high-density lipoprotein: Comparison with high-density lipoprotein cholesterol.
Topics: Adult; Carbon Monoxide; Cholesterol, HDL; Humans; Lipoproteins, HDL; Smoking; Smoking Cessation; Var | 2022 |
[Performance of exhaled carbon monoxide measurement in smoking cessation clinics and its influence on patients' willingness and behavior for smoking cessation].
Topics: Carbon Monoxide; China; Humans; Smoking; Smoking Cessation; Tobacco Smoking | 2023 |
Comparisons of early and delayed abstainers and its effects on long-term smoking cessation in Taiwan.
Topics: Adult; Age Factors; Breath Tests; Carbon Monoxide; Female; Humans; Male; Middle Aged; Retrospective | 2019 |
Effectiveness of smoking cessation in smokers with COPD and nocturnal oxygen desaturation: Functional analysis.
Topics: Adult; Blood Gas Analysis; Carbon Monoxide; Case-Control Studies; Exhalation; Female; Forced Expirat | 2020 |
Exhaled Carbon Monoxide Levels in Forty Resistant to Cessation Male Smokers after Six Months of Full Switch to Electronic Cigarettes (e-Cigs) or to A Tobacco Heating Systems (THS).
Topics: Adult; Carbon Monoxide; Electronic Nicotine Delivery Systems; Exhalation; Humans; Male; Middle Aged; | 2019 |
Novel Application of Exhaled Carbon Monoxide Monitors: Smoking Cessation in Orthopaedic Trauma Patients.
Topics: Adolescent; Adult; Age Factors; Aged; Carbon Monoxide; Exhalation; Female; Humans; Male; Middle Aged | 2019 |
Outcomes and predictive factors for successful smoking cessation therapy in COPD patients with nicotine dependence.
Topics: Aged; Carbon Monoxide; Female; Forced Expiratory Volume; Humans; Male; Mental Disorders; Middle Aged | 2020 |
No evidence of differences in smoking levels, nicotine dependence, carbon monoxide or motivational indices between cigarette smokers and cigarette + e-cigarette dual users in two samples.
Topics: Adolescent; Adult; Aged; Carbon Monoxide; Electronic Nicotine Delivery Systems; Humans; Middle Aged; | 2021 |
Mobile, Remote, and Individual Focused: Comparing Breath Carbon Monoxide Readings and Abstinence Between Smartphone-Enabled and Stand-Alone Monitors.
Topics: Adult; Breath Tests; Carbon Monoxide; Case-Control Studies; Cotinine; Female; Humans; Male; Non-Smok | 2021 |
Can You Believe Your Patients If They Say They Have Quit Smoking?
Topics: Carbon Monoxide; Humans; Prospective Studies; Reproducibility of Results; Smoking; Smoking Cessation | 2021 |
Evaluation of the MoMba Live Long Remote Smoking Detection System During and After Pregnancy: Development and Usability Study.
Topics: Adult; Carbon Monoxide; Female; Humans; Pregnancy; Smartphone; Smokers; Smoking; Smoking Cessation | 2020 |
Monitoring expiratory carbon monoxide to study the effect of complete smoking cessation on definitive radiation therapy for early stage glottic carcinoma.
Topics: Carbon Monoxide; Carcinoma, Squamous Cell; Glottis; Humans; Laryngeal Neoplasms; Neoplasm Recurrence | 2021 |
Reduction of bronchial response to mannitol after partial switch from conventional tobacco to electronic cigarette consumption.
Topics: Bronchi; Bronchial Provocation Tests; Carbon Monoxide; Electronic Nicotine Delivery Systems; Female; | 2021 |
Pilot trial of QuitBet: A digital social game that pays you to stop smoking.
Topics: Adult; Carbon Monoxide; Female; Humans; Male; Motivation; Pilot Projects; Smoking; Smoking Cessation | 2022 |
Comparison of saliva cotinine and exhaled carbon monoxide concentrations when smoking and after being offered dual nicotine replacement therapy in pregnancy.
Topics: Bayes Theorem; Carbon Monoxide; Cotinine; Female; Humans; Nicotine; Observational Studies as Topic; | 2022 |
Factors Associated With Quitting Among Smoking Pregnant Women From Small Town and Rural Areas in Poland.
Topics: Adult; Breath Tests; Carbon Monoxide; Educational Status; Family; Female; Humans; Marital Status; Mo | 2017 |
Assessment of exhaled carbon monoxide in exacerbations of chronic obstructive pulmonary disease.
Topics: Adult; Aged; Biomarkers; Breath Tests; Carbon Monoxide; Case-Control Studies; Disease Progression; E | 2016 |
[Factors Associated With Successful Smoking Cessation in Male Patients With Coronary Artery Disease at 3 Months After Hospital Discharge].
Topics: Breath Tests; Carbon Monoxide; Coronary Artery Disease; Humans; Logistic Models; Male; Patient Disch | 2017 |
Levels of exhaled carbon monoxide measured during an intervention program predict 1-year smoking cessation: a retrospective observational cohort study.
Topics: Age Factors; Carbon Monoxide; Exhalation; Female; Humans; Male; Middle Aged; Retrospective Studies; | 2017 |
An open-label pilot study of an intervention using mobile phones to deliver contingency management of tobacco abstinence to high school students.
Topics: Adolescent; Carbon Monoxide; Cell Phone; Cognitive Behavioral Therapy; Cotinine; Female; Humans; Mal | 2017 |
Mobile contingency management as an adjunctive treatment for co-morbid cannabis use disorder and cigarette smoking.
Topics: Adult; Carbon Monoxide; Cigarette Smoking; Cognitive Behavioral Therapy; Comorbidity; Dronabinol; Fe | 2018 |
Effects of six weeks of electronic cigarette use on smoking rate, CO, cigarette dependence, and motivation to quit smoking: A pilot study.
Topics: Adult; Breath Tests; Carbon Monoxide; Cigarette Smoking; Electronic Nicotine Delivery Systems; Femal | 2018 |
Smokers' Views on Personal Carbon Monoxide Monitors, Associated Apps, and Their Use: An Interview and Think-Aloud Study.
Topics: Adult; Carbon Monoxide; Female; Humans; Male; Middle Aged; Mobile Applications; Motivation; Patient | 2018 |
Smoking behaviour and sensations during the pre-quit period of an exercise-aided smoking cessation intervention.
Topics: Adult; Affect; Carbon Monoxide; Cigarette Smoking; Cognition; Exercise; Female; Humans; Middle Aged; | 2018 |
Acceptability and compliance with a remote monitoring system to track smoking and abstinence among young smokers.
Topics: Adult; Breath Tests; Carbon Monoxide; Cigarette Smoking; Ecological Momentary Assessment; Female; Hu | 2018 |
Pilot Tobacco Treatment Intervention for Women in Residential Treatment for Substance Use Disorder.
Topics: Adult; Breath Tests; Carbon Monoxide; Cotinine; Exercise; Female; Humans; Longitudinal Studies; Male | 2018 |
Varenicline for long term smoking cessation in patients with COPD.
Topics: Adult; Airway Obstruction; Carbon Monoxide; Cohort Studies; Female; Humans; Longitudinal Studies; Ma | 2018 |
A Machine-Learning Approach to Predicting Smoking Cessation Treatment Outcomes.
Topics: Carbon Monoxide; Cognitive Behavioral Therapy; Cotinine; Female; Health Behavior; Humans; Machine Le | 2020 |
Are We Justified in Introducing Carbon Monoxide Testing to Encourage Smoking Cessation in Pregnant Women?
Topics: Adult; Carbon Monoxide; Female; Harm Reduction; Humans; Pregnancy; Pregnant Women; Prenatal Care; Sm | 2019 |
Ten-year experience of smoking cessation in a single center in Japan.
Topics: Aged; Breath Tests; Carbon Monoxide; Exhalation; Female; Forecasting; Hospitals, Community; Hospital | 2019 |
Pharmacokinetic Profile of Spectrum Reduced Nicotine Cigarettes.
Topics: Adolescent; Adult; Carbon Monoxide; Cigarette Smoking; Double-Blind Method; Female; Humans; Male; Mi | 2020 |
Saliva cotinine concentrations in pregnant women who smoke and use nicotine patches.
Topics: Adult; Breath Tests; Carbon Monoxide; Cigarette Smoking; Cotinine; Female; Humans; Nicotine; Nicotin | 2019 |
"Readiness to Change" Predicts Efficacy of Reduction among Smokers with Severe Mental Illness.
Topics: Adult; Bipolar Disorder; Carbon Monoxide; Female; Humans; Longitudinal Studies; Male; Middle Aged; M | 2019 |
Challenges for dedicated smoking cessation services in developing countries.
Topics: Adult; Ambulatory Care; Anxiety; Breath Tests; Carbon Monoxide; Cigarette Smoking; Depression; Devel | 2019 |
Brief psycho-education affects circadian variability in nicotine craving during cessation.
Topics: Adult; Carbon Monoxide; Circadian Rhythm; Cotinine; Female; Humans; Male; Mindfulness; Patient Educa | 2013 |
The association between probable personality disorders and smoking cessation and maintenance.
Topics: Adult; Breath Tests; Carbon Monoxide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Personal | 2013 |
Fifty-two-week continuous abstinence rates of smokers being treated with varenicline versus nicotine replacement therapy.
Topics: Benzazepines; Breath Tests; Carbon Monoxide; Drug Administration Routes; Female; Humans; Male; Middl | 2013 |
Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications.
Topics: Adult; Benzhydryl Compounds; Bupropion; Carbon Monoxide; Cross-Over Studies; Dopamine Uptake Inhibit | 2013 |
The effect of reducing the threshold for carbon monoxide validation of smoking abstinence--evidence from the English Stop Smoking Services.
Topics: Biomarkers; Breath Tests; Carbon Monoxide; England; Humans; Logistic Models; Outcome Assessment, Hea | 2013 |
Escalating doses of transdermal nicotine in heavy smokers: effects on smoking behavior and craving.
Topics: Administration, Cutaneous; Adult; Affect; Behavior, Addictive; Biomarkers; Carbon Monoxide; Comorbid | 2013 |
Short-term effectiveness of smoking-cessation treatment on respiratory function and CEA level.
Topics: Benzazepines; Carbon Monoxide; Carboxyhemoglobin; Carcinoembryonic Antigen; Combined Modality Therap | 2013 |
Utilizing exhaled carbon monoxide measurement with self-declared smoking cessation: enhancing abstinence effectiveness in Taiwanese outpatients.
Topics: Adult; Aged; Aged, 80 and over; Breath Tests; Carbon Monoxide; Female; Humans; Longitudinal Studies; | 2015 |
Fully Bayesian inference under ignorable missingness in the presence of auxiliary covariates.
Topics: Adolescent; Adult; Aged; Bayes Theorem; Behavior Therapy; Carbon Monoxide; Computer Simulation; Coti | 2014 |
Early changes in the components of the metabolic syndrome in a group of smokers after tobacco cessation.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Carbon Monoxide; Cholestero | 2014 |
Nasal and systemic inflammatory profile after short term smoking cessation.
Topics: Adult; Anthropometry; Breath Tests; Carbon Monoxide; Carboxyhemoglobin; Cytokines; Female; Forced Ex | 2014 |
How low should you go? Determining the optimal cutoff for exhaled carbon monoxide to confirm smoking abstinence when using cotinine as reference.
Topics: Adult; Biomarkers; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Refer | 2014 |
How low should you go? Determining the optimal cutoff for exhaled carbon monoxide to confirm smoking abstinence when using cotinine as reference.
Topics: Adult; Biomarkers; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Refer | 2014 |
How low should you go? Determining the optimal cutoff for exhaled carbon monoxide to confirm smoking abstinence when using cotinine as reference.
Topics: Adult; Biomarkers; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Refer | 2014 |
How low should you go? Determining the optimal cutoff for exhaled carbon monoxide to confirm smoking abstinence when using cotinine as reference.
Topics: Adult; Biomarkers; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Refer | 2014 |
How low should you go? Determining the optimal cutoff for exhaled carbon monoxide to confirm smoking abstinence when using cotinine as reference.
Topics: Adult; Biomarkers; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Refer | 2014 |
How low should you go? Determining the optimal cutoff for exhaled carbon monoxide to confirm smoking abstinence when using cotinine as reference.
Topics: Adult; Biomarkers; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Refer | 2014 |
How low should you go? Determining the optimal cutoff for exhaled carbon monoxide to confirm smoking abstinence when using cotinine as reference.
Topics: Adult; Biomarkers; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Refer | 2014 |
How low should you go? Determining the optimal cutoff for exhaled carbon monoxide to confirm smoking abstinence when using cotinine as reference.
Topics: Adult; Biomarkers; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Refer | 2014 |
How low should you go? Determining the optimal cutoff for exhaled carbon monoxide to confirm smoking abstinence when using cotinine as reference.
Topics: Adult; Biomarkers; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Refer | 2014 |
Changes in the profiles of smokers seeking cessation treatment and in its effectiveness in Galicia (Spain) 2001-10.
Topics: Adult; Carbon Monoxide; Counseling; Female; Health Behavior; Humans; Male; Middle Aged; Motivation; | 2014 |
Lung nodule and functional changes in smokers after smoking cessation short-term treatment.
Topics: Carbon Monoxide; Female; Humans; Male; Middle Aged; Multiple Pulmonary Nodules; Oxygen; Partial Pres | 2014 |
Peptide YY and ghrelin predict craving and risk for relapse in abstinent smokers.
Topics: Adult; Carbon Monoxide; Cotinine; Craving; Female; Ghrelin; Humans; Male; Peptide YY; Recurrence; Ri | 2014 |
Back to the future: a return to psychedelic treatment models for addiction.
Topics: Carbon Monoxide; Cotinine; Female; Humans; Male; Psilocybin; Serotonin Receptor Agonists; Smoking Ce | 2014 |
Effect of smoking cessation on non-surgical periodontal therapy: results after 24 months.
Topics: Adult; Aged; Carbon Monoxide; Chronic Periodontitis; Dental Calculus; Dental Plaque Index; Female; F | 2014 |
Foucault, surveillance, and carbon monoxide testing within stop-smoking services.
Topics: Adult; Aged; Carbon Monoxide; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Motivation | 2015 |
Characterizing Concurrent Tobacco Product Use Among Homeless Cigarette Smokers.
Topics: Adult; Age Factors; Breath Tests; Carbon Monoxide; Comorbidity; Female; Humans; Ill-Housed Persons; | 2015 |
Readiness for smoking cessation in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey.
Topics: Age Factors; Aged; Breath Tests; Carbon Monoxide; Coronary Disease; Cross-Sectional Studies; Europe; | 2015 |
Agreement between exhaled breath carbon monoxide threshold levels and self-reported cigarette smoking in a sample of male adolescents in Jordan.
Topics: Adolescent; Carbon Monoxide; Cross-Sectional Studies; Exhalation; Health Surveys; Humans; Jordan; Ma | 2015 |
Biochemically verified smoking cessation and vaping beliefs among vape store customers.
Topics: Adult; Carbon Monoxide; Commerce; Cross-Sectional Studies; Electronic Nicotine Delivery Systems; Fem | 2015 |
Heavy dependent nicotine smokers--Newfound lifestyle appreciation after quitting successfully. Experiences from inpatient smoking cessation therapy.
Topics: Carbon Monoxide; Female; Follow-Up Studies; Humans; Inpatients; Life Style; Male; Middle Aged; Perso | 2015 |
[Use of COPD-6 Vitalograph in Primary Care as tool for smoking cessation].
Topics: Adult; Carbon Monoxide; Equipment Design; Female; Forced Expiratory Volume; Humans; Male; Middle Age | 2016 |
Should the threshold for expired-air carbon monoxide concentration as a means of verifying self-reported smoking abstinence be reduced in clinical treatment programmes? Evidence from a Malaysian smokers' clinic.
Topics: Adolescent; Adult; Carbon Monoxide; Exhalation; Female; Follow-Up Studies; Humans; Malaysia; Male; M | 2015 |
Changes in circulating leptin levels during the initial stage of cessation are associated with smoking relapse.
Topics: Adult; Carbon Monoxide; Cotinine; Craving; Female; Humans; Leptin; Male; Nicotine; Nicotinic Agonist | 2015 |
Successful Nicotine Intake in Medical Assisted Use of E-Cigarettes: A Pilot Study.
Topics: Adolescent; Adult; Biomarkers; Carbon Monoxide; Cotinine; Craving; Electronic Nicotine Delivery Syst | 2015 |
Effects of Switching to Electronic Cigarettes with and without Concurrent Smoking on Exposure to Nicotine, Carbon Monoxide, and Acrolein.
Topics: Acetylcysteine; Acrolein; Adult; Aerosols; Biomarkers; Breath Tests; Carbon Monoxide; Cohort Studies | 2015 |
Self-regulation strategies may enhance the acute effect of exercise on smoking delay.
Topics: Adult; Analysis of Variance; Carbon Monoxide; Exercise Therapy; Female; Goals; Heart Rate; Humans; M | 2016 |
Prevalence and Correlates of Smoking and Readiness to Quit Smoking in People Living with HIV in Austria and Germany.
Topics: Adult; Age Factors; Anti-HIV Agents; Antidepressive Agents; Attitude to Health; Austria; Breath Test | 2016 |
Does cigarette reduction while using nicotine replacement therapy prior to a quit attempt predict abstinence following quit date?
Topics: Adult; Aged; Breath Tests; Carbon Monoxide; Female; Humans; Male; Middle Aged; Primary Health Care; | 2016 |
Which measures of cigarette dependence are predictors of smoking cessation during pregnancy? Analysis of data from a randomized controlled trial.
Topics: Adult; Breath Tests; Carbon Monoxide; England; Exercise; Female; Humans; Logistic Models; Odds Ratio | 2016 |
Reasons for failure to quit: a cross-sectional survey of tobacco use in major cities in Pakistan.
Topics: Adult; Affect; Biomarkers; Breath Tests; Carbon Monoxide; Cross-Sectional Studies; Female; Health Be | 2016 |
'Opt-out' referrals after identifying pregnant smokers using exhaled air carbon monoxide: impact on engagement with smoking cessation support.
Topics: Adult; Carbon Monoxide; Female; Humans; Pregnancy; Pregnancy Complications; Prenatal Care; Referral | 2017 |
Neural response to pictorial health warning labels can predict smoking behavioral change.
Topics: Adult; Amygdala; Biomarkers; Breath Tests; Carbon Monoxide; Female; Humans; Intention; Male; Nerve N | 2016 |
The effects of smoking and smoking cessation on nasal mucociliary clearance, mucus properties and inflammation.
Topics: Adult; Carbon Monoxide; Cell Count; Cotinine; Female; Humans; Inflammation; Interleukin-6; Interleuk | 2016 |
Predictors of smoking cessation in smokers with chronic periodontitis: a 24-month study.
Topics: Adult; Age Factors; Brazil; Carbon Monoxide; Chronic Periodontitis; Female; Humans; Logistic Models; | 2016 |
Antenatal Clinic and Stop Smoking Services Staff Views on "Opt-Out" Referrals for Smoking Cessation in Pregnancy: A Framework Analysis.
Topics: Ambulatory Care Facilities; Breath Tests; Carbon Monoxide; Female; Humans; Motivation; Pregnancy; Pr | 2016 |
English Stop-Smoking Services: One-Year Outcomes.
Topics: Carbon Monoxide; England; Female; Humans; Male; Middle Aged; National Health Programs; Odds Ratio; P | 2016 |
Validating Use of Internet-Submitted Carbon Monoxide Values by Video to Determine Quit Status.
Topics: Breath Tests; Carbon Monoxide; Humans; Internet; Reproducibility of Results; Self Report; Smoking; S | 2017 |
Evaluation of a complex healthcare intervention to increase smoking cessation in pregnant women: interrupted time series analysis with economic evaluation.
Topics: Adolescent; Adult; Carbon Monoxide; England; Female; Health Care Costs; Humans; Interrupted Time Ser | 2018 |
Internet-based self-tailored deposit contracts to promote smoking reduction and abstinence.
Topics: Adolescent; Adult; Behavior Therapy; Breath Tests; Carbon Monoxide; Female; Humans; Internet; Male; | 2017 |
A brief abstinence test for college student smokers: a feasibility study.
Topics: Adult; Carbon Monoxide; Feasibility Studies; Female; Humans; Male; Neuropsychological Tests; Smoking | 2008 |
Acute nicotine effects on sexual function in men.
Topics: Arousal; Carbon Monoxide; Chewing Gum; Double-Blind Method; Ganglionic Stimulants; Humans; Male; Nic | 2008 |
Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls.
Topics: Administration, Cutaneous; Adult; Carbon Monoxide; Cues; Female; Humans; Male; Nicotine; Schizophren | 2008 |
'Breathe': the stop smoking service for pregnant women in Glasgow.
Topics: Breath Tests; Carbon Monoxide; Counseling; Female; Ganglionic Stimulants; Humans; Nicotine; Nurse Mi | 2010 |
[Specific program for smoking cessation: thus your patients become nonsmokers].
Topics: Behavior Therapy; Benzazepines; Bupropion; Carbon Monoxide; Contraindications; Humans; Nicotinic Ago | 2008 |
[Smoking].
Topics: Austria; Breath Tests; Carbon Monoxide; Health Policy; Humans; Risk Factors; Smoking; Smoking Cessat | 2009 |
[Outpatient smoking cessation: a report on 3,260 cases].
Topics: Administration, Inhalation; Administration, Sublingual; Adult; Breath Tests; Carbon Monoxide; Female | 2009 |
Nocturnal sleep-disturbing nicotine craving and accomplishment with a smoking cessation program.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Behavior Therapy; Breath Tests; Bu | 2009 |
Topiramate for smoking cessation and the importance to distinguish withdrawal-motivated consumption and cue-triggered automatisms.
Topics: Carbon Monoxide; Cues; Fructose; Humans; Neuroprotective Agents; Randomized Controlled Trials as Top | 2009 |
The relationship between self-efficacy and reductions in smoking in a contingency management procedure.
Topics: Adult; Breath Tests; Carbon Monoxide; Cross-Over Studies; Female; Humans; Male; Regression Analysis; | 2009 |
Validity of the timeline followback among treatment-seeking smokers in Germany.
Topics: Adult; Alcoholism; Carbon Monoxide; Education; Employment; Female; Follow-Up Studies; Germany; Human | 2009 |
[A regional plan against tobacco smoking during pregnancy].
Topics: Breath Tests; Carbon Monoxide; Female; France; Humans; Patient Education as Topic; Pregnancy; Premat | 2009 |
How many cigarettes did you smoke? Assessing cigarette consumption by global report, Time-Line Follow-Back, and ecological momentary assessment.
Topics: Adult; Bias; Breath Tests; Carbon Monoxide; Computers, Handheld; Cotinine; Cross-Sectional Studies; | 2009 |
Electronic recording, self-report, and bias in measuring cigarette consumption.
Topics: Adult; Bias; Breath Tests; Carbon Monoxide; Computers, Handheld; Cotinine; Data Collection; Female; | 2009 |
Anxiety sensitivity and panic reactivity to bodily sensations: relation to quit-day (acute) nicotine withdrawal symptom severity among daily smokers making a self-guided quit attempt.
Topics: Adolescent; Adult; Anxiety; Carbon Monoxide; Diagnostic and Statistical Manual of Mental Disorders; | 2009 |
Behavioral filter vent blocking on the first cigarette of the day predicts which smokers of light cigarettes will increase smoke exposure from blocked vents.
Topics: Administration, Inhalation; Adult; Carbon Monoxide; Female; Filtration; Health Knowledge, Attitudes, | 2009 |
Hostility, cigarette smoking, and responses to a lab-based social stressor.
Topics: Adolescent; Adult; Blood Pressure; Carbon Monoxide; Hostility; Humans; MMPI; Psychometrics; Regressi | 2009 |
Acceptability and outcome of an Internet-based smoking cessation programme.
Topics: Adult; Aged; Breath Tests; Carbon Monoxide; Combined Modality Therapy; Female; Follow-Up Studies; Hu | 2010 |
Internet-based intervention may help smokers quit, study finds.
Topics: Behavior Therapy; Breath Tests; Carbon Monoxide; Counseling; Follow-Up Studies; Humans; Internet; Pa | 2010 |
Comparison assessment methods of smoking consequences use in primary care.
Topics: Breath Tests; Carbon Monoxide; Causality; Comorbidity; Emphysema; Environmental Monitoring; Epidemio | 2009 |
Effect of motivational interviewing on smoking cessation in pregnant women.
Topics: Adult; Behavior Therapy; Breath Tests; Carbon Monoxide; Cotinine; Counseling; Female; Humans; Models | 2010 |
[About interpretation of exhaled CO in smoking cessation].
Topics: Asthma; Bronchiectasis; Carbon Monoxide; Carboxyhemoglobin; Exhalation; Female; Humans; Male; Pulmon | 2010 |
Breath carbon monoxide output is affected by speed of emptying the lungs: implications for laboratory and smoking cessation research.
Topics: Adolescent; Adult; Breath Tests; Carbon Monoxide; Female; Humans; Male; Middle Aged; Smoking Cessati | 2010 |
Recurrent carbon monoxide poisoning from cigarette smoking.
Topics: Carbon Monoxide; Carbon Monoxide Poisoning; Carboxyhemoglobin; Female; Humans; Middle Aged; Smoking; | 2010 |
Defining and understanding success at smoking reduction: a mixed-methods study.
Topics: Behavior, Addictive; Carbon Monoxide; Counseling; Female; Humans; Male; Middle Aged; Smoking; Smokin | 2010 |
Contingency management in the 21st century: technological innovations to promote smoking cessation.
Topics: Behavior Therapy; Breath Tests; Carbon Monoxide; Computer Peripherals; Health Services Accessibility | 2011 |
Stop smoking clinics in Malaysia: characteristics of attendees and predictors of success.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Carbon Monoxide; Demography; Female; Health Status; H | 2011 |
Waterpipe (hookah) tobacco smoking among youth.
Topics: Adolescent; Adolescent Behavior; Age Factors; Carbon Monoxide; Child; Child Welfare; Female; Health | 2011 |
Internet-based group contingency management to promote abstinence from cigarette smoking: a feasibility study.
Topics: Adult; Behavior Therapy; Carbon Monoxide; Feasibility Studies; Female; Humans; Internet; Interview, | 2011 |
Deficits in inhibitory control in smokers during a Go/NoGo task: an investigation using event-related brain potentials.
Topics: Behavior; Brain; Breath Tests; Carbon Monoxide; Case-Control Studies; Cues; Electroencephalography; | 2011 |
Reversibility of impaired nasal mucociliary clearance in smokers following a smoking cessation programme.
Topics: Adult; Aged; Carbon Monoxide; Carboxyhemoglobin; Case-Control Studies; Cilia; Exhalation; Female; Fo | 2011 |
Using NicAlert strips to verify smoking status among pregnant cigarette smokers.
Topics: Adult; Biomarkers; Breath Tests; Carbon Monoxide; Cotinine; Female; Health Promotion; Humans; Indica | 2011 |
Assessment of smoking behaviour in the dental setting. A study comparing self-reported questionnaire data and exhaled carbon monoxide levels.
Topics: Adolescent; Adult; Aged; Ambulatory Care Facilities; Breath Tests; Carbon Monoxide; Chi-Square Distr | 2012 |
Predictors of short-term success in smoking cessation in relation to attendance at a smoking cessation program.
Topics: Adaptation, Psychological; Adult; Carbon Monoxide; Counseling; Depression; Female; Humans; Logistic | 2011 |
Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Cotinine; Female; Follow-Up Studies; Head and Neck | 2012 |
Microsatellite alterations at 3p and 19q in EBC DNA of smokers: are they reversible after smoking cessation?
Topics: Adult; Aged; Breath Tests; Carbon Monoxide; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 3; | 2011 |
Cigarette smoking among a sample of PONS study subjects: preliminary assessment.
Topics: Analysis of Variance; Carbon Monoxide; Chi-Square Distribution; Cohort Studies; Educational Status; | 2011 |
Possible reasons for elevated carbon monoxide levels in self-reported ex-smokers.
Topics: Air; Breath Tests; Carbon Monoxide; Humans; Self Report; Sensitivity and Specificity; Smoking; Smoki | 2012 |
Does it matter who you see to help you stop smoking? Short-term quit rates across specialist stop smoking practitioners in England.
Topics: Behavior Therapy; Carbon Monoxide; Community Health Services; Counseling; England; Female; Humans; M | 2012 |
Implementation of routine biochemical validation and an 'opt out' referral pathway for smoking cessation in pregnancy.
Topics: Adult; Carbon Monoxide; Cotinine; England; Female; Humans; Patient Acceptance of Health Care; Pilot | 2012 |
Counseling and exercise intervention for smoking reduction in patients with schizophrenia: a feasibility study.
Topics: Adult; Carbon Monoxide; Counseling; Exercise; Feasibility Studies; Female; Humans; Male; Middle Aged | 2013 |
[Management of smoking in the perioperative period: survey of practices amongst anaesthetists in Lorraine].
Topics: Anesthesia; Carbon Monoxide; Exercise; Female; France; Guidelines as Topic; Health Care Surveys; Hum | 2013 |
[A new cause of false positives when analyzing expired air carbon monoxide].
Topics: Aged; Breath Tests; Candy; Carbon Monoxide; Central Nervous System Stimulants; Chewing Gum; False Po | 2002 |
Acute effects of Advance: a potential reduced exposure product for smokers.
Topics: Adolescent; Adult; Air Pollutants; Carbon Monoxide; Cross-Over Studies; Environmental Exposure; Fema | 2002 |
[Guidelines for a diagnostic and therapeutic approach to smoking addiction. A consensus report].
Topics: Carbon Monoxide; Humans; Oximetry; Practice Guidelines as Topic; Risk Factors; Smoking; Smoking Cess | 2003 |
Shaping exhale durations for breath CO detection for men with mild mental retardation.
Topics: Adult; Carbon Monoxide; Humans; Intellectual Disability; Male; Respiration; Smoking Cessation; Time | 2002 |
Evaluation of objective measures of smoking status--a prospective clinical study in a group of head and neck cancer patients treated with radiotherapy.
Topics: Aged; Aged, 80 and over; Biomarkers; Breath Tests; Carbon Monoxide; Cotinine; Head and Neck Neoplasm | 2003 |
[Correlation between carbon-monoxide levels in exhaled air and nicotine-dependence measurements systems (DSM-IV, Fagerström test and ARU-SMQ-9) in adolescent smokers].
Topics: Adolescent; Carbon Monoxide; Carboxyhemoglobin; Child; Cross-Sectional Studies; Female; Humans; Male | 2003 |
Optimal cutoff level of breath carbon monoxide for assessing smoking status in patients with asthma and COPD.
Topics: Adolescent; Adult; Aged; Asthma; Breath Tests; Carbon Monoxide; Cotinine; Cross-Sectional Studies; F | 2003 |
A study of the use of free nicotine patches by Indigenous people.
Topics: Administration, Cutaneous; Adult; Carbon Monoxide; Counseling; Drug Prescriptions; Female; Humans; M | 2003 |
Lack of startle modulation by smoking cues in smokers.
Topics: Adult; Analysis of Variance; Behavior, Addictive; Carbon Monoxide; Case-Control Studies; Cues; Elect | 2004 |
Quantitative comparisons between a nicotine delivery device (Eclipse) and conventional cigarette smoking.
Topics: Adult; Blood Pressure; Carbon Monoxide; Equipment Design; Female; Heart Rate; Humans; Male; Middle A | 2004 |
Smoking cessation increases gingival blood flow and gingival crevicular fluid.
Topics: Adult; Analysis of Variance; Carbon Monoxide; Cotinine; Female; Follow-Up Studies; Gingiva; Gingival | 2004 |
Prospective examination of effects of smoking abstinence on cortisol and withdrawal symptoms as predictors of early smoking relapse.
Topics: Adolescent; Adult; Affect; Aged; Area Under Curve; Carbon Monoxide; Circadian Rhythm; Cotinine; Fema | 2004 |
Improving contingency management programs for addiction.
Topics: Behavior Therapy; Breath Tests; Carbon Monoxide; Female; Humans; Male; Reward; Smoking; Smoking Cess | 2004 |
[Complex assessment of nicotine dependence using questionnaires and measurement of carbon oxide concentration in exhaled air].
Topics: Adult; Biomarkers; Breath Tests; Carbon Monoxide; Female; Humans; Male; Middle Aged; Respiratory Mec | 2004 |
[Usefulness of biological markers in the evaluation of smoking at the first visit of a smoking cessation program].
Topics: Adolescent; Adult; Aged; Biomarkers; Breath Tests; Carbon Monoxide; Cotinine; Female; France; Humans | 2004 |
Alterations of gene expression in human neutrophils induced by smoking cessation.
Topics: Adult; Analysis of Variance; Carbon Monoxide; Cotinine; Gene Expression; Humans; Interleukin-1; Inte | 2004 |
Predictors of success in smoking cessation among hospitalized patients.
Topics: Age of Onset; Asthma; Attitude to Health; Breath Tests; Carbon Monoxide; Cohort Studies; Counseling; | 2005 |
Smoke constituent exposure and smoking topography of adolescent daily cigarette smokers.
Topics: Adolescent; Adolescent Behavior; Carbon Monoxide; Cotinine; Cross-Sectional Studies; Female; Ganglio | 2004 |
Assessing missing data assumptions in longitudinal studies: an example using a smoking cessation trial.
Topics: Bias; Carbon Monoxide; Clinical Trials as Topic; Computer Graphics; Data Collection; Data Interpreta | 2005 |
[Veracity of smokers' reports of abstinence at smoking cessation clinics].
Topics: Adult; Breath Tests; Bupropion; Carbon Monoxide; Data Interpretation, Statistical; Dopamine Uptake I | 2005 |
Predictors of initial abstinence in smokers enrolled in a smoking cessation program.
Topics: Adult; Breath Tests; Carbon Monoxide; Demography; Female; Humans; Logistic Models; Male; Patient Acc | 2005 |
Voucher-based incentives for cigarette smoking reduction in a women's residential treatment program.
Topics: Adult; Analysis of Variance; Arkansas; Breath Tests; Carbon Monoxide; Female; Humans; Motivation; Re | 2005 |
Placebo cigarettes in a spaced smoking paradigm.
Topics: Adult; Analysis of Variance; Behavior, Addictive; Carbon Monoxide; Female; Heart Rate; Humans; Male; | 2005 |
Pretreatment cue reactivity predicts end-of-treatment smoking.
Topics: Adolescent; Adult; Aged; Behavior Therapy; Carbon Monoxide; Cues; Female; Heart Rate; Humans; Male; | 2006 |
The influence of gender, race, and menthol content on tobacco exposure measures.
Topics: Adult; Analysis of Variance; Attitude to Health; Biomarkers; Black or African American; Carbon Monox | 2005 |
Effects of asbestos and smoking on gas diffusion in people exposed to crocidolite.
Topics: Age Distribution; Asbestos, Crocidolite; Carbon Monoxide; Cohort Studies; Environmental Exposure; En | 2005 |
Evaluating the program of a smoking cessation support group for adult smokers: a longitudinal pilot study.
Topics: Administration, Cutaneous; Adult; Breath Tests; Carbon Monoxide; Carboxyhemoglobin; Cognitive Behavi | 2005 |
Pragmatic, observational study of bupropion treatment for smoking cessation in general practice.
Topics: Adolescent; Adult; Age Distribution; Aged; Bupropion; Carbon Monoxide; Dopamine Uptake Inhibitors; F | 2005 |
Exhaled carbon monoxide level as an indicator of cigarette consumption in a workplace cessation program in Taiwan.
Topics: Adult; Breath Tests; Carbon Monoxide; Feasibility Studies; Humans; Male; Occupational Health Service | 2006 |
Smoking cessation advice for patients with chronic periodontitis.
Topics: Adult; Breath Tests; Bupropion; Carbon Monoxide; Central Nervous System Stimulants; Chronic Disease; | 2006 |
Disruption in Th1/Th2 immune response in young adult smokers.
Topics: Adult; Analysis of Variance; Autoimmune Diseases; Biomarkers; Breath Tests; Carbon Monoxide; Case-Co | 2007 |
Maximum yields might improve public health--if filter vents were banned: a lesson from the history of vented filters.
Topics: Carbon Monoxide; Consumer Product Safety; Filtration; History, 20th Century; Humans; Nicotiana; Nico | 2006 |
How to help smokers quit: part 1.
Topics: Carbon Monoxide; Humans; Smoking Cessation; Tobacco Use Disorder | 2006 |
Concordance of self-reported abstinence and measurement of expired air carbon monoxide in a self-help smoking cessation treatment.
Topics: Adult; Air; Carbon Monoxide; Exhalation; Female; Humans; Male; Program Development; Self Care; Self- | 2006 |
Developing nursing care tool for pregnant woman to quit first and secondhanded smoking.
Topics: Carbon Monoxide; Female; Humans; Japan; Nursing Care; Pregnancy; Smoking Cessation; Surveys and Ques | 2006 |
Thinking and/or doing as strategies for resisting smoking.
Topics: Adaptation, Psychological; Adult; Breath Tests; Carbon Monoxide; Cognitive Behavioral Therapy; Compu | 2006 |
Clinical laboratory evaluation of potential reduced exposure products for smokers.
Topics: Adult; Biomarkers; Carbon Monoxide; Carcinogens; Cotinine; Female; Humans; Male; Middle Aged; Nicoti | 2006 |
[Weight gain and anxiety levels in recent ex-smokers].
Topics: Adult; Anxiety; Basal Metabolism; Breath Tests; Bupropion; Carbon Monoxide; Chewing Gum; Feeding Beh | 2007 |
Effects of high dose transdermal nicotine replacement in cigarette smokers.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Algorithms; Blood Pressure; Body Weight; Carbon | 2007 |
Biochemical verification of smoking status in pregnant and recently postpartum women.
Topics: Adult; Biomarkers; Breath Tests; Carbon Monoxide; Chromatography, Gas; Cotinine; Female; Humans; Imm | 2007 |
Exhaled carbon monoxide as a marker for evaluating smoking abstinence in a Brazilian population sample.
Topics: Adult; Bayes Theorem; Biomarkers; Brazil; Breath Tests; Carbon Monoxide; Cross-Sectional Studies; Fe | 2007 |
[Seventy-five cases in which serum concentrations of cotinine were monitored prior to nicotine replacement therapy for smoking cessation].
Topics: Adult; Aged; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Nicotine; Smoking Cessati | 2007 |
[Tobacco cessation. Action-stage result as a predictor of successful long-term maintenance].
Topics: Administration, Cutaneous; Adult; Behavior Therapy; Breath Tests; Carbon Monoxide; Cohort Studies; C | 2007 |
Effect of smoking cessation on markers of inflammation and endothelial cell activation among individuals with high risk for cardiovascular disease.
Topics: Adult; Biomarkers; C-Reactive Protein; Carbon Monoxide; Cardiovascular Diseases; Endothelial Cells; | 2007 |
Cough following initiation of smoking abstinence.
Topics: Adult; Carbon Monoxide; Cough; Female; Humans; Male; Middle Aged; Recurrence; Smoking; Smoking Cessa | 2007 |
Smoking cessation among patients with head and neck cancer: cancer as a 'teachable moment'.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Carbon Monoxide; Cotinine; Female; Follow-Up Studies; He | 2008 |
The axial distribution of nicotine content along hair shaft as an indicator of changes in smoking behaviour: evaluation in a smoking-cessation programme with or without the aid of nicotine chewing gum.
Topics: Adult; Breath Tests; Carbon Monoxide; Chewing Gum; Female; Hair; Humans; Male; Middle Aged; Nicotine | 1995 |
Changes in smoking behavior and body weight after implementation of a no-smoking policy in the workplace.
Topics: Body Weight; Carbon Monoxide; Female; Health Policy; Humans; Male; Multivariate Analysis; Smoking; S | 1994 |
Effects of smoking cessation on blood pressure.
Topics: Blood Pressure; Body Weight; Carbon Monoxide; Cotinine; Female; Follow-Up Studies; Humans; Male; Mid | 1993 |
[Campaign against smoking and the general practitioner. Evaluation of a simple method allowing immediate measurement of compliance with smoking cessation in the physicians office].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breath Tests; Carbon Monoxide; Cross-Sectional Studies; | 1993 |
Glycerol particle cigarettes: a less harmful option for chronic smokers.
Topics: Carbon Monoxide; Cotinine; Female; Glycerol; Humans; Male; Nicotine; Patient Satisfaction; Risk Fact | 1993 |
Relation between the Tolerance Questionnaire (nicotine dependence) and assessment of carbon monoxide in smokers who participated in treatment for smoking.
Topics: Adult; Breath Tests; Carbon Monoxide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Smoking; | 1995 |
Managing nicotine dependence.
Topics: Carbon Monoxide; Exercise Test; Humans; Myocardial Ischemia; Nicotine; Smoking; Smoking Cessation | 1997 |
Usefulness of markers in managing tobacco withdrawal.
Topics: Administration, Cutaneous; Adult; Biomarkers; Carbon Monoxide; Carboxyhemoglobin; Cotinine; Female; | 1997 |
Self-reported smoking and measurement of expired air carbon monoxide in a clinical treatment.
Topics: Adult; Behavior Therapy; Breath Tests; Carbon Monoxide; Female; Humans; Male; Sensitivity and Specif | 1998 |
Coping in real time: using Ecological Momentary Assessment techniques to assess coping with the urge to smoke.
Topics: Adaptation, Psychological; Adult; Breath Tests; Carbon Monoxide; Cross-Sectional Studies; Environmen | 1998 |
Olfactory thresholds for nicotine and menthol in smokers (abstinent and nonabstinent) and nonsmokers.
Topics: Administration, Inhalation; Adult; Carbon Monoxide; Humans; Male; Menthol; Nicotine; Sensory Thresho | 1998 |
A harmful aid to stopping smoking.
Topics: Breath Tests; Carbon Monoxide; Humans; Male; Smoking Cessation; Vegetables | 1999 |
[Smoking cessation in patients with stable or unstable ischemic heart disease].
Topics: Adult; Aged; Angina, Unstable; Carbon Monoxide; Female; Hemoglobins; Humans; Male; Middle Aged; Myoc | 1999 |
Acute smoking increases ST depression in humans during general anesthesia.
Topics: Acute Disease; Adult; Anesthesia, General; Anesthetics, Inhalation; Blood Pressure; Carbon Monoxide; | 1999 |
Effects of abstinence on cigarette smoking among outpatients with schizophrenia.
Topics: Adult; Breath Tests; Carbon Monoxide; Humans; Outpatients; Reinforcement Schedule; Schizophrenic Psy | 1999 |
Evaluation of smoking prevalence: will there be an end to self-administered questionnaires?
Topics: Adult; Austria; Carbon Monoxide; Evaluation Studies as Topic; Female; Humans; Male; Population Surve | 2000 |
Pharmacodynamic effects of new de-nicotinized cigarettes.
Topics: Adult; Blood Pressure; Carbon Monoxide; Electroencephalography; Female; Ganglionic Stimulants; Heart | 1999 |
A combination of exhaled carbon monoxide (CO) measurement and the Fagerström Test for Nicotine Dependence (FTND) is recommended to complete information on smoking rates in population-based surveys.
Topics: Adult; Aged; Breath Tests; Carbon Monoxide; Female; Health Surveys; Humans; Male; Middle Aged; Popul | 2000 |
Does smoking reduction result in reduction of biomarkers associated with harm? A pilot study using a nicotine inhaler.
Topics: Administration, Inhalation; Adult; Aged; Aminobiphenyl Compounds; Biomarkers; Carbon Monoxide; Cotin | 2000 |
Are patients truthful about their smoking habits? A validation of self-report about smoking cessation with biochemical markers of smoking activity amongst patients with ischaemic heart disease.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Carbon Monoxide; Case-Control Studies; Chi-Square | 2001 |
Assessment of the smoker who wants to quit.
Topics: Carbon Monoxide; Humans; Motivation; Prognosis; Risk Factors; Smoking; Smoking Cessation; Tobacco Us | 2001 |
Smoking during pregnancy and intention to quit: a profile of methadone-maintained women.
Topics: Adult; Attitude to Health; Carbon Monoxide; Cotinine; Ethnicity; Female; Follow-Up Studies; Heroin D | 2001 |
Exhaled carbon monoxide in COPD.
Topics: Breath Tests; Carbon Monoxide; Carboxyhemoglobin; Humans; Pulmonary Disease, Chronic Obstructive; Sm | 2002 |
Observer reports of smoking status: a replication.
Topics: Adult; Breath Tests; Carbon Monoxide; Cotinine; Female; Follow-Up Studies; Humans; Male; Smoking Ces | 1992 |
Effect of smoking cessation on pulmonary carbon monoxide diffusing capacity and capillary blood volume.
Topics: Adult; Carbon Monoxide; Female; Humans; Lung; Male; Microcirculation; Pulmonary Diffusing Capacity; | 1992 |
A time series investigation of three nicotine regulation models.
Topics: Adult; Attitude to Health; Behavior, Addictive; Carbon Monoxide; Cotinine; Female; Humans; Male; Mod | 1992 |
Smoking habits in relapsed subjects from a smoking cessation trial after one year.
Topics: Administration, Cutaneous; Adult; Body Weight; Carbon Monoxide; Cotinine; Female; Follow-Up Studies; | 1992 |
Human avoidance responding with added point loss: effects of tobacco and abstinence.
Topics: Adult; Avoidance Learning; Carbon Monoxide; Chewing Gum; Chromatography, Gas; Cotinine; Humans; Male | 1992 |
Smoking deprivation in "early" and "late" smokers and memory functions.
Topics: Adult; Carbon Monoxide; Cognition; Dizziness; Electrocardiography; Electroencephalography; Female; H | 1992 |
Biochemical evidence of persistent heavy smoking after a coronary diagnosis despite self-reported reduction: analysis from the Scottish Heart Health Study.
Topics: Breath Tests; Carbon Monoxide; Coronary Disease; Cotinine; Cross-Sectional Studies; Female; Humans; | 1992 |
A trial of health education aimed to reduce cigarette smoking among pregnant women.
Topics: Breath Tests; Carbon Monoxide; England; Female; Health Education; Humans; Pregnancy; Pregnancy Compl | 1992 |
Phase-out filter perforation: effects on human tobacco smoke exposure.
Topics: Adult; Carbon Monoxide; Female; Filtration; Humans; Male; Middle Aged; Nicotine; Smoking; Smoking Ce | 1992 |
Processes of change across five stages of smoking cessation.
Topics: Adult; Aged; Aged, 80 and over; Breath Tests; Carbon Monoxide; Female; Follow-Up Studies; Humans; Ma | 1992 |
Compliance to nicotine gum recommendations in a multicomponent group smoking cessation program: an exploratory study.
Topics: Adult; Breath Tests; Carbon Monoxide; Chewing Gum; Combined Modality Therapy; Female; Humans; Male; | 1992 |
Comparison of smoking behavior change for SI and UC study groups. MRFIT Research Group.
Topics: Adult; Carbon Monoxide; Clinical Trials as Topic; Cohort Studies; Coronary Disease; Follow-Up Studie | 1991 |
[Evaluation of the effectiveness of medical consultation regarding smoking cessation].
Topics: Adult; Breath Tests; Carbon Monoxide; Electronics; Female; Humans; Male; Mass Screening; Middle Aged | 1991 |